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ABSTRACT 
 
ELUCIDATING THE ROLE OF HEPATIC PPP1R3B GENE IN GLUCOSE AND 
LIPID METABOLISM 
Minal B. Mehta 
Genetic variants mapping to chromosome 8p23.1 have been associated with 
multiple metabolic traits in humans, including plasma constituents (glucose, 
lactate, insulin, HDL and non-HDL cholesterol), and hepatic steatosis with 
genome-wide significance. The closest gene of known function, PPP1R3B, 
(Protein Phosphatase 1 Regulatory Subunit 3B), encodes a protein (GL) that is 
known to regulate glycogen metabolism. We sought to test the hypothesis that 
hepatic PPP1R3B is the causal gene underlying the human genetic association 
with these metabolic attributes and to understand the mechanisms. We 
generated two separate mice with liver-specific deletion (Ppp1r3b∆hep) or liver-
specific overexpression of Ppp1r3b. Hepatic deletion of Ppp1r3b significantly 
reduced glycogen levels and glycogen synthase activity in the liver, impairing 
fasting glucose homeostasis, and prompting early onset of non-carbohydrate 
metabolite utilization to sustain energy under long term fasting.  Conversely, mice 
with overexpression of hepatic Ppp1r3b maintained augmented glycogen storage 
capacity, with larger glycogen pool creating a buffer towards delayed onset of 
hypoglycemia. Mice harboring deletion of hepatic Ppp1r3b exhibited glucose 
intolerance and insulin resistance, with increased hepatic triglyceride content, 
leading to hepatic steatosis, under chronic high sucrose feeding.  In contrast,  
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mice overexpressing hepatic Ppp1r3b remained glucose responsive, and insulin 
sensitive, and were protected from hepatic steatosis under chronic sucrose diet 
feeding. These studies implicate a major role of Ppp1r3b in glycogen and lipid 
homeostasis in the liver, and provide concrete evidence for its pleiotropic effect 
on metabolic state in a mammalian system, consistent with the human GWAS 
association. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Human genome wide association studies (GWAS) can identify novel 
genetic loci for disease risk  
Driven by recent technological advances, genome wide association studies 
(GWAS) have been widely used to identify genetic loci associated with common 
traits such as body mass index, plasma metabolic traits, and complex diseases 
including obesity, and Type 2 diabetes (1-4). This has led to substantial progress 
in the field of human genetics with respect to identifying genetic risk factors for 
many metabolic and chronic diseases.  These large-scale population-based 
genetic studies leverage common variants known as single nucleotide 
polymorphisms (SNPs) defined as single base-pair changes in the DNA 
sequence that occur with high frequency in the human genome (5) to determine 
their statistical association with a given trait or disease.  Assessment of the 
statistical significance of GWAS SNP signals depend on two factors: 1) Large 
sample and effect size 2) allele frequency, and its correlation with the causal 
variant (6).  The larger the population size interrogated, the greater the statistical 
power. Further analysis of initial GWAS-identified SNPs for replication studies in 
independent population cohort samples provides further validation of these 
disease or trait-variant associations.  
Several GWAS conducted for diseases in the recent past have identified 
novel genetic associations for complex disease traits. One of the early successful 
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examples of GWAS was the identification of the Complement Factor H gene as a 
major risk factor for age-related macular degeneration (AMD) (7). Association of 
DNA sequence variations in this gene with AMD was further functionally 
validated in a knockout mouse model (8) to access its functionality and provide a 
biological basis for the phenotype effect that was detected in humans.  GWAS for 
common, complex phenotype such as obesity unraveled several biologically 
important SNPs within various genes, including Zinc Finger Protein 90 (ZFP90) 
and Complement C3a receptor 1 (C3AR1) that were substantiated upon 
replication in transgenic and knockout mice respectively, and are implicated in  
regulating adiposity (9,10). SNPs in another gene, Melonocortin-4 receptor 
(MC4R) are associated with body weight and fat distribution in childhood obesity 
(11).  Similarly, SNPs associated with another common and complex disease, 
Type 2 diabetes (T2D), revealed several susceptible gene loci, including KCNQ1, 
which encodes a voltage-gated potassium channel, that is important in regulating 
insulin secretion by the pancreatic β-cells. Functional analysis of the common 
SNPs associated with this gene showed significant correlation with reduced 
stimulated second-phase insulin secretion in subjects that underwent 
hyperglycemic-glucose clamps, suggesting a plausible biological underpinning of 
these variations (12,13). Another significant example includes a large GWAS 
meta-analysis of blood lipid traits, which identified SNPs in 95 unique genetic loci  
in population of European-descent (14).  Of these, three novel genes, GALNT2, 
PPP1R3B and TTC39B, which were associated with total and HDL cholesterol 
levels, were functionally validated for their biological significance in mice (15).  
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These genome-wide association studies in humans have been a valuable 
resource to identify novel common genetic variations associated with complex 
traits, and to provide insight into the genomic architecture associated with 
disease etiology. Further functional biological validations of these loci underlying 
the SNP associations would provide a greater understanding of the 
pathophysiology of complex diseases and novel opportunities for therapeutic 
interventions.  
1.2 PPP1R3B: a novel genetic locus associated with multiple metabolic 
traits 
The focus of this dissertation is PPP1R3B, a genetic locus identified in multiple 
GWAS for complex disease-traits (14-22). Variants near this genetic locus are 
associated with glycemic traits, including plasma glucose, insulin and lactate 
levels in humans (18,19). GWAS meta-analysis also identified lead SNP 
(rs9987289) near PPP1R3B gene as linked to plasma lipids, specifically total 
plasma cholesterol (TPC), HDL cholesterol (HDL-C) and LDL cholesterol(LDL-C), 
(plasma triglycerides (TG) were unaffected) in ~100,000 individuals of European 
descent (14,15).  Moreover, SNPs near this gene were also subsequently shown 
to be associated with hepatic steatosis in various ethnic populations (16,17,20); 
and with elevated alkaline phosphatase (ALP) (21) and with C-reactive Protein 
(CRP) levels (22), indicating liver inflammation and injury typically associated 
with chronic liver diseases.  Importantly, using expression quantitative trait locus 
(eQTL) mapping, PPP1R3B was identified as a liver eQTL for these associated 
metabolic traits, with the minor allele variant correlated with the increased 
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expression of PPP1R3B in the liver (15).  The PPP1R3B SNPs identified in these 
separate GWAS comprise a linkage block with the LD R2 value between 0.8 and 
1.  Collectively, based on these GWAS, it is logically predicted that expression of 
PPP1R3B has a pleiotropic effect on the above metabolic traits, and further 
functional validation is an important next step to study the biologic basis of the 
significance of these metabolic effects. Table 1 summarizes these GWAS 
associations with hepatic PPP1R3B in various population cohorts.  
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Table 1a:  GWAS SNP near the PPP1R3B genetic locus are associated with multiple metabolic traits 
 
SNP ID Minor 
alleleb 
eQTL 
MAF Liver 
PPP1R3B 
mRNA 
Trait P-Value Trait 
Direction 
Population Sample 
Size 
Year of 
Study 
rs9987289 
(15) 
A 
 
 
0.114  HDL-C  
 
6x10-25  European  100,000 2010 
rs9987289 
(15) 
A 0.114  LDL-C 7.43 ×10-15  European  100,000 2010 
rs9987289 
(15) 
A 0.114  Total 
Cholesterol 
8.98 × 10-
24 
 European  100,000 2010 
rs4841132 
(18) 
A 0.093  Fasting 
plasma 
glucose 
7.6 × 10−9 
 
 Various 
Populations 
96,496 2012 
rs4841132 
(18) 
A 0.093  Fasting 
insulin 
1.7x10-10  Various 
Populations 
83,116 2012 
rs4240624 
(16) 
A 0.114  Hepatic 
Steatosis 
 
0.03  Various 
Populations 
 
4804 
(1825 
NHW, 
1442NHB, 
1537 MA) 
2013 
 
rs4240624 
 (20) 
A 0.114   
Hepatic 
Steatosis 
 
3.68x10-18 
 
 African 
American 
 
3124  
 
2013 
0.114 0.025  Mexican 
American   
839 
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Table 1: GWAS SNPs near the PPP1R3B locus in different ethnic populations and their association with 
metabolic traits.  SNPs near PPP1R3B associated with plasma HDL-cholesterol, LDL-cholesterol, total 
cholesterol, glucose, insulin, lactate, alkaline phosphatase, and C-reactive protein levels and with accumulation of 
hepatic fat and Non-alcoholic fatty liver disease (NAFLD) from multiple GWAS studies.  For some GWAS, various 
population cohorts were used to compile meta-analyses of SNP associations from previous GWAS. Abbreviations: 
MAF- minor allele frequency;.  Various: NHW = Non Hispanic Whites; NHB= Non Hispanic Blacks; MA = Mexican 
Americans 
a Adapted from Dr. Nicholas Hand (unpublished, personal communication) 
 
b Liver PPP1R3B is an expression quantitative trait locus (eQTL) for the minor allele 
rs6984305 
(21) 
A 0.124 NA Alkaline 
phosphatase 
2.1 × 10–10 
 
NA Multiple 
Populations 
61,089 2011 
rs9987289 
(22) 
A 0.114  C-reactive 
Protein  
2.3×10-12  Various 
Populations 
>100,000 2015 
rs9987289 
(19) 
A 0.114  Plasma 
Lactate 
1.6x10-9  European 6901 2016 
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1.3 PPP1R3B: a liver glycogen targeting subunit that regulates hepatic 
glycogen synthesis and storage 
PPP1R3B encodes a glycogen targeting subunit, also called GL that is 
predominantly expressed in liver in rodents but is also expressed in skeletal 
muscle, parathyroid, thyroid, and adrenal glands, in humans (23,24). PPP1R3B 
regulates hepatic glycogen synthesis in the postprandial (fed) state, and its 
expression is hormonally regulated by insulin(25).  It is a scaffolding protein that 
recruits a ubiquitously expressed cellular protein phosphatase 1 (PP1) to 
glycogen granules, and specifically activates PP1 towards specific glycogen 
enzymes such as glycogen synthase (GS) and glycogen phosphorylase (GP). 
The PP1-GL complex mediates dephosphorylation and activation of GS (26-28). 
A short conserved binding motif (-RVXF-), is a common feature of glycogen 
targeting subunits, including GL, which enables their interaction with a small 
hydrophobic groove on the surface of PP1(26-28).  These glycogen targeting 
subunits share conserved structural domains.  The N-terminal region contains 
the putative RVXF( motif that is required for binding to PP1; the central region is 
required for binding to glycogen; and the C-terminal region mediates binding to 
other substrates and enzymes including glycogen synthase, and glycogen 
phosphorylase, which binds to GL and another targeting subunit, PTG, and 
allosterically regulates GL(29-32), and cAMP dependent protein kinase that 
regulates the activity of another targeting subunit, GM (33-35). Figure 1 shows the 
basic protein structure of these glycogen targeting subunits.  
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Figure 1: Protein domain structure of glycogen targeting subunits 
 
 
 
 
 
 
 
 
 
Figure 1: General schematic of protein domain structure with substrate and 
enzyme binding sites of glycogen targeting subunits. Abbreviations: PP1- 
Protein Phosphatase; RVXF-a short conserved consensus motif that enables 
binding to PP1; CBD-carbohydrate binding domain that enables binding to 
glycogen granules; SBD-Substrate binding domain which enables binding to 
substrates and enzymes.  For GL and PTG, Glycogen phosphorylase (GP) binds 
at this site. GP mediates allosteric regulation of GL.  For GM, cAMP dependent 
protein kinase binds at this site and regulates its activity by phosphorylation.  
Adapted from Armstrong et al., Biochem J, 1998 (30) 
Printen et al., Science, 1997 (32) and  
Liu et al., J Biol Chem, 2000 (35) 
 
To date, there are at least seven well-characterized genes that encode 
these glycogen targeting subunits.  PPP1R3A (GM/RGL; 124kDa) is mainly 
expressed in the striated, skeletal muscle and heart and deletion of this gene 
leads to reduction of glycogen level in skeletal muscle, accompanied by glucose 
intolerance and insulin resistance (33). As mentioned above, PPP1R3B (GL; 
33kDa) is the primary glycogen targeting subunit expressed in the rodent liver, 
and mice with overexpression of a mutant form of PPP1R3B that had an 
impaired binding site for GP displayed improved glucose tolerance (36). 
PPP1R3C (GC/R5/PTG; 36kDa) is widely expressed in many tissues including 
skeletal and cardiac muscle, adipose tissue, and liver, and mice with 
heterozygous deletion of PPP1R3C have reduced glycogen levels in various 
PP1 
   RVXF CBD SBD 
GP (PTG/GL) 
GS (PTG, GL, GM) 
cAMP dependent Protein  
Kinase (GM) 
 
N  C
 
Glycogen 
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tissues, accompanied by progressive glucose intolerance, hyperinsulinemia, and 
insulin resistance with aging (37). PPP1R3D (GD/R6; 33kda) is mainly expressed 
in the brain and predicted to play a role in glycogen accumulation in neurons 
(38).  PPP1R3E (GE; 31kDa) is highly expressed in the liver and heart muscle in 
rodents (39); PPP1R3F (GF; 79kDa), is expressed at high levels in the brain and 
has been reported to regulate GS in astrocytoma cells (40) and the PPP1R3G 
(GG; 38kDa), is expressed at high levels in the rodent liver and regulates GS 
activity under fasting-feeding cycle (41). 
These glycogen targeting subunits have emerged as important modulators 
of glycogen metabolism. Several studies have indicated the role of these proteins 
to regulate glycogen homeostasis in tissues. Examples of such studies include 
utilization of overexpression of GL, PTG and GM in hepatocytes and adipocytes 
which significantly increases the glycogen levels in these cells (23), (42,43).  
Three distinct mechanisms contribute to the glycogenic effects of these glycogen 
targeting subunits: 1) dephosphorylation of glycogen phosphorylase (inactivation) 
and glycogen synthase (activation); 2) enhanced targeting of glycogen synthase 
and glycogen phosphorylase to the glycogen particle and 3) stabilization of the 
glycogen synthase protein (44). The implication of presence of multiple isoforms 
of these proteins in tissues such as liver, and their effect on glycogen regulation 
under different metabolic stresses remains to be elucidated.   The role of 
PPP1R3B (GL) in hepatic glucose metabolism will be further explored in Chapter 
2.    
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1.4 Interactions between hepatic glucose and lipid metabolism 
Glucose and lipid metabolism are interconnected in various ways. One of 
the major metabolic processes in a mammalian system that occur is the 
synthesis of fat from dietary glucose. The process occurs through entry of 
glucose into the glycolysis pathway.  The product of glycolysis, pyruvate can 
subsequently be converted into acetyl-CoA, a major precursor for fatty acid 
synthesis. Glucose is capable of undergoing conversion into fat in a process 
known as de novo lipogenesis (45,46).  Glucose is able to induce de novo 
synthesis of fatty acids from acetyl-CoA through indirect mechanisms by inducing 
insulin secretion from pancreatic β cells (47).  Insulin stimulates the gene 
expression of transcription factor SREBP1(48), while also increases its 
processing in the endoplasmic reticulum (ER)(49).   This occurs when an 
inactive-membrane bound SREBP precursor in the ER binds to SREBP-
cleavage-activating protein (SCAP), which escorts it to the Golgi apparatus.  In 
the Golgi, SREBP1 is cleaved by site-1 and 2 serine proteases and the mature 
SREBP1 translocates to the nucleus to activate transcription of target genes. 
Transcriptional control requires the presence of an octamer sequence termed the 
sterol regulatory element, SRE-1 in the promoter/enhancer regions of multiple 
target genes. SREBP1 binds to these elements and activates gene expression.  
SREBP1 specifically activates the genes encoding the ATP citrate lyase, which 
produces acetyl-CoA, acetyl-CoA carboxylase, and fatty acid synthase, which 
together produce palmitate and other enzymes in the lipogenic pathway. Figure 2 
summarizes the lipogenic enzymes regulated by SREBP1(49).   
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Figure 2: Insulin and SREBP1 mediated regulation of fatty-acid synthesis 
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Figure 2: Fatty Acid Synthesis regulated by Insulin and SREBP1 in the liver. Upon 
entry into hepatocytes, glucose mediates insulin secretion by pancreatic β-cells, and 
insulin then induces expression and activation of SREBP1 transcription factor. Activated 
SREBP1 then translocates to the nucleus and activates lipogenic genes that include: 
ACACA, FASN, ELOVL6, SCD1, GPAT and DGAT. Abbreviations: L-PK- Liver pyruvate 
kinase; ACLY-ATP citrate lyase; ACACA- Acetyl-coA carboxylase; FASN- Fatty acid 
synthase; ELOVL6- fatty acid elongase-6; SCD1- Stearoyl-coA desaturase; GPAT- 
glycerol-3-phosphate acyltransferase; DGAT- diacylglycerol acyltransferase.  (+) symbol 
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Carbohydrate feeding also promotes lipogenesis, independent of insulin, by 
activation of another transcription factor, known as carbohydrate responsive 
element binding protein (ChREBP) (46,50)((51). ChREBP is induced by high 
glucose concentrations. This was shown in primary rat hepatocytes cultured with 
high glucose and minimal insulin, where the mRNA levels of major lipogenic 
genes were upregulated (45), and in mice lacking SREBP1, high-carbohydrate 
feeding still maintained upregulation of these genes (52).  In adipose tissue (53) 
and liver (54), glucose stimulates the transcription of several genes encoding 
glycolytic and lipogenic genes including glucokinase, and liver-pyruvate kinase 
(L-PK) for glycolysis, adenosine triphosphate (ATP) citrate lyase (ACLY), acetyl-
CoA carboxylase (ACC), fatty acid synthase (FAS) for lipogenesis, elongase-6 
(ELOVL6) and stearoyl-CoA desaturase  (SCD1) for catalyzing fatty acid 
elongation and desaturation steps; and mitochondrial glycerol-3-phosphate 
acyltransferase (GPAT) and diacylglycerol acyltransferase (DGAT) for 
triglyceride (TG) synthesis. Transcription of genes such as L-PK for glycolysis 
and ACLY, ACC, FAS, SCD1, and ELOVL6 for lipogenesis is also mediated 
through the activation of ChREBP (51). Glucose mediates activation of ChREBP 
by regulating its entry from the cytosol into the nucleus through 
phosphorylation/dephosphorylation mechanisms. More specifically, Xylulose-5-
phosphate (Xu-5P), an intermediary glucose metabolite is thought to promote 
protein phosphatase 2A mediated dephosphorylation and activation of ChREBP 
(46,51).  Dephosphorylated ChREBP subsequently translocates to the nucleus 
and binds a conserved consensus sequence, known as the carbohydrate 
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response element (ChoRE), which is required for ChREBP binding and glucose 
responsiveness (55). Increased expression of liver-pyruvate kinase provides 
increased substrate availability for free fatty acid and TG synthesis.  Figure 3 
summarizes the glucose-responsive enzymes regulated by ChREBP (51).  
In addition, studies have also shown that SREBP1 and ChREBP work 
synergistically with each other to induce de novo lipogenesis in the liver (52,56-
59) . Evidence for this phenomenon is provided by several studies. First it was 
noted that in mice lacking hepatic glucokinase (GK) which is a rate limiting 
enzyme that converts intracellular glucose into metabolically favorable substrate, 
Glucose-6-phospate (G6P), for further glucose metabolism, overexpression of 
SREBP1c in the liver did not elicit maximal upregulation glycolytic and lipogenic 
genes, including L-PK, ACC and FAS, as the effect of glucose on the induction of 
these genes was lost, due to impaired ability of the liver to efficiently metabolize 
glucose.  It was also shown that the ChREBP gene expression was also 
decreased in the livers from these mice (56).  Similarly, in another study, it was 
shown that SREBP1 activity alone cannot sufficiently stimulate glycolytic and 
lipogenic gene expression in response to glucose, since there was only a 50% 
reduction in mice harboring SREBP1 deletion (52).  Furthermore, the expression 
of the key glycolytic enzyme, L-PK is predominantly regulated by ChREBP (57) 
and not SREBP1(58).  Likewise, the hepatic expression of ELOVL6, which 
mediates elongation of saturated and mono-saturated fatty acids, is dependent 
on the activation of  both transcription factors (59).  These studies collectively 
support a model in which SREBP1 and glucose metabolism, acting via ChREBP 
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are both required for dietary induction of glycolytic and lipogenic genes, 
consequently driving fatty acid and TG synthesis in the liver.   
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Figure 3: Genes regulated by ChREBP in a glucose responsive manner 
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state or under high glucose concentrations, there is elevation in glucose metabolite, 
Xylulose-5 phosphate (Xu-5P) which promotes PP2A mediated dephosphorylation (De-P) 
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1.5 Interactions of glucose and lipid metabolism in Type 2 Diabetes 
Mellitus 
Type 2 Diabetes Mellitus (Type 2 DM) is the disorder of abnormally high 
blood glucose levels (hyperglycemia), with a concurrent rise in plasma insulin 
(hyperinsulinemia) that is a driving factor in the development of systemic insulin 
resistance.  In insulin resistance, impaired insulin response by skeletal muscle 
causes decreased glucose uptake, and enhanced glucose production by the liver 
as the inhibition of this process by the insulin is attenuated(60).  Postprandial 
storage of glucose into glycogen in the liver is also reduced, further contributing 
to increase in plasma glucose(61). Pancreatic β-cells secrete more insulin, 
resulting in hyperinsulinemia, followed by cellular exhaustion leading to 
inadequate insulin secretion, promoting a pathological cycle that maintains the 
state of hyperglycemia. Diabetes is a major risk factor for cardiovascular 
diseases, as approximately 75% of deaths in diabetics are due to coronary artery 
disease, and other macrovascular diseases including stroke and peripheral 
vascular disease (62-65).   
Type 2 Diabetes (Type 2 DM) is a metabolic disease associated with 
whole-body insulin resistance.  Extensive evidence from studies supports the 
notion that multi-organ insulin resistance precedes the development of clinical 
Type 2 DM.   One of the hallmarks of insulin resistance is the distinct ectopic fat 
accumulation in tissues such as liver and skeletal muscle (66-68).  Accretion of 
fatty acids, specifically in the liver is also referred to as hepatic steatosis and is a 
characteristic of Non-alcoholic Fatty Liver disease (NAFLD), which is now 
 
 
17 
  
 
considered to be the most chronic form of liver disease associated with obesity 
and Type 2 diabetes (69,70).  In patients with Type 2 DM, the prevalence of 
NAFLD has reached to approximately 75%(70), and the escalating increase in 
the incidence of obesity and Type 2 DM in the United States and worldwide has 
extended NAFLD to emerge as a major health problem.     
NAFLD spectrum ranges from benign, simple hepatic neutral lipid 
accumulation (steatosis/NAFL) to non-alcoholic steatohepatitis (NASH), which is 
characterized by oxidative stress and inflammatory cytokines that are important 
contributing factors to the progression of the disease (71,72).  A subset of NASH 
patients are susceptible to development of fibrosis, which is marked by 
deposition of collagen fibers, leading to scarring of the liver, and development to 
cirrhosis. A very small percentage of patients with cirrhosis (1-2%) are at 
increased risk towards development of hepatocellular carcinoma (HCC) (73).  
Although a benign accumulation of neutral lipids in the liver is not harmful, it is 
characterized by impaired insulin responses in metabolic tissues, which leads to 
the development of overt Type 2 DM.  As such, the development of fatty liver is 
essentially the manifestation of impaired insulin signaling, that leads to hepatic 
steatosis (67). Steatosis is the result of imbalance between fatty acid synthesis 
/storage and its secretion from the liver. The major processes that contribute to 
fatty acid anabolism and catabolism include: 1) De novo fatty acid and TG 
synthesis derived from dietary glucose, 2) Free fatty acids (FFA) derived from 
adipose tissue lipolysis contributing to the hepatic FFA uptake and esterification 
into TG, 3) Utilization of FFA for energy production through the mitochondrial β-
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oxidation pathway, and 4) Export of FFA in the form of VLDL-triglyceride particles 
from the liver.  Fatty acid accumulation results when the anabolic pathways 
exceed the catabolic processes, causing perturbation in the homeostasis of this 
major macronutrient in the liver.  Insulin resistance plays a key role in this 
pathogenesis, as insulin promotes suppression of lipolysis from adipose tissue in 
a normal healthy state, curtailing the flux of FFA towards liver.  In insulin resistant 
states, this suppression is inhibited, resulting in increased adipose-tissue derived 
FFA driving fat accumulation in the liver, which contributes to 59% of the hepatic 
fatty acid pool (74).  There is also increased recruitment of pro-inflammatory 
macrophages into adipocytes, leading to increased secretion of adipocytokines 
including IL-6, MCP-1 and TNFα, which can underlie increased plasma FFA pool 
in NAFLD.  Additionally, increased, accumulation of intramyocellular lipids (IMCL) 
in skeletal muscle, due to decreased oxidative capacity, can further impair 
glucose uptake in muscle, contributing to systemic glucose intolerance (68,75).  
This combination of events leads to peripheral insulin resistance, and 
compensatory hyperinsulinemia, resulting in exacerbation of FFA delivery to liver.  
Furthermore, insulin insensitivity leads to de-suppression of hepatic glucose 
production (HGP)(60), despite elevated insulin levels, which further contributes to 
the development of hyperglycemia.  As outlined earlier, excessive glucose can 
also drive de novo lipogenesis in the liver, contributing to the fatty liver phenotype 
with approximately 30% input to the hepatic fatty acid pool (74). Hence, this 
pathological cycle results as a consequence of insulin resistance which causes 
impaired insulin signaling in multiple tissues, leading to increased lipolysis from 
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adipose tissue, which drives FFA uptake and ectopic fat deposition in liver 
(hepatic steatosis and NAFLD), combined with de-suppression of hepatic 
glucose production, decreased oxidative capacity with accumulation of IMCL, 
and decreased glucose uptake in skeletal muscle. Collective dysregulation of 
these coordinated metabolic processes among tissues results in the 
development of Type 2 diabetes.  Figure 4 summarizes the metabolic 
perturbations in glucose and fatty acid metabolism in major metabolic tissues in 
Type 2 diabetes(76).  
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Figure 4: Metabolic dysregulation of glucose and lipid metabolism in 
pathophysiology of Diabetes mellitus 
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Figure 4: Pathophysiology of Type 2 DM. Development of insulin resistance in tissues 
is the primary event that triggers the deregulation in metabolic processes leading to Type 
2 DM. 1) Impaired insulin signaling in adipose tissue drives increased FFA to liver 
contributing to ectopic hepatic fat accumulation (steatosis/NAFLD). 2) Insulin insensitivity 
causes decreased glucose uptake, and impaired oxidative capacity, leading to accretion 
of IMCL in skeletal muscle. 3) Impaired response to insulin in the liver causes de-
suppression of HGP. 4) Increased plasma glucose drives DNL in the liver exacerbating 
the fatty acid accumulation, and it also drives overproduction of insulin by pancreatic β-
cells, leading to their exhaustion and dysfunction.  This combinatorial metabolic effect 
leads to Type 2 DM. Adapted from Kahn et al., Nature 2006 (76). 
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1.6 Outline of the Dissertation 
 
Interactions between glucose and lipid metabolism are important for the 
maintenance of energy balance in a mammalian system, and perturbations in 
these metabolic pathways lead to many chronic disorders that are widespread in 
our global society.  Studying the molecular mechanisms underlying these 
pathways is critically important to our understanding of the pathophysiology of 
these metabolic disorders, and to developing therapeutic strategies to target 
these defects.    
GWAS have identified various novel genetic loci not previously implicated 
in the pathophysiology of carbohydrate and/or lipid metabolic disorders which are 
classically defined by known genetic players. These studies reveal new genetic 
associations, and provide a basis for further characterizing the functional 
validation of the biology behind these novel genes and their implications in 
disease etiology.    
This dissertation focuses on characterization of one such novel GWAS-
associated genetic locus, PPP1R3B, which is a glycogen targeting subunit and is 
an important activator of glycogen synthesis in the liver.  As outlined earlier, 
PPP1R3B was also identified to have a pleiotropic effect on multiple other 
plasma metabolites (lipids, lactate, glucose, insulin, and liver enzymes), and with 
hepatic steatosis (15-22). I sought to study the overarching role of PPP1R3B in 
maintenance of systemic energy balance in a mammalian system. 
I wanted to characterize the physiological role of PPP1R3B in hepatic 
glucose and lipid metabolism, by studying both the loss of function and gain of 
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function of this gene utilizing mouse models.  To directly study this gene in the 
liver, I used the Cre-lox system using a liver-specific promoter to generate mice 
with deletion of Ppp1r3b gene restricted to the liver. For gain of function studies, I 
used adeno-associated virus (AAV) to drive the expression of this gene in the 
liver in wildtype mice on C57BL/6J background and studied the effects on their 
metabolic pathways.   
I have investigated the role of PPP1R3B at the intersection of glucose and 
lipid metabolism, which has not been previously explored in vivo.   This led to the 
two broader questions related to this dissertation:  
1. Does hepatic Ppp1r3b play an important role in hepatic glycogen 
metabolism? How does it affect systemic energy homeostasis?  
2. Does modulation of hepatic Ppp1r3b alter lipid metabolism, and if so, 
how is this pathway regulated?  
In our first investigative study described in Chapter 2,  I used the 
reciprocal liver-specific Ppp1r3b knockout and overexpression mouse models to 
specifically study the role of Ppp1r3b in hepatic glycogen metabolism, and the 
impact of its modulation on systemic glucose homeostasis and energy balance.  
Our hypothesis was that, the loss of hepatic Ppp1r3b would lead to reduced 
hepatic glycogen storage in the liver, and consequently would cause adaptive 
physiological alterations in energy homeostasis under long-term fasting duration.  
In our second research study, which is described in Chapter 3, I further 
characterized the role of Ppp1r3b in hepatic lipid metabolism. More specifically, I 
have used these two genetic mouse models to test the association of Ppp1r3b 
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with hepatic steatosis. As outlined earlier, hepatic steatosis is a result of 
imbalance of fatty acid synthesis and storage and its utilization. Our hypothesis 
was that in the absence of Ppp1r3b in the liver, carbons from glucose are 
shunted towards synthesis into fatty acids and triglycerides, as a consequence of 
diminished hepatic glycogen storage capacity, thereby promoting increased 
substrate availability for fatty acid metabolism. In the overexpression of Ppp1r3b, 
we hypothesize that this mechanism would be attenuated.   
Since this genetic locus is also associated with plasma lipids, in the 
context of loss of hepatic Ppp1r3b, we hypothesized that the perturbation in fatty 
acid and TG storage in the liver resulting from loss of hepatic Ppp1r3b would 
prompt changes in the remodeling and secretion of the different lipid sub-
fractions (HDL, non-HDL, PL), resulting in changes in their levels and 
composition.    
The work presented in this dissertation explores the importance and 
significance of Ppp1r3b in maintaining metabolic energy homeostasis, with 
providing several mechanistic insights in the complex interactions between 
glucose and lipid metabolism with respect to the pathophysiology of common 
metabolic derangements including insulin resistance, associated with NAFLD 
and Type 2 diabetes. In Chapter 4, I will culminate my discussion by providing 
comprehensive conclusions and interpretations of our research and several 
future research directions from the findings from this work that would be of 
interest to gaining deeper understanding of glucose and lipid metabolic 
pathways, for researchers studying this field.    
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CHAPTER 2 
MATERIALS AND METHODS 
Generation of Liver-Specific Ppp1r3b Knockout Mice  
Ppp1r3bflox/flox mice were provided by Merck and were produced for Merck by 
Taconic. Full details of the design of the Ppp1r3bflox/flox mice may be found at 
http://www.taconic.com/10482. Briefly, in the conditional allele, two loxP sites 
were introduced flanking Ppp1r3b exon 2, which contains the entire protein 
coding sequence of the gene (Fig.5A). Ppp1r3b liver specific knockout mice 
(Ppp1r3b∆hep) were generated by crossing Ppp1r3bflox/flox mice on a C57BL/6J 
background with transgenic mice expressing Cre recombinase-expressing under 
the expression of the hepatocyte specific albumin promoter (C57BL/6-Cg-Tg 
(Alb-Cre) 21Mgn/J; Jackson Laboratories). The resultant Ppp1r3bflox/+;Alb-Cre+ 
progeny were crossed with Ppp1r3bflox/flox mice to obtain tissue-specific knockout 
mice (Ppp1r3bflox/flox; Alb-Cre+), termed liver-specific Ppp1r3b knockout mice 
(Ppp1r3b∆hep). Mice without the Cre transgene (Ppp1r3bflox/flox) were used as 
control mice. Genotyping was confirmed for the expression of Cre transgene and 
Ppp1r3bflox/flox alleles prior to the onset of studies. We also developed a liver 
specific knockout of Ppp1r3b utilizing AAV-TBG-Cre approach in Ppp1r3bflox/flox 
mice. Animals were housed under controlled temperature (23°C) and lighting (12-
hour light/dark cycle) with free access to water and standard mouse chow diet 
(LabDiet, 5010), or High Sucrose Diet (66% Sucrose Content, D11725i, 
Research Diets), or High Fat diet (45%kcal fat, D12451i, OpenSource Diets) for 
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upto12 weeks. Data from High fat diet is described in Appendix.  All animal 
experiments were reviewed and approved by Institutional Animal Care and Use 
Committees of the University of Pennsylvania, Philadelphia, USA. 
For 36-hour fasting experiments, indicated mice were initiated on a fasting 
protocol in the morning (8:00AM), which was considered as ad libitum fed state. 
Blood glucose measurements were taken at time points indicated. Mice were 
continued to fast for 36 hours until the second day evening (8:00PM) at which 
point food was returned back to their cages. All Animal experiments were 
reviewed and approved by Institutional Animal Care and Use Committees of the 
University of Pennsylvania, Philadelphia, USA. 
Adeno-Associated (AAV) Viral Vector Preparation  
Adeno-associated viral (AAV) vectors, serotype 8, containing either an empty 
expression cassette (AAV-Null), Cre recombinase (AAV-Cre), or mouse Ppp1r3b 
gene (AAV-Ppp1r3b) were generated by the University of Pennsylvania Vector 
Core (Philadelphia, PA, USA). The transgene is selectively expressed in 
hepatocytes these vectors from the Thyroxine-binding globulin (TBG/Serpina7) 
promoter (Wang et al., 2010). For overexpression experiments utilizing AAV-
Ppp1r3b, C57BL/6J wild type mice were injected with AAV vectors at a dose of 
1x1012 genome copies (GC) via intraperitoneal (i.p.) injection and examined at 
the indicated time points. For experiments utilizing AAV-TBG-Cre, Ppp1r3bflox/flox 
mice were injected with AAV vectors at a dose of 1.5x1011 genome copies (GC) 
via i.p. injection and examined at the stated time points. 
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Western Blotting Analysis  
Tissues were isolated from mice both in fed and fasted conditions at different 
ages and then immediately frozen in liquid nitrogen. Approximated 50mg flash 
frozen liver tissue was used to prepare homogenates in RIPA buffer containing 
50mM Tris-HCl (pH 7.4), 150mM NaCl, 1mM EDTA, 1% Triton-X-100, 1% 
Sodium deoxycholate and 0.1% SDS with 1X protease and phosphatase inhibitor 
cocktail (Cat#: 5872, Cell Signaling Technology) using Tissuelyser (Qiagen, Inc). 
Homogenates were quantified for protein concentrations using the bicinchoninic 
acid assay (BCA) method. Thirty to fifty micrograms of total protein was resolved 
on 4-12% SDS-PAGE gels and subjected to Western Blotting.  Immunoblots 
were performed using the antibodies against the following proteins: 
Homogenates were quantified for protein by the BCA method. GS, Phospho-GS 
(Ser641) (GS, Cat#3886, Phoshpho-GS, Cat#3891; Cell Signaling Technology), 
PP1, GP (PP1,Cat#AB-53315, GP, AB-198268; Abcam) ,GSK3β, Phospho-
GSK3β (Ser9), Akt (pan), Phospho-Akt (Ser473), and Fatty Acid Synthase (FAS), 
(GSK3β,Cat# 12456, Phospho-GSK3β(Ser9), Cat#5558,  Akt (pan), Cat#: 4691, 
Phospho-Akt (Ser473), Cat# 9271, and FAS, Cat# 3180,  all from Cell Signaling 
Technology), and β-actin (SC-81178; Santa Cruz Biotechnology) was used as a 
loading control. All primary antibodies were used at a dilution of 1:1000 for 
westerns. Primary antibodies were detected using secondary IgG labeled with 
Horseradish-peroxidase (HRP), and developed with ECL reagent (Luminata 
Crescendo Western Blot HRP Substrate, Millipore, Inc.) 
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RNA Isolation and Quantitative RT-PCR 
Tissues were isolated from mice and flash-frozen in liquid nitrogen. Total RNA 
was extracted from approximately 50mg flash-frozen liver tissue following 
homogenization in Trizol solution (Invitrogen, Inc.) using a Tissuelyser (Qiagen, 
Inc.), and then isolated according to the manufacturer’s instructions. The quality 
and quantity of the RNA was determined by absorbance at 260/280nm. cDNA 
was synthesized from 2.0-2.5µg total RNA using the High-Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems) according to the manufacturer’s 
protocol. Real-time PCR (qPCR) was performed using SYBR Green Mix (Applied 
Biosystems) on an ABI7900 RT-PCR machine. The relative quantity of each 
mRNA was calculated using the comparative delta CT method with β-actin and 
18S genes used for normalization (77). The sequences for the primer pairs used 
in the studies are listed in Tables 2 and 3.  
Intraperitoneal Glucose, Insulin and Pyruvate Tolerance Tests 
For glucose (GTT) and pyruvate challenge test (PTT), mice were overnight 
fasted for 14-16 hours, and then administered 2g/kg of body weight of dextrose 
(FisherScientific) or sodium pyruvate (Sigma-Aldrich) by intraperitoneal (i.p.) 
injection. Tail blood was used to measure glucose concentrations using a One-
Touch Ultra glucometer (Lifescan, Inc.) at the indicated time points. For insulin 
tolerance test (ITT), mice were fasted for 6 hours before intraperitoneal (i.p.) 
administration of 0.75U/kg body weight of recombinant insulin (Novolin R; Novo 
Novodisk A/S). Tail blood was used to measure glucose concentrations using a 
One-Touch Ultra glucometer (Lifescan, Inc.) at the indicated time points. 
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Metabolic Measurements 
Blood glucose, lactate and ketone bodies were measured using a One-Touch 
Ultra glucometer (Lifescan, Inc.), Lactate Plus lactate meter (Nova Biomedical) 
and Nova Max Plus Ketone meter respectively at indicated nutritional conditions. 
Insulin and leptin assays were conducted on blood collected from mice at 4-hour 
fasting conditions by tail bleed into heparinized micro-hematocrit capillary tubes 
(FisherScientific). Plasma was obtained after centrifugation at 10,000 x g for 
10min at 4°C and measurements were conducted using ELISA kits (Insulin: 
Cat#90080, Leptin: Cat# 90030, Crystal Chem, Inc).  Hepatic triglycerides were 
measured from animals sacrificed by isofluorane inhalation and cervical 
dislocation, flash frozen in liquid nitrogen and stored at -80°C until processed. 
Frozen liver (250mg) were weighed and homogenized in 1xPBS. Liver 
homogenates were diluted (0.2-0.5mg) and then incubated with 1% deoxycholate 
[Deoxycholic acid (Acros Organics, Inc) dissolved in sterile water] and 
triglycerides were measured calorimetrically using Infinity Triglyceride Reagent 
(ThermoScientific). 
Measurement of Tissue Glycogen Levels 
Non-fasting and fasting male mice were sacrificed and tissues were flash frozen 
in liquid nitrogen. Frozen tissue samples (~50µg) were homogenized in 300μL 
PBS. Homogenates were quantified for protein by the BCA method (Thermo 
Scientific). Tissue samples (4µg of total protein for liver and 50ug total protein for 
skeletal muscle) were used for detection of glycogen levels by colorimetric assay 
protocol according to manufacturer’s instructions (Biovision). Glycogen levels in 
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samples were determined from a standard-curve method generated by the 
assay. 
Incorporation of 2-deoxy-D-[3H] glucose into Liver Glycogen 
Incorporation of glucose into glycogen was accessed as described 
previously(37). As a tracer, 2-deoxy-D-[3H] glucose (PerkinElmer) was combined 
with 20% (0.2g/ml) glucose and then administered 2g/kg of body weight at 
1mCi/mouse by intraperitoneal injection into 6hr-fasted mice. Tissues (liver, 
skeletal muscle, and kidney) were harvested and flash frozen in liquid nitrogen at 
30 minutes and 60 minutes after glucose and tracer injection. Plasma glucose 
concentrations were measured at these indicated time points. Frozen tissue 
samples (100mg) were digested in 750uL of 30% KOH at 100°C for 10 minutes. 
Upon digestion, a sample aliquot was used for measurement of protein 
concentration by the BCA method (ThermoScientific). Samples were then 
neutralized with 200uL 20% Na2SO4 and macromolecules were precipitated with 
1mL 100% ethanol overnight at -20°C. Macromolecules were pelleted by 
centrifugation at 10,000 x g for 15minutes and washed twice with 70% ethanol. 
Sample pellets were air-dried and then glycogen was digested by heat and acid 
with 500uL 4N H2SO4 for 10 minutes at 100°C. Pellets were then neutralized with 
an equal volume of 4N NaOH and radioactivity was determined by liquid 
scintillation counting. 2-deoxy-D-3[H] glucose incorporation into glycogen was 
determined by dividing radioactivity of digested samples by glucose specific 
activity in plasma (total radioactivity in plasma) over time course and by sample 
protein content using protein BCA method. 
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Primary Hepatocytes Isolation 
Primary hepatocytes were isolated from ad libitum fed male WT and Ppp1r3b∆hep 
mice by collagenase perfusion, as described previously(78). Briefly, cells were 
suspended in Dulbecco’s modified Eagle’s medium (DMEM, Life technologies, 
Inc.), supplemented with 10% fetal bovine serum, 25mM glucose, and antibiotics 
(2 units/mL penicillin, 2ug/mL streptomycin) and seeded onto collagen-coated 
plates at a cell density of 6x105 cells per well for a standard 6-well plate. After 
attachment (4hours at 37°C), hepatocytes were washed and harvested for 
isolation of protein immune-blotting. 
Gene-expression profiling 
RNA was collected from approximately 50mg flash-frozen liver tissue using Trizol 
solution (Invitrogen, Inc.) following the manufacturer’s protocol. Total liver RNA 
samples (1µg) from mice on high sucrose diet study (12 weeks) were used for 
microarray analysis on the Agilent 4 x 44 Whole Mouse Genome Array. 
Microarray and data analysis were performed by the Penn Functional Genomics 
Core (Philadelphia, PA, USA).  Differential expression was determined using a 
False Discovery Rate of 10% and a minimum fold change of 1.5. 
Plasma Lipid and Lipoprotein Analysis 
For plasma lipid measurements, all mice were fasted for 4 hours prior to 
collection unless stated otherwise.  Retrorbital blood was collected into EDTA-
coated tubes (FisherScientific) from 4-hour fasted mice under isoflurane 
anesthesia at weeks indicated timepoints.  Plasma was separated from red blood 
cells by centrifugation at 10,000 x g for 10min at 4°C. Plasma total cholesterol, 
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HDL cholesterol, triglycerides, phospholipids, free fatty acids (NEFA), and ALTs 
were analyzed on ACE Alfa Wasserman Axcel autoanalyzer using commercially 
available colorimetric assay kits/reagents (TG and TC reagents, Alfa 
Wasserman; HDL cholesterol, Wako; NEFA-HR Kit, Wako; Phospholipid Kit, 
Wako;  ALT, Alfa Wasserman respectively).  Non-HDL cholesterol was calculated 
as the difference between total cholesterol and HDL cholesterol. Additionally, 
mouse plasma samples from each group on diet studies were pooled by 
combining equal amount of plasma from 5-7 animals per pool (total 150μL) for 
fast protein liquid chromatography (FPLC) analysis using two Superose 6 
columns (Amhersham Biosciences, Piscataway, NJ) as previously described 
(79). Each fraction was collected in 500μl and cholesterol concentrations were 
determined using enzymatic assay kit (Wako, Richmond, VA). For estimation of 
the component of the plasma cholesterol present in each lipoprotein fraction, the 
percentages of cholesterol recovered from the column in the fractions forming the 
first peak, the second peak, and the third peak were considered to be VLDL, 
intermediate density lipoprotein (IDL)/LDL, and HDL respectively. 
Distribution of apolipoproteins in lipoprotein classes 
After separating the pooled plasma samples on FPLC, 15μL samples from 
fractions 21-35 were subjected to 4-12% SDS-PAGE.  Mouse ApoA1, ApoE, and 
ApoB (ApoA1, Cat#K23500R, ApoE, Cat#K23100R, ApoB-48/100, 
Cat#K23300R, all from Meridian Life Science, Inc., Memphis, TN) were detected 
by Western blotting as described above. 
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De-Novo Lipogenesis Assay 
Conscious, freely moving mice in the fed state or mice were injected 
intraperitoneally with 400uL per 20g body weight of each mouse with deuterated 
water (D2O) (Sigma-Aldrich). Plasma glucose was measured using glucometer 
(OneTouch Ultra Mini, Lifescan) and blood was collected into heparinized tubes 
before injection and plasma was obtained by centrifugation at 10,000x g for 10 
min at 4°C.  Sixty minutes after the injection, the mice were sacrificed and tissues 
were perfused with 10mL of cold saline before collection. Liver and 
Inguinal/Epididymal fat pads were removed and flash frozen in liquid nitrogen. 
About 100mg of liver, 50mg of fat pads, and 50ul plasma were submitted to Dr. 
John Millar, of Institute of Diabetes, Obesity and Metabolism (IDOM) Metabolic 
Tracer Core at the University of Pennsylvania for analysis of palmitate synthesis 
as previously reported (80). Briefly, palmitate was analyzed as its trimethylsilyl 
derivative using gas chromatography-electron impact ionization mass 
spectrometry. The oven temperature was initially held for 1 min at 150° C, then 
increased by 20° C per min to 310° C and maintained for 8 min. The split ratio 
was 20:1 with helium flow 1 ml per min. The inlet temperature was set at 270° C 
and MS transfer line was set at 310° C. Under these conditions, palmitate elutes 
at ~ 5.7 min. The 2H-enrichment was determined by using selective ion 
monitoring under electron impact ionization of m/z 313 and 314 (M+0 and M+1), 
10 ms dwell time per ion. The concentration of palmitate was determined by 
comparing the corrected abundance of m/z 313 to 314 to that of heptadecanoate 
(17:0, m/z 327). To account for possible differences in the ionization efficiency of 
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each fatty acid, the profile was compared against standards prepared by mixing 
known quantities of each fatty acid. Rate of lipid synthesis was determined as the 
percent contribution of newly made using the equation: % newly made palmitate 
= [total 2H-labeling palmitate / (2H-labeling body water × n)] × 100 where n is the 
number of exchangeable hydrogens, assumed to equal 22. The absolute amount 
of newly made palmitate was determined by multiplying the % percent (%) newly 
made palmitate by the concentration of palmitate.  Values are reported as [µg 
palmitate synthesis/mg tissue] for the data obtained. 
Hepatic VLDL-Triglyceride Secretion 
Hepatic VLDL-triglyceride secretion rate was accessed as described 
previously(81). Mice were fasted for 4 hours and baseline blood was collected 
into heparinized tubes through retro-orbital bleed. Each mouse was administered 
400μL of 1mg/g Pluronic P407 detergent (BASF Chemical Company, Inc.) 
resuspended in PBS  via intraperitoneal (i.p.) injection, to mediate inhibition of 
lipolysis.  Blood samples (100μL) were collected at 1, 2 and 4 hours after 
Pluronic injection. Plasma was obtained after centrifugation at 10,000 x g for 
10min at 4°C. Plasma triglyceride concentration from each time point was 
measured as described previously using by plate assay using the colorimetric 
infinity triglyceride reagent assay kit (Infinity TG reagent, ThermoScientific). 
Tissue Staining 
The liver and adipose tissue sections were prepared from mice at indicated ages 
and fixed in 4% paraformaldehyde overnight. Following paraffin embedding and 
sectioning (5-10μm), tissues were stained with hematoxylin and eosin (H&E).  To 
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detect polysaccharide content in liver, slices of 5-10μm were de-paraffinized, 
oxidized with 0.5% periodic acid for 5 minutes, stained with Schiff reagent for 15 
minutes, and then counterstained with H&E for 15 minutes (82). To access lipid 
droplet formation, frozen sections were also prepared from liver tissues by 
embedding in sucrose and OCT compound (Sakura Finetek), frozen in -80°C, 
and then sectioned into 10µm cryosections. Sections were then fixed in 4% 
formalin and stained with Oil-Red-O solution (Pathology Core Laboratory, 
Research Institute at Children’s Hospital of Philadelphia, Philadelphia, PA, USA). 
Image Manipulation 
All images for the histological sections presented were captured using NIS-
Elements-D Version 4.12.01, in a single session under identical settings with a 
Nikon Digital Sight DS-U3 camera, attached to a Nikon Eclipse 80i microscope, 
using a Plan Fluor 10x objective [0.30 DIC L/N1; 0.17 WD: 16.0]. A 500μm scale 
bar was digitally added using NIS Elements-D. Each set of images was 
incorporated into a single Adobe Photoshop file; the image flattened, and the 
white balance calibrated for the entire field using the lumen of a vein as a 
reference. A 1mm scale bar was superimposed in Adobe Illustrator. 
Statistical Analyses 
All results are presented as mean +S.E. Results were analyzed by the unpaired 
two-tailed Student’s t-test using Microsoft Excel or GraphPad Prism Software 
(Version 7.0, GraphPad Software, Inc.) as appropriate. Statistical significance 
was defined as*p<0.05, **p<0.005, ***p<0.0001. 
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CHAPTER 3 
Hepatic Protein Phosphatase 1 Regulatory Subunit 3B (PPP1R3B) regulates 
liver glycogen and fasting energy homeostasis 
ABSTRACT 
Genetic variants mapping to chromosome 8p23.1 have been associated with 
glycemic traits in humans with genome-wide significance. The closest gene of 
known function, PPP1R3B, (Protein Phosphatase 1 Regulatory Subunit 3B), 
encodes a protein (GL) that is known to regulate glycogen metabolism. I sought 
to test the hypothesis that hepatic PPP1R3B is responsible for the human 
genetic association with glycemic traits. I separately generated mice with liver-
specific deletion (Ppp1r3b∆hep) or liver-specific overexpression of Ppp1r3b. 
Deletion of Ppp1r3b in the liver significantly reduced glycogen synthase protein 
abundance, and the remaining protein was predominantly in a phosphorylated, 
inactive state. As a consequence, the incorporation of glucose into hepatic 
glycogen was significantly impaired, total hepatic glycogen was substantially 
decreased, and the mice had lower fasting plasma glucose than controls. Loss of 
liver glycogen impaired whole body glucose homeostasis, and increased hepatic 
expression of glycolytic enzymes in Ppp1r3b∆hep relative to control livers in the 
postprandial state. Eight hours of fasting significantly increased the expression of 
critical gluconeogenic enzymes, Phosphoenol-pyruvate Carboxykinase (PEPCK), 
and Glucose-6-Phosphatase (G6PC) above the levels in control livers. 
Conversely, liver-specific overexpression of hepatic Ppp1r3b enhanced hepatic 
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glycogen storage above that of controls, and as a result, delayed the onset of 
fasting-induced hypoglycemia. These studies implicate a major role for Ppp1r3b 
in regulating hepatic glycogen stores and glucose/energy homeostasis. 
INTRODUCTION 
The Meta-Analysis of Glucose and Insulin related traits Consortium 
(MAGIC) study analyzed datasets from multiple cohorts that contained both 
genome-wide genotype data as well as quantitative clinical measurements of 
human plasma glycemic traits. Among the twelve loci identified in this study, one 
signal mapping to chromosome 8p23.1 was associated both with fasting plasma 
glucose and fasting plasma insulin levels. The lead variant, rs4841132, most 
strongly associated with fasting plasma glucose mapped to an intergenic region 1 
kilobase (kb) from the 5’ end of LOC157273 gene, a long non-coding RNA 
transcript of unknown function, and 174kb from the protein-coding PPP1R3B 
gene. Despite the 174kb separation from the PPP1R3B gene, rs9987289 has 
been identified as an expression quantitative trait locus (eQTL) for PPP1R3B: the 
minor allele is associated with higher levels of PPP1R3B mRNA in the liver (and 
is also associated with higher fasting glucose and insulin levels). This 
observation prompted us to investigate the possibility that the genetic association 
with glycemic traits identified by these non-coding variants was due to their 
effects on the expression of PPP1R3B.   
PPP1R3B (Protein Phosphatase 1 Regulatory Subunit 3B; also historically 
known as GL) is a regulator of liver glycogen metabolism. In the liver, 
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sequestration of dietary glucose into glycogen is an important and tightly 
regulated component of whole-body glucose homeostasis, promoting 
maintenance of systemic homeostasis in blood glucose levels through glycogen 
storage during the postprandial period and its breakdown during fasting(83), (84), 
(85), (86). Dysregulation of this pathway is associated with metabolic disorders 
including glycogen storage diseases and diabetes. Glycogen synthase (GS) and 
glycogen phosphorylase (GP) promote glycogen synthesis and glycogen 
catabolism respectively, and their activities are tightly controlled by endocrine 
signaling pathways that are in turn coupled to nutritional status. Glycogen-
targeting subunits recruit the phosphatases and kinases that post-translationally 
regulate the activation of GS and inactivation of GP. Several proteins have been 
characterized that target protein phosphatase 1 (PP1) to glycogen (28), (87). In 
liver, two major subunits, PPP1R3B (GL) and PPP1R3C (PTG) are expressed at 
approximately equivalent levels, and together facilitate the storage of hepatic 
glycogen. 
Previous in vitro studies of GL and PTG in cell culture have revealed that 
overexpression increases glycogen content, due to a redistribution of PP1 and 
GS to glycogen particles, and a corresponding increase in GS activity and 
glycogen synthesis(23,32,88). Ppp1r3c knockout mice had reduced hepatic 
glycogen and were glucose intolerant and insulin resistant(37); conversely, 
Ppp1r3c transgenic mice had increased hepatic glycogen and improved glucose 
and insulin sensitivity(89). However, mice genetically modified to lack or 
overexpress Ppp1r3b have not been reported to date. 
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GL is unique among the glycogen targeting subunits, in that in addition to 
promoting the activation of glycogen synthase by PP1 dephosphorylation, GL 
also targets PP1 to glycogen phosphorylase (GP), where the dephosphorylation 
inactivates GP. Thus, under conditions of abundant cellular glucose (as glucose-
6-phosphate), the PP1-GL complex simultaneously activates the glycogen 
synthetic pathway and inactivates glycogen catabolism. Mice in which this GP 
regulatory binding site has been mutated had improved glucose disposal and 
hepatic glycogen storage capacity (36). 
Inspired by the human genetics suggesting that variation in hepatic 
expression of PPP1R3B is an important determinant of glycemic traits, I 
generated mice with liver-specific deletion of Ppp1r3b (Ppp1r3b∆hep) or with 
hepatic overexpression of Ppp1r3b using adeno-associated virus (AAV). Floxed 
Ppp1r3b was inactivated in liver either by a transgenic albumin promoter-driven 
Cre recombinase, or by injecting adeno-associated virus expressing Cre (AAV-
Cre). Despite an almost complete lack of hepatic glycogen, Ppp1r3b∆hep mice are 
viable but are prone to hypoglycemia upon fasting and utilize non-carbohydrate 
precursors to maintain fasted glucose levels. Conversely, liver-specific 
overexpression of Ppp1r3b enhanced hepatic glycogen storage, and as a 
consequence, AAV-Ppp1r3b mice had a delayed decrease in plasma glucose 
upon fasting. These observations are consistent with the fact that natural human 
genetic variants associated with higher liver expression of PPP1R3B have higher 
fasting plasma glucose. 
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RESULTS 
Hepatic Ppp1r3b deficiency leads to depletion of hepatic glycogen stores 
with significant reduction in incorporation of glucose into hepatic 
glycogen.  
To investigate the role of Ppp1r3b in the liver, we generated mice lacking 
this gene exclusively in the liver (see Chapter 2-Materials and Methods, Fig. 
10A). Liver-specific Ppp1r3b knockout mice (Ppp1r3b∆hep) were viable, born at 
the expected frequency for Mendelian inheritance, and showed normal fertility. In 
all subsequent experiments, mice without the Cre transgene (Ppp1r3bflox/flox) were 
used as controls. In Ppp1r3b∆hep mice, transcript levels were negligible in the 
liver, with 97% deletion efficiency observed, and there was no compensatory 
increase in gene expression of other glycogen targeting subunits— GM (Ppp1r3a) 
and PTG (Ppp1r3c) (Fig. 6A). Ppp1r3b∆hep mice showed normal growth rates on 
chow diet, with no differences observed in body weights between genotypes up 
to 50 weeks of age (Fig. 5B).  Hepatic glycogen content was significantly 
reduced in ad libitum fed state in Ppp1r3b∆hep mice, which was rapidly depleted 
upon short term four- hour fasting as measured biochemically (Fig. 6B). Periodic-
acid Schiff (PAS) staining of liver sections showed positive staining for glycogen 
in control hepatocytes as indicated by the purple color under these two 
conditions (Fig. 6C). The weight of the liver of Ppp1r3b∆hep mice was also 
modestly decreased compared to controls (Fig. 5C), likely due to lack of 
glycogen stores, which with their associated water content account for 5% of liver 
mass (85). I used AAV-Cre in Ppp1r3bflox/flox mice as a second approach to 
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generate liver specific knockout of Ppp1r3b, and found comparable effects on 
hepatic glycogen and plasma glucose (Fig. 7) to those in the Alb-Cre mice. Alb-
Cre mice were used for the studies presented here, unless otherwise specified. 
Glycogen content in skeletal muscle presented no substantial differences among 
genotypes under ad libitum fed and four-hour fasted conditions (Fig. 5D). To 
investigate the glycogen synthesis rate in these mice, I performed 2-deoxy-D-
3[H]glucose incorporation into glycogen in glucose-responsive tissues: liver, 
skeletal muscle (gastrocnemius) and kidney, as a measurement of glycogen 
synthase (GS) activity. Radioactivity in the glycogen pellet from tissue lysates 
were measured at 30 and 60 minutes and quantified as percent of glucose 
specific activity of total radioactivity in plasma and of total protein content. In this 
experiment, Ppp1r3b∆hep mice exhibited significantly reduced glycogen synthase 
activity in the liver, while its activity was not different in skeletal muscle or kidney 
(Fig. 6D). Thus, loss of hepatic Ppp1r3b results in a smaller liver with reduced 
GS activity and glycogen content in ad libitum fed and four-hour fasted mice. 
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Figure 5: Generation of Ppp1r3b∆hep mice and other metabolic parameters 
on Chow Diet   
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Figure 5: Generation of Ppp1r3b∆hep mice and other metabolic parameters 
on Chow Diet (A) Ppp1r3b Exon 2 containing the coding sequence (CDS) is 
flanked by floxed sites. Tail DNA was used to genotype mice using PCR 
following manufacturer’s instructions from Qiagen DNA extraction kit –Detection 
of the Cre recombinase (350bp) (upper panel) and the floxed allele (361bp) 
(lower panel).  (B) Body weights of Ppp1r3b∆hep mice compared to WT control 
mice over 50 weeks (n=7-8/genotype). (C) Liver mass as expressed as percent 
of body weight of four-hour fasted Ppp1r3b∆hep mice compared to WT control 
mice (n=10-14/genotype).  (D)Skeletal Muscle (Gastrocnemius) glycogen content 
in ad-libitum fed and four-hour fasted liver lysates from Ppp1r3b∆hep mice 
compared to WT control mice (n=5-7/genotype). Results are replicated in at least 
two independent experiments. The data are expressed as the means + S.E.  
Significance was determined in all panels by unpaired Student’s t-test (*P<0.05, 
**P<0.005, ***P<0.0001). (n.s), not significant.  
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Figure 6: Liver-specific deletion of Ppp1r3b results in depletion of hepatic 
glycogen content 
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Figure 6: Liver-specific deletion of Ppp1r3b results in depletion of hepatic 
glycogen content. (A) Hepatic mRNA levels of Ppp1r3a, Ppp1r3b, and Ppp1r3c 
measured by SYBR-Green RT-qPCR in control and Ppp1r3b∆hep [Alb-Cre] mice 
(n=10-14/genotype). (B) Hepatic glycogen content in ad libitum chow-fed and 
four-hour fasted control and Ppp1r3b∆hep mice (n=6/genotype). (C) PAS staining 
of paraffin-embedded liver sections from ad lib fed, and four-hour fasted 
Ppp1r3b∆hep and control mice shows depletion of glycogen (purple stain). (D) 2-
deoxy-D-[3H] glucose (2-DOG) incorporation into glycogen was measured after 6-
hour of fasting in control and Ppp1r3b∆hep mice (n=3-4/genotype). Label 
incorporation was measured as counts per minute (CPM) from precipitated 
glycogen from tissue lysates and normalized to plasma CPM/mg protein. Results 
were replicated in at least two independent experiments. All mice were adults (2-
8 months) and were age-matched within experiments. The data are expressed as 
the mean + S.E. Significance was determined in all panels by unpaired Student’s 
t-test (*p<0.05, **p<0.005, ***p<0.0001). (n.s), not significant. 
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Figure 7: Ppp1r3b gene deletion obtained in adult Ppp1r3b flox/flox mice by 
utilizing AAV-TBG- Cre-recombinase delivery approach 
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Figure 7: Ppp1r3b gene deletion obtained in adult Ppp1r3b flox/flox mice by 
utilizing AAV-TBG- Cre-recombinase delivery approach. (A) Four-hour fasted 
liver lysates were used for measurement of transcript levels of Ppp1r3b to 
confirm gene deletion from Ppp1r3bflox/flox mice injected with AAV.Null and 
AAV.TBG.Cre (n=4-5/group).  (B) Hepatic glycogen content in four-hour fasted 
liver lysates from mice injected with Ppp1r3bflox/flox mice injected with AAV.Null 
and AAV.TBG.Cre (n=4-5/group (C) Protein expression of total GS liver lysates 
from four-hour fasted Ppp1r3bflox/flox mice injected with AAV.Null and 
AAV.TBG.Cre (n=4-5/group). (D) Blood glucose levels of four-hour fasted 
Ppp1r3bflox/flox mice injected with AAV.Null and AAV.TBG.Cre at baseline, 2, 4, 6 
and 8 weeks after injection (n=5-7/group).  Mice were injected at 10 weeks of age 
and liver lysates were analyzed at 8 weeks post viral delivery.  Results are 
replicated in at least two independent experiments. The data are expressed as 
the means + S.E.  Significance was determined in all panels by unpaired 
Student’s t-test (*P<0.05, **P<0.005, ***P<0.0001). (n.s), not significant.  
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Deletion of Ppp1r3b in the liver causes significant reduction in total 
glycogen synthase protein and activity state.  
Ppp1r3b∆hep mice have significant reduction in glycogen synthase (GS) but 
not glycogen phosphorylase (GP) at the protein level, but no differences at the 
mRNA levels in both the liver and primary hepatocytes (Fig. 8A, 8B, 8C). The 
ratio of GS phosphorylated at Serine position 641 to total GS, which determines 
the activity status of GS, is increased, suggesting that GS is phosphorylated and 
largely inactivated in Ppp1r3b∆hep mice (Fig. 8C). The reduction in GS protein 
likely reflects the lack of glycogen: overnight fasted control mice reached a 
similar depletion of glycogen, and protein levels of GS were similar in control and 
Ppp1r3b∆hep livers after an overnight fast (Fig. 8D). Thus, loss of hepatic Ppp1r3b 
results in a reduced glycogen synthase protein and activity state in the liver, 
consistent with the observation of reduced glucose incorporation of into liver 
glycogen and overall glycogen depletion. 
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Figure 8: Ppp1r3b deficient livers have reduced total GS protein but higher 
relative phospho-GS  
 
 
 
B 
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Figure 8: Ppp1r3b deficient livers have reduced total GS protein but higher 
relative phospho-GS. (A) Four-hour fasted liver lysates were used for 
measurement of transcript levels of Gys2 and Pygl (n=6-9/genotype). (B) Protein 
expression of total GS in primary hepatocytes isolated from ad libitum chow-fed 
control and Ppp1r3b∆hep mice. (C) Protein expression of total GS, P-GS (S641), 
total GP, and PP1 in liver lysates from four-hour fasted control and Ppp1r3b∆hep 
mice. Ratio of total GS to β-actin is decreased and P-GS to total GS is increased 
Ppp1r3b∆hep compared to control mice (n=6/genotype). (D) Liver GS protein 
expression and PAS staining in ad libitum chow-fed and overnight fasted 
Ppp1r3b∆hep mice compared to control mice (n=4-6/genotype). All mice were 
adults (2-8 months) and were age-matched within experiments. Results were 
replicated in at least two independent experiments. The data are expressed as 
the means + S.E. Significance was determined in all panels by unpaired 
Student’s t-test (*p<0.05, **p<0.005, ***p<0.0001). (n.s), not significant. 
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Hepatic loss of Ppp1r3b promotes dysregulated glycogen metabolism and 
is associated with impaired glucose homeostasis and glucose mobilization.  
Postprandial glucose levels in Ppp1r3b∆hep mice are modestly lower and 
Ppp1r3b∆hep mice become mildly hypoglycemic after a four-hour fast (Fig. 9A). 
Within four to eight hours of fasting, blood glucose in Ppp1r3b∆hep mice dropped 
to a significantly lower value than control mice, which reached similarly low blood 
glucose only after longer term fasting (Fig. 9B). I hypothesized that alternative 
metabolites compensate for the lack of hepatic glycogen stores to substitute for 
the maintenance of energy source to peripheral tissues. In the post-prandial 
state, plasma lactate levels were increased in Ppp1r3b∆hep mice compared to 
controls (Fig. 9C). Upon prolonged fasting (12-hour), total plasma ketone bodies 
were significantly increased, and were progressively elevated at 24-hour and 36-
hour fasting periods in Ppp1r3b∆hep mice, compared to controls (Fig. 9D). 
Moreover, after an overnight fast gluconeogenesis was increased in Ppp1r3b∆hep 
mice, as evidenced by a challenge with sodium pyruvate in which these mice 
were more efficiently able to synthesize glucose from an exogenous pyruvate 
load, compared to controls (Fig. 9E). Taken together, these data suggest that 
while the Ppp1r3b∆hep mice are more prone to enter into a quasi-fasted state 
following short-term food deprivation, they are nonetheless able to maintain 
stable long-term fasting plasma glucose levels by compensatory upregulation of 
the gluconeogenic pathway from alternative precursors. 
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Figure 9: Plasma glucose homeostasis is impaired in Ppp1r3b∆hep mice 
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Figure 9: Plasma glucose homeostasis is impaired in Ppp1r3b∆hep mice. (A) 
Blood glucose levels of ad libitum chow-fed, and four-hour fasted mice (n=10-
14/genotype). (B) Blood glucose levels during a 36-hour fasting period in 
Ppp1r3b∆hep mice compared to control mice (n=6/genotype). (C) Blood lactate 
levels in ad libitum chow-fed and in four-hour fasted control and Ppp1r3b∆hep 
mice (n=10-14/genotype). (D) Total ketone bodies in blood measured during ad 
libitum ad fed, 12, 24 and 36-hour fasting conditions in Ppp1r3b∆hep mice 
compared to control mice (n=6-8/genotype). (E) Pyruvate tolerance test (PTT) in 
control and Ppp1r3b∆hep mice (n=6/genotype). PTT was performed in mice by 
administering 2g/kg body weight sodium pyruvate by intraperitoneal injection 
after overnight (14-16hr) fasting. Values are reported as percentage of basal 
glucose levels; area under the curve (AUC) is expressed as arbitrary units. All 
mice were adults (2-8 months) and were age-matched within experiments). 
Results were replicated in at least two independent experiments. The data are 
expressed as the means + S.E. Significance was determined in all panels by 
unpaired Student’s t-test (*p<0.05, **p<0.005, ***p<0.0001). (n.s), not significant. 
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Hepatic deletion of Ppp1r3b causes upregulation of glycolytic genes in the 
postprandial state and upregulation of gluconeogenic genes within 8-hours 
of fasting.  
In the Ppp1r3b-deficient livers, under ad lib fed conditions, genes that 
encode enzymes critical in the glycolytic pathway are upregulated compared to 
control livers (Fig. 10A); these included aldolase (Aldob), triose phosphate 
isomerase (Tpi), glyceraldehyde phosphate dehydrogenase (Gapdh), 
phosphoglycerate kinase (Pgk1), phosphoglycerate mutase (Pgam1), enolase 
(Eno1), and L-pyruvate kinase (Pklr). Upon an 8-hour fasting period, there was 
upregulation of gluconeogenic genes (Pepck and G6pc) in Ppp1r3b∆hep mice (Fig. 
10B), suggesting that de-novo synthesis of glucose is initiated much earlier on in 
these mice compared with controls. Collectively, these data suggest that with 
Ppp1r3b deficiency there is a significant perturbation in nutrient balance which 
favors shunting of glucose into the glycolysis pathway in the fed state, and an 
early upregulation of the gluconeogenic pathway in response to fasting.   
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Figure 10: Ppp1r3b deficient livers undergo rapid switching from glycolysis 
to gluconeogenesis 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Ppp1r3b deficient livers undergo rapid switching from glycolysis 
to gluconeogenesis. (A) Ad libitum chow-fed liver lysates were used for 
measurement of transcript levels of glycolytic and gluconeogenic genes (Gck, 
Gpi1, Pfk1, Aldob, Tpi1, Gapdh, Pgk1, Pgam1, Eno1, Pklr, Pepck, and G6pc 
(n=6-9/genotype). (B) Eight-hour fasted liver lysates were used for measurement 
of transcript levels of the above glycolytic and gluconeogenic genes 
(n=5/genotype). Results were replicated in at least two independent experiments. 
The data are expressed as the means + S.E. Significance was determined in all 
panels by unpaired Student’s t-test (*p<0.05, **p<0.005, ***p<0.0001). (n.s), not 
significant. 
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Overexpression of Ppp1r3b in the liver enhances hepatic glycogen storage.  
We generated a reciprocal mouse model to express Ppp1r3b at higher 
than wild-type levels, combining the tropism of AAV serotype 8 and the liver-
specificity of the TBG/Serpina7 promoter, which has been previously shown to 
promote efficient, specific, and persistent gene expression in the liver(90), to 
overexpress Ppp1r3b in hepatocytes in vivo. Ppp1r3b was approximately 4-fold 
higher compared to control mice receiving a null AAV vector (Fig. 11A). There 
were no compensatory changes in the mRNA expression of other glycogen 
targeting subunits (Ppp1r3a and Ppp1r3c), glycogen synthase (Gys2), or 
glycogen phosphorylase (Pygl), in mice overexpressing Ppp1r3b. Following a 
short term four-hour fasting period, mice overexpressing Ppp1r3b had ~4-fold 
higher levels of hepatic glycogen content than controls, and this was maintained 
at eight hours of fasting (Fig. 11B, 11C). Levels of total GS protein were also 
higher in livers from mice overexpressing Ppp1r3b, and the ratio of phospho-GS 
to total GS protein was decreased, consistent with increased activation status at 
four and eight hour fasting period (Fig. 11D). Blood glucose levels were not 
different between the two groups at ad libitum and 12-hour fasting conditions, 
indicating that despite the larger reservoir of available glycogen, glucose levels 
are maintained, without exceeding the normal physiological range (Fig. 11E). 
Between 24 and 48 hours of fasting, AAV-Ppp1r3b mice maintained persistently 
higher plasma glucose levels than the control group (Fig. 11E). Upon long term 
fasting, AAV-Ppp1r3b were protected from the onset of ketogenesis (Fig. 11F), 
suggesting that the enhanced glycogen storage buffered the onset of the fasting-
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induced metabolic shift to lipolysis. Taken together, these data suggest that 
enhancement of hepatic glycogen reservoir in mice overexpressing Ppp1r3b 
improves the capacity for maintenance of plasma glucose homeostasis and 
minimizes the dependence on other energy substrates under longer term fasting 
conditions. 
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Figure 11: Overexpression of Ppp1r3b in liver enhances hepatic glycogen 
storage and delayed responses to fasting 
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Figure 11: Overexpression of Ppp1r3b in liver enhances hepatic glycogen 
storage and delayed responses to fasting. (A) Four-hour fasted liver lysates 
were used for measurement of transcript levels of Ppp1r3b, Ppp1r3c (PTG), 
Ppp1r3a (GM), Gys2, and Pygl from C57BL/6J mice injected with AAV-Null and 
AAV-Ppp1r3b (n=4/group). (B) Hepatic glycogen content in four-hour and eight-
hour fasted liver lysates from C57BL/6J mice injected with AAV-Null and AAV-
Ppp1r3b (n=3-4/group). (C) PAS staining of paraffin-embedded liver sections 
from four-hour and eight-hour fasted C57BL/6J mice injected with AAV-Null and 
AAV-Ppp1r3b, showing increased amount of glycogen (purple stain) in AAV-
Ppp1r3b overexpressing mice. (D) Protein expression of total GS, P-GS (S641), 
total GP, and PP1 in liver lysates from four-hour fasted from C57BL/6J mice 
injected with AAV-Null and AAV-Ppp1r3b (n=4/group). Ratio of total GS to β-actin 
is increased and P-GS to total GS is decreased in AAV-Ppp1r3b overexpressing 
mice compared to the Null group (n=4/genotype). (E) Blood glucose levels during 
a 36-hour fasting period in C57BL/6J mice injected with AAV-Null and AAV-
Ppp1r3b (n=7-8/group). (F) Total ketone bodies in blood measured during ad 
libitum fed, 12, 24 and 36- hour fasting conditions in C57BL/6J mice injected with 
AAV-Null and AAV-Ppp1r3b (n=7-8/group). Mice were injected at 9 weeks of age 
and liver lysates were analyzed at 11-12 weeks post injection. Results were 
replicated in at least two independent experiments. The data are expressed as 
the means + S.E. Significance was determined in all panels by unpaired 
Student’s t-test (*p<0.05, **p<0.005, ***p<0.0001). (n.s), not significant. 
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Table 2: Chapter 3  
Oligonucleotides used for Gene Expression Analysis by RT-PCR 
Name Gene Symbol Primer Sequence  
GM Ppplr3a 5’-TCTGTCTGATTCTGTGTGTGAGG-3’ 
5’-GAGGTTGGAGTGTCCAGATACA-3’ 
GL Ppp1r3b 5’-AGCCGTACAATGGACCAGAT -3’ 
5’-AGTAGTAGGGCCCCAGCTTT-3’ 
PTG Ppp1r3c 5’-AGGAAGCCAAATCGCAGAGT-3’ 
5’-AAGTTTTAAGCTGGAGGAGATA-3’ 
GYS2 Gys2 5’-CGCTCCTTGTCGGTGACATC-3’ 
5’-CATCGGCTGTCGTTTTGGC-3’ 
Glycogen 
Phosphorylase (GP) 
Pygl 5’-GAGAAGCGACGGCAGATCAG-3’ 
5’-CTTGACCAGAGTGAAGTGCAG-3’ 
Glucokinase Gck 5’-CCCTGAGTGGCTTACAGTTC-3’ 
5’-ACGGATGTGAGTGTTGAAGC-3’ 
Glucose Phosphate 
Isomerase  
Gpi1 
 
5’-TCAAGCTGCGCGAACTTTTTG-3’ 
5’-GGTTCTTGGAGTAGTCCACCAG-3’ 
Liver 
Phosphofructokinase 
Pfk1 5’-GGAGGCGAGAACATCAAGCC-3’ 
5’-CGGCCTTCCCTCGTAGTGA-3’ 
Aldolase-B Aldob 5’-GAAACCGCCTGCAAAGGATAA-3’ 
5’-GAGGGTCTCGTGGAAAAGGAT-3’ 
Triose Phosphate 
Isomerase  
Tpi1 5’-CCAGGAAGTTCTTCGTTGGGG-3’ 
5’-CAAAGTCGATGTAAGCGGTGG-3’ 
Glyceraldehyde-3-
Phosphate 
Dehydrogenase 
Gapdh 5’-AGGTCGGTGTGAACGGATTTG-3’ 
5’-GGGGTCGTTGATGGCAACA-3’ 
Phosphoglycerate 
kinase  
Pgk1 5’-ATGTCGCTTTCCAACAAGCTG-3’ 
5’-GCTCCATTGTCCAAGCAGAAT-3’ 
Phosphoglycerate 
mutase 
Pgam1 5’-TCTGTGCAGAAGAGAGCAATCC-3’ 
5’-CTGTCAGACCGCCATAGTGT-3’ 
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Enolase Eno1 5’-TGCGTCCACTGGCATCTAC-3’ 
5’-CAGAGCAGGCGCAATAGTTTTA-3’ 
Liver Pyruvate 
Kinase (L-PK) 
Pklr 5’-TCAAGGCAGGGATGAACATTG-3’ 
5’-CACGGGTCTGTAGCTGAGTG-3’ 
PEP Carboxykinase 
(PEPCK) 
Pck1 5’-CTGCATAACGGTCTGGACTTC-3’ 
5’-CAGCAACTGCCCGTACTCC-3’ 
Glucose-6-
Phosphatase 
G6pc 5’-CGACTCGCTATCTCCAAGTGA-3’ 
5’-GGGCGTTGTCCAAACAGAAT-3’ 
β-actin Actb 5’-TTGGGTATGGAATCCTGTGG-3’ 
5’-CTTCTGCATCCTGTCAGCAA-3’ 
18S 18s 5’-CTTAGAGGGACAAGTGGCG-3’ 
5’-ACGCTGAGCCAGTCAGTGTA-3’ 
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DISCUSSION 
Variants at chromosomal locus 8p23.1, in an intergenic region 174kb from 
the PPP1R3B gene, have recently been associated with human glycemic traits 
including fasting plasma insulin and glucose in a large-scale meta-analysis of 
genome wide association studies (18). Rs4841132 has two alleles (G or A) in the 
1000 Genomes database (Phase 3), of which the minor A allele has an overall 
frequency of 0.093. The rs4841132 A allele is associated with increases in both 
fasting plasma glucose and insulin (18). Rs4841132 is in high linkage 
disequilibrium with another SNP, rs9987289 (linkage disequilibrium R-squared=1; 
physical distance, 238 base pairs). The minor allele at rs9987289 was associated 
with increased plasma lactate levels in individuals of European ancestry, and this 
effect was found to be strongest in diabetics taking metformin (19). The locus 
was also identified with other plasma lipid traits (total cholesterol, and both high 
and low-density lipoprotein cholesterol (15). Lastly, several subsequent 
independent GWAS studies have associated the locus with plasma lactate levels 
(19), and with hepatic steatosis (16), (20).  
The centrality of the liver in the maintenance of whole-body glucose 
homeostasis has been well established, and glycogen metabolism is in turn a 
critical mediator of this function, serving as a source of glucose that can be 
rapidly mobilized to buffer falling plasma glucose levels, and conversely, as a 
reservoir to capture excess glucose. Glycogen Synthase (GS) is a rate-limiting 
glycogen synthetic enzyme that is allosterically regulated by glucose-6-
phosphate (G6P). Binding of G6P induces a conformational shift that promotes 
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binding of protein phosphatases that dephosphorylate and activate GS(86), (91). 
Phosphorylation at serine at position 641 (S641) inactivates GS: PPP1R3B 
promotes dephosphorylation of GS at S641 by juxtaposing Protein phosphatase 
1 (PP1) to GS reversing the inactivation. To elucidate the role of Ppp1r3b in vivo, 
we generated liver-specific knockout mice, and investigated hepatic glycogen 
metabolism and whole-body glucose homeostasis. Liver-specific genetic ablation 
of Ppp1r3b gene yielded viable mice in which liver glycogen storage and 
glycogen synthase activity were severely impaired. Despite the absence of 
Ppp1r3b, there were no compensatory changes in liver mRNA expression of 
Ppp1r3a and Ppp1r3c, and muscle glycogen content and incorporation of plasma 
glucose into muscle glycogen were unaffected. It has been previously suggested 
that liver glycogen is essential for neonatal survival until gluconeogenesis is fully 
established in the newborn liver (92). The Alb-Cre has been shown to drive 
incomplete deletion at birth, with progressively complete ablation over the first six 
weeks of life(93), (94), which is presumably what permitted the survival of the 
Ppp1r3b∆hep pups. The residual signal in livers from Ppp1r3b∆hep mice in 
biochemical assays and histological stains for glycogen, likely is due to the 
combination of the presence of rare hepatocytes that escaped Cre-deletion of 
Ppp1r3b, as well as simple glucose polymers in hepatocytes throughout the 
lobule. 
I sought to study the importance of Ppp1r3b in regulation of systemic 
plasma glucose homeostasis. In many regards, the Ppp1r3b∆hep phenotype 
resembles that of mice with liver specific knockout of glycogen synthase (95) and 
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patients with liver specific glycogen storage disease 0 (GSD0) due to mutation of 
the GYS2 gene (96) (97). All three cases are characterized by fasting 
hypoglycemia, with elevated lactate in postprandial state. Interestingly, while no 
mutations in PPP1R3B have been reported in GSD0 patients to date, our 
findings suggest that human genetic deficiency of PPP1R3B would likely 
manifest with GSD0. Ad libitum fed Ppp1r3b∆hep mice have modestly reduced 
blood glucose levels, compared with controls. In euglycemia, glucose in the liver 
can be either stored as glycogen or converted to pyruvate and lactate by 
glycolysis. In Ppp1r3b∆hep mice, synthesis of glycogen is blocked, and this is 
associated with a reduced ability to dispose of glucose after feeding. Under these 
conditions, increased lactate in postprandial state is consistent with an increase 
in glucose flux through glycolysis. Since the expression of Ppp1r3b is restricted 
mainly to liver in adult mice, the contribution of plasma lactate should presumably 
be derived mainly from the liver. The fact that human PPP1R3B is also 
expressed in skeletal muscle (24), may explain the lack of observed PPP1R3B 
GSD0 patients: the combination of deficiency in both liver and muscle may be 
incompatible with life. 
In the fasted state, when plasma glucose levels are lower, the Ppp1r3b∆hep 
mice are incapable of liver glycogenolysis and they rely on gluconeogenesis. My 
understanding, based on the metabolic status of Ppp1r3b∆hep mice, is that even 
when fed, they are already conditioned toward fasting physiology, which they 
attain more rapidly than control animals. Blood glucose, decreases more rapidly 
upon fasting, but is nonetheless maintained through increased gluconeogenesis, 
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as evidenced by a greater and earlier upregulation of key gluconeogenic 
enzymes. Further supporting this interpretation, our results from the pyruvate 
tolerance test also show that Ppp1r3b∆hep mice depend on utilization of pyruvate 
as one of the non-carbohydrate precursors to maintain plasma glucose levels. 
Decreased levels of plasma lactate by four hours of fasting suggest that liver 
begins to utilize non-carbohydrate precursors at an earlier onset of fasting in 
these mice. By 12 hours of fasting, blood ketone bodies produced by the liver are 
already elevated and are sustained compared with control animals. 
In reciprocal experiments to determine the effects of activating the 
glycogen synthesis pathway, I overexpressed mouse Ppp1r3b in liver in WT 
mice. Many of the phenotypes we observe in the overexpressing mice are 
reciprocal to mice lacking hepatic expression of the Ppp1r3b gene. Both the 
protein abundance and activation state of GS were increased, mirroring the 
effects of the Ppp1r3b∆hep. With respect to blood glucose, there were no 
significant differences between AAV-Ppp1r3b mice and controls under fed and 
short-term fasted conditions, but the overexpressing mice were resistant to 
reduced plasma glucose upon 36 hours of fasting. Reflecting this, the rise in 
plasma total ketone bodies was significantly delayed in AAV-Ppp1r3b mice, 
suggesting that the requirement for the liver to shift to utilization of fat and protein 
for fuel sources was obviated by the larger glycogen reservoir. 
Hepatic overexpression of another glycogen targeting protein, PTG, 
impaired activation of glycogenolysis by forskolin and glucagon, resulting in a 
failure to mobilize glycogen stores even during longer term fasting (98). In 
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contrast, mice overexpressing hepatic Ppp1r3b remained responsive to various 
nutritional states, and have increased capacity for maintenance of plasma 
glucose under long term fasting conditions, perhaps because GL is allosterically 
regulated by binding to Glycogen Phosphorylase α (99), rather than by post-
translational modification. Moreover, mice expressing a Ppp1r3b transgene with 
a mutated allosteric binding site for glycogen phosphorylase α, had improved 
hepatic glycogen synthesis capacity under fed conditions, but impaired 
glycogenolysis led to hypoglycemia and weight loss upon longer term (36hr) 
fasting (36). Further mechanistic studies will be required to specifically test the 
hypothesis that increasing hepatic Ppp1r3b might provide the benefit of improved 
glucose disposal, without inappropriate sequestration of glycogen during fasting. 
In summary, when combined with the human genetics pointing to the 
PPP1R3B locus as compellingly associated with glycemic traits in humans, our 
studies in mice genetically deficient in or overexpressing hepatic Ppp1r3b 
indicate the central role of this protein in regulating hepatic glycogen stores and 
energy homeostasis in the fasting state. 
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CHAPTER 4 
Carbohydrate overload induces hepatic steatosis, insulin resistance, and 
plasma dyslipidemia in Ppp1r3bΔhep mice 
ABSTRACT 
Nonalcoholic fatty liver disease (NAFLD) is a common co-morbidity in patients 
with Type 2 diabetes and obesity caused by hepatic neutral lipid accumulation 
(steatosis). If not addressed, relatively benign steatosis can progress to 
nonalcoholic steatohepatitis, fibrosis/cirrhosis, and hepatocellular carcinoma in 
the absence of excessive alcohol consumption. Increased incidence of NAFLD 
due to the epidemic rise in obesity is an emerging world-wide health problem. 
Development of NAFLD is highly influenced by genetic variations, and certain 
ethnic populations, such as individuals of Hispanic origin are at higher risk. 
Recent GWAS have identified several genetic variants associated with hepatic 
steatosis and NAFLD in these populations, and of these genetic loci, PPP1R3B 
(Protein Phosphatase 1 Regulatory Subunit 3B), which encodes a protein GL; 
was identified to be associated with hepatic steatosis and plasma lipids (HDL-C, 
LDL-C, and total cholesterol). We sought to test the hypothesis that PPP1R3B, 
known to regulate glycogen metabolism, is the causal gene also underlying the 
human genetic association with accretion of hepatic fat and plasma lipids. We 
used gain and loss of function mice and demonstrated that under chronic high 
sucrose diet feeding, liver-specific Ppp1r3b knockout mice (Ppp1r3b∆hep mice) 
had increased hepatic triglycerides, developed systemic insulin resistance, and 
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had selective plasma dyslipidemia characteristic of metabolic syndrome. 
Conversely, liver-specific overexpression of Ppp1r3b was protective against 
these phenotypes irrespective of diet. These studies implicate Ppp1r3b in diet-
induced hepatic steatosis, dyslipidemia, and metabolic syndrome.  
INTRODUCTION 
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of chronic liver 
diseases associated with excess hepatic fat deposition, independent of alcohol 
consumption.  NAFLD is the most frequent form of chronic liver disease which is 
also commonly linked to other metabolic diseases such as obesity and Type 2 
diabetes mellitus (T2DM).   In patients with T2DM, the prevalence of NAFLD is  
approximately 75% (70). The escalating prevalence of obesity and T2DM in the 
United States and worldwide has led to the emergence of NAFLD as a major 
health problem (69). Furthermore, recent evidence suggests that NAFLD is an 
independent risk factor exacerbating other chronic diseases, including 
cardiovascular disease (CVD), coronary artery disease, and chronic kidney 
disease (CKD) (70,72,100,101). Patients with NAFLD have increased carotid-
intima media thickness (CIMT), a characteristic of atherosclerosis and an 
important predictor of myocardial infarction (102).  In United States alone, the 
prevalence of NAFLD is estimated to be 30%, with higher incidence reported in 
certain high-risk ethnic populations, including Hispanics with (34-58%), than 
European Americans (28-45%), and African Americans (19-35%) (103). 
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The clinical presentation of NAFLD ranges from benign, simple hepatic 
neutral lipid accumulation (steatosis) to non-alcoholic steatohepatitis (NASH) that 
is characterized by presence of inflammation in addition to hepatic fat deposition. 
A subset of patients with NASH can subsequently develop fibrosis, which is 
characterized by increase in collagen fiber accumulation within liver, and could 
lead to cirrhosis, which causes scarring of the tissue. A very small percentage of 
patients can also develop hepatocellular carcinoma (HCC)(73).  It is now 
accepted that the development of hepatic steatosis and NASH is a result of 
multiple factors that promote injury to the liver, leading to differences in range of 
progression of the disease observed in patients (104). This theory is called the 
“multiple-hit hypothesis”, which predicts that the liver undergoes multiple insults 
from combination of perturbations in several processes, such as development of 
insulin resistance, leading to free fatty acid overflow which can result in ER stress 
and mitochondrial dysfunction and activation of inflammatory responses, and 
genetic factors that may account for the variations in NAFLD progression. 
Hepatic steatosis occurs due to an imbalance in lipid homeostasis in the 
liver. Neutral lipid accumulation develops when de novo synthesis of lipids is 
excessive and when an increase in free fatty acid (FFA) synthesis and deposition 
in the liver exceeds its utilization by mitochondrial β-oxidation and secretion into 
the circulation as VLDL-triglycerides. The mechanisms underlying the association 
between NAFLD progression and insulin resistance that coincide prior to onset of 
diabetes are not fully understood. Studies have shown that NAFLD is a predictor 
of the incidence of Type 2 diabetes independently of the traditional risk factors 
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such as obesity and peripheral insulin resistance (105), and uncontrolled 
diabetes can also promote worsening of hepatic steatosis, thus fueling a 
reoccurring pathological cycle that closely links the two conditions together. 
Ectopic lipid accumulation in insulin responsive tissues including adipose 
tissue, liver, and skeletal muscle, can result from direct impairment in insulin 
signaling (insulin resistance).  More specifically, an impairment in insulin-
mediated suppression of lipolysis in adipocytes, promotes increased hydrolysis of 
adipocyte TG stores, releasing free fatty acids, resulting in recruitment of pro-
inflammatory macrophages into adipocytes, and leads to increased secretion of 
adipocytokines including IL-6, MCP-1, and TNFα (106).  Recruitment of these 
pro-inflammatory macrophages is likely a result of increased concentrations of 
fatty acids driving adipocytokine induction, as previously shown by studies in 
which elevation in TNFα was detected upon stimulation with saturated free fatty 
acids, such as palmitate (107).    Combination of elevation in these pro-
inflammatory markers and increase in plasma FFA pool, lead to lipid 
accumulation in the liver, exacerbated by increased uptake of FFA in the NAFLD 
state. In patients with NAFLD, the majority of hepatic fat can be accounted from 
the plasma FFA pool (~60%); and the remainder comes from DNL (~30%) which 
is increased in NAFLD due to underlying insulin resistant state as shown through 
stable isotope studies (74).  Additionally, accumulation of intramyocellular lipids 
(IMCL) in skeletal muscle, can further impair glucose uptake in the muscle, 
contributing to systemic glucose intolerance(75).  The combination of defective 
insulin signaling in these metabolically-response tissues, and a compensatory 
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hyperinsulinemia driven by pancreatic β-cells, can lead to insulin resistance that 
both promotes increased delivery of FFA to liver, and the activation of the 
transcription factors SREBP1 and ChREBP, which promote de novo lipogenesis 
(DNL). This combination leads to the buildup of triacylglycerols (TG) in the liver 
from both internal and external sources. 
The causal association between the development of hepatic steatosis and 
insulin resistance is unclear. Numerous studies in humans and animals have 
shown that hepatic steatosis is associated with the onset of insulin resistance; 
however the two events are not dependent on each other. Mice challenged with a 
high-fat diet (HFD) develop severe insulin resistance and hepatic steatosis (67) 
(108,109). Mouse models with altered hepatic lipid storage (110,111), 
mobilization (112,113) and oxidation (114), present with significantly increased 
hepatic lipid accumulation without accompanying insulin resistance.   Conversely, 
defects in hepatic insulin signaling are sufficient to induce hepatic steatosis 
(115).  This dissociation between the two incidents has been a topic of 
comprehensive research over the past several years. 
There is growing evidence that genetic factors play a key role in the 
development of NAFLD.  Recent unbiased large scale genome-wide association 
studies (GWAS) have identified novel genetic variants associated with NAFLD. 
(16,17,103,116).  Single nucleotide polymorphisms (SNPs) (rs9987289, 
rs4240624, rs4841132, and rs6984305) were identified near the gene PPP1R3B, 
and were linked to hepatic steatosis in various populations including European 
and Hispanic Americans (16,17,20,103).  The SNPs near the PPP1R3B spanned 
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a non-coding region approximately 174kilobases from the gene, and were also 
associated with serum lipids including HDL, and LDL cholesterol levels and 
fasting glucose and plasma lactate (15,17,19). These variants also linked 
PPP1R3B with alkaline phosphatase (ALP), one of the key liver enzymes 
typically measured as a marker of liver injury (21).  And importantly, PPP1R3B 
was identified as an expression quantitative trait locus (eQTL) for these variants 
(17): the SNPs correlated with the expression level of PPP1R3B, suggesting its 
causality to the phenotypes that are observed in these populations. Taken 
together, these unbiased genetic studies identified PPP1R3B as a novel genetic 
locus associated with pleiotropic effects on metabolic traits in addition to its role 
in hepatic glycogen metabolism. 
Extensive literature provide evidence that hepatic glycogen synthesis itself 
is regulated by insulin, and in insulin resistant states, a major portion of the 
resistance stems from impaired ability of insulin to activate Glycogen Synthase 
(GS)(117-119).  Insulin indirectly activates GS through both allosteric and 
dephosphorylation mechanisms. Allosteric activation is primarily mediated by rise 
in glucose-6-phoshphate (G6P) levels.  In skeletal muscle, insulin raises 
intracellular G6P levels mainly by promoting translocation of GLUT4 transporter 
to the sarcolemma to increase glucose import and conversion to G6P. In the 
liver, glucose transport is not regulated by insulin and remains unrestricted, 
equivalent to free diffusion (120,121). Instead, insulin raises G6P levels in the 
liver by promoting increased transcription of glucokinase (GCK), which mediates 
phosphorylation of incoming glucose to G6P, a biologically favorable metabolite 
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used for fuel synthesis that can no longer diffuse out of the cell (120).  
Conversely, it decreases transcription of glucose -6-phosphatase (G6PC), which 
mediates the opposite dephosphorylation step to allow glucose to leave the 
hepatocytes.  Insulin activation of GS through dephosphorylation proceeds 
through the inhibition of glycogen synthase kinase-3 (GSK3) through the 
canonical insulin signaling pathway: insulin receptor phosphorylation and 
activation leads to recruitment of Insulin receptor substrate 1/2, resulting in 
phosphatidylinositol-3’ kinase (PI3K)-dependent phosphorylation and activation 
of protein kinase B (PKB/Akt) (i.e.p-AKT). AKT inhibits phosphorylation and 
activation of glycogen synthase kinase-3 (GSK-3), which relieves the repression 
of GS activation mediated by GSK3-mediated phosphorylation (122). Moreover, 
insulin simultaneously promotes dephosphorylation and activation of GS by 
targeting protein phosphatase-1 (PP1) to GS, mediated through important 
adaptor proteins (PTG, GL, GM, RGL or R6) that bind GS and PP1 (28,43,88). 
In Chapter 2, we had shown that GL (PPP1R3B) plays a critical role in 
regulation of the glycogen synthesis pathway, by promoting dephosphorylation 
and activation of GS through recruitment of PP1 to Glycogen synthase enzyme 
and glycogen storage in the liver, and in the absence of this protein in the liver, 
hepatic glycogen metabolism was severely deregulated in mice with 
consequences in long-term  energy homeostasis, including utilization of non-
carbohydrate fuel sources, such as lactate, pyruvate and NEFAs to maintain 
sustained vitality. 
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This chapter focuses on the functional role of PPP1R3B in hepatic lipid 
metabolism.  Since PPP1R3B is associated with hepatic steatosis in humans, we 
wanted to test this phenotype, using the loss of function and gain of function 
mouse models for Ppp1r3b that we generated.   
We tested the following major pathways involved in progression of NAFLD to 
determine whether Ppp1r3b expression in the liver regulates hepatic lipid 
accumulation: 
 1) Are there changes in de novo lipogenesis/DNL?  
 2) Are there changes in plasma free fatty acid levels?  
  3) Are there changes in mitochondrial fatty acid beta oxidation pathway in 
liver, leading to decreased utilization of fat for energy production?  
 4) Are there changes in VLDL-triglyceride secretion by the liver, and 
 5) Does alteration in hepatic Ppp1r3b expression promote insulin 
resistance through a) alterations in hepatic insulin signaling? b) Are there 
changes in systemic glucose disposal  
 6) And if insulin resistance exists, does modulation of Ppp1r3b gene in 
mouse liver affect plasma lipids? 
We hypothesized that in the absence of liver Ppp1r3b expression, there 
would be increased fatty acid synthesis as carbons from glucose would be 
shunted towards DNL, as a consequence of diminished hepatic glycogen 
storage, leading to hepatic steatosis and promoting insulin resistance.  As a 
result of dysregulated fatty acid metabolism, the plasma lipids in these mice 
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would also be altered.  In the overexpression of Ppp1r3b, we hypothesized that 
these phenotypes would be attenuated.  
For these studies, we first used standard chow diet that contains less than 
5% sucrose content, but then subsequently shifted to mice that were challenged 
with high sucrose diet (HSD) that contains 66% sucrose content. We reasoned 
that since PPP1R3B is a regulator of glycogen and glucose metabolism that 
excess dietary carbohydrate would elicit a more pronounced effect on 
phenotypes that would highlight the importance of the association of PPP1R3B 
with hepatic steatosis and other metabolic traits that were observed in prior 
human GWAS. 
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RESULTS 
Hepatic Ppp1r3b deletion in mice leads to modest elevation in plasma 
cholesterol, and fasting non-esterified free fatty acids, with a delayed 
impairment in systemic glucose disposal capacity upon chow diet feeding.  
Since Ppp1r3b∆hep mice have reduced glycogen synthesis and this genetic 
locus was also implicated to impact hepatic fat and plasma lipids from human 
GWAS, we wanted to further study the effect of Ppp1r3b deletion on baseline 
metabolic parameters in standard chow diet fed mice. After a short-term four 
hour fast, plasma lipids including total cholesterol, HDL-cholesterol, and 
phospholipids were modestly increased by approximately 28%, ~38%, and 25% 
respectively, but no effect on plasma triglycerides and non-HDL-cholesterol was 
observed in Ppp1r3b∆hep mice (Fig. 12A). Additionally, plasma free fatty acids 
were also significantly increased by 38% in Ppp1r3b∆hep mice (Fig. 12B).  
Overnight fasting (14-16hr) blood glucose was not different from the control 
group (Fig. 12C); however the rate of clearance of injected glucose in the 
glucose tolerance test (GTT) was modestly impaired in overnight fasted mice 
(Fig. 12D).  These data indicate that deletion of Ppp1r3b in liver promotes 
selective impairment in plasma lipids and systemic glucose homeostasis that 
were specifically associated with this locus in human GWAS. 
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Figure 12: Liver Ppp1r3b deletion promotes elevation in plasma lipids 
(cholesterol, HDL-C and phospholipids) and modest impairment in 
systemic glucose disposal capacity on standard chow diet 
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 Figure 12: Liver Ppp1r3b deletion promotes elevation in plasma lipids 
(cholesterol, HDL-C and phospholipids) and modest impairment in 
systemic glucose disposal capacity on standard chow diet (A) Plasma lipids 
(including plasma total cholesterol, HDL-cholesterol, non-HDL-cholesterol, 
triglycerides, and phospholipids) were measured in four-hour fasted plasma 
collected from control and Ppp1r3b∆hep mice on standard chow diet (n=7-
9/genotype). (B) Non-esterified free fatty acids (NEFA) were measured in four-
hour fasted plasma collected from control and Ppp1r3b∆hep mice on standard 
chow diet (n=10-12/genotype). (C) Overnight fasted plasma glucose levels were 
measured from control and Ppp1r3b∆hep mice (n=10-14/genotype). (D) Glucose 
disposal capacity is measured by glucose tolerance test (GTT) in overnight 
fasted 4-month old control and Ppp1r3b∆hep mice on standard chow diet (n=6-
8/genotype). Values are reported as glucose levels and area under the curve 
(AUC) is expressed as arbitrary units.  All mice were adults (2-8 months) and 
were age-matched within experiments. The data are expressed as the mean + 
S.E. Significance was determined in all panels by unpaired Student’s t-test 
(*p<0.05, **p<0.005, ***p<0.0001). (n.s), not significant. 
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Hepatic Ppp1r3b deletion in mice promotes elevation in hepatic 
triglycerides with increased expression of lipogenic genes under ad libitum 
chow-fed state.  
Ppp1r3b∆hep mice had significantly reduced hepatic glycogen content 
associated with reduced GS activity under standard chow diet and a modest 
elevation in liver triglycerides under ad libitum chow-fed state, in Ppp1r3b∆hep 
mice compared to the control group (Fig. 13A). To investigate the pathways that 
promote hepatic fat accumulation in this mouse model, we first examined the 
lipogenic pathway, which primarily converts into acetyl-coA units into newly 
synthesized fatty acids  and triglycerides (50) (123). In the fed state, Ppp1r3b∆hep 
mice had increased expression of the lipogenic genes, including, Acetyl-CoA-
carboxylase alpha (Acaca), Fatty acid synthase (Fasn), Stearoyl-CoA desaturase 
(Scd1), and Fatty acid elongase 6 (Elovl6) suggesting that de novo lipogenesis 
(DNL) could likely be one of the pathways that is upregulated in these mice, as a 
consequence of reduced hepatic glycogenosis (Fig. 13B).   
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Figure 13: Ppp1r3b deletion in liver promotes TG accumulation and 
upregulation of lipogenic genes in ad libitum chow-fed state 
Figure 13: Ppp1r3b deletion in liver promotes TG accumulation and 
upregulation of lipogenic genes in ad libitum chow-fed state (A) Liver 
triglyceride content in ad libitum chow-fed control and Ppp1r3b∆hep mice (n=6-
8/genotype). (B) Total RNA extracted from liver was used for measurement of 
transcript levels of key lipogenic genes in the lipogenic pathway: Acaca, Fasn, 
Scd1, and Elovl6 (n=6-8/genotype).  All mice were adults (2-8 months) and were 
age-matched within experiments. The data are expressed as the mean + S.E. 
Significance was determined in all panels by unpaired Student’s t-test (*p<0.05, 
**p<0.005, ***p<0.0001). (n.s), not significant. 
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Hepatic Ppp1r3b deletion in mice promotes increased liver triglyceride 
accumulation under chronic high-sucrose diet 
Based on the progressive hepatic TG phenotype in chow fed mice, I 
decided use a dietary stress (carbohydrate overload) to exacerbate the 
phenotype for mechanistic investigation. I challenged Ppp1r3b∆hep mice on a 12-
week high sucrose (66%) diet to elicit the metabolic phenotypes that were 
modestly affected on chow diet. Even under high sucrose diet feeding conditions, 
Ppp1r3b∆hep mice were not able to synthesize and store liver glycogen, and had 
diminished activation of glycogen synthase (GS) (Fig. 14A, 14B).  The liver 
triglyceride content was significantly increased in Ppp1r3b∆hep mice compared to 
the control group.  Histological analyses of liver sections via H&E staining to 
characterize gross morphology of hepatocytes and Oil-Red-O to stain neutral 
lipids revealed a visible elevation of microvesicular type lipid droplets in 
hepatocytes from Ppp1r3b∆hep mice compared to the control group (Fig. 14C, 
14D), suggesting that hepatic triglyceride deposition was pronounced under 
chronic high sucrose diet feeding. 
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Figure 14: Liver-specific deletion of Ppp1r3b promotes sustained reduction 
in liver glycogen stores, with increased liver triglycerides upon chronic 12 
weeks of high sucrose diet 
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Figure 14: Liver-specific deletion of Ppp1r3b promotes sustained reduction 
in liver glycogen stores, with increased liver triglycerides upon chronic 12 
weeks of high sucrose diet (A) Liver glycogen content in four-hour fasted 
control and Ppp1r3b∆hep mice at 12 weeks on sucrose diet (n=5-7/genotype). 
(ND) Not detectable. (B) Protein expression and densitometry analysis of total 
GS, and P-GS (S641) in liver lysates from four-hour fasted control and 
Ppp1r3b∆hep mice at 12 weeks on sucrose diet(n=5-7/genotype). (C) Liver 
triglyceride content  in four-hour fasted control and Ppp1r3b∆hep mice at 12 weeks 
on sucrose diet (n=5-7/genotype). (D) H&E and Oil-Red-O staining of liver 
sections from four-hour fasted control and Ppp1r3b∆hep mice at 12 weeks on 
sucrose diet shows increased hepatic TG content (n=5-7/genotype).  Four-hour 
fasted livers from control and Ppp1r3b∆hep mice at 12 weeks on sucrose diet were 
used for these analyses. All mice were adults (2-8 months) and were age-
matched within experiments. The data are expressed as the mean + S.E. 
Significance was determined in all panels by unpaired Student’s t-test (*p<0.05, 
**p<0.005, ***p<0.0001). (n.s), not significant. 
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Overexpression of Ppp1r3b in liver ameliorates hepatic glycogen storage 
and reverses TG accumulation despite chronic sucrose diet feeding. 
I generated a reciprocal Ppp1r3b overexpression mouse model to express 
Ppp1r3b using Adeno Associated Virus (AAV). Briefly, there was increased 
hepatic glycogen synthesis in mice overexpressing hepatic Ppp1r3b, thus 
augmenting total hepatic glycogen storage, buffering the plasma glucose levels 
under long-term fasting. I further characterized the effect on hepatic triglycerides 
in these mice, challenging them with chronic high sucrose diet feeding for 12 
weeks and characterizing the effects on plasma and hepatic lipid metabolism.  
Under chronic high sucrose diet feeding, mice overexpressing Ppp1r3b 
(AAV.Ppp1r3b) had increased activation of glycogen synthase and improved 
glycogen synthesis (Fig.15A, 15B).   Reciprocally, there was a significant decline 
in liver triglyceride content in mice overexpressing Ppp1r3b compared to the null 
control group (AAV-Null), suggesting that the shift in energy equivalents into 
glycogen storage greatly diminishes hepatic lipid accumulation (Fig. 15C, 15D). 
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Figure 15:  Mice overexpressing Ppp1r3b have improved glycogen storage 
and reduced triglyceride accumulation in the liver despite chronic HSD 
feeding 
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Figure 15: Mice overexpressing Ppp1r3b have improved glycogen storage 
and reduced triglyceride accumulation in the liver despite chronic HSD 
feeding (A) Liver glycogen content in four-hour fasted AAV-Null and AAV-
Ppp1r3b mice at 12 weeks on sucrose diet (n=8/group). (B) Protein expression 
and densitometry analysis of total GS, and P-GS (S641) in liver lysates from four-
hour fasted AAV-Null and AAV-Ppp1r3b mice at 12 weeks on sucrose diet 
(n=5/group). (C) Liver triglyceride content in four-hour fasted AAV-Null and AAV-
Ppp1r3b mice at 12 weeks on sucrose diet (n=8/group). (D) Oil-Red-O staining of 
liver sections from four-hour fasted AAV-Null and AAV-Ppp1r3b mice at 12 
weeks on sucrose diet shows decreased lipid droplet formation (n=3-4/group). 
Mice were injected with AAV at 12 weeks of age and were subjected to sucrose 
diet and tissue lysates were analyzed at 12 weeks post injection and diet. The 
data are expressed as the mean + S.E. Significance was determined in all panels 
by unpaired Student’s t-test (*p<0.05, **p<0.005, ***p<0.0001). (n.s), not 
significant. 
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Hepatic Ppp1r3b deletion in mice promotes increased expression of de 
novo lipogenic genes, however does not affect de novo lipogenesis in the 
liver under short-term high sucrose diet for 4 weeks.  
I wanted to ask how the deficiency in hepatic Ppp1r3b leads to metabolic 
perturbations under chronic sucrose diet feeding.  I first focused on the de novo 
lipogenesis (DNL) pathway, which was previously shown to be upregulated at 
transcription level of key lipogenic genes in Ppp1r3b∆hep mice on standard chow 
diet.  At 12 weeks of high sucrose diet, although the mRNA levels of lipogenic 
transcription factors Srebp1 and ChREBP did not change, their target lipogenic 
genes were upregulated, including, Acaca, Fasn, Scd1, and Elovl6 in 
Ppp1r3b∆hep mice compared to the control group, similar to the effect seen on 
chow diet (Fig. 16A, 16B). Supporting the elevation of Fasn mRNA levels, there 
was also  upregulation of Fatty acid synthase (FAS) protein by almost 2.5 fold 
(Fig. 16C), suggesting that there may be an increase in fatty acid synthesis in 
Ppp1r3b∆hep mice compared to the control group. Interestingly, however, upon 4 
weeks of high sucrose diet feeding, when we directly measured de novo 
lipogenesis using stable isotope method (with deuterated water) under both ad 
libitum and overnight fasting-refeeding conditions, we did not see an effect on de 
novo lipogenesis and the corresponding TG levels in Ppp1r3b∆hep mice compared 
to the control group, suggesting that chronic sucrose feeding likely potentiates 
the lipogenic capacity in Ppp1r3b∆hep mice, while this pathway is not altered 
under shorter period of carbohydrate feeding (Fig. 16D, 16E).  
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Figure 16: Liver deletion of Ppp1r3b promotes increased expression of 
lipogenic genes under chronic 12-week sucrose diet feeding 
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Figure 16: Liver deletion of Ppp1r3b promotes increased expression of 
lipogenic genes under chronic 12-week sucrose diet feeding (A) Hepatic 
transcript levels of Srebp1, and ChREBP, and (B) their target genes in the 
lipogenic pathway: Acaca, Fasn, Scd1, and Elovl6 (n=5-7/genotype).  (C) Protein 
expression and densitometry analysis of total FAS in liver lysates from four-hour 
fasted control and Ppp1r3b∆hep mice at 12 weeks on sucrose diet (n=5/genotype). 
Four-hour fasted livers from control and Ppp1r3b∆hep mice at 12 weeks on 
sucrose diet were used for these analyses.  (D)  Newly synthesized palmitate 
was measured in liver using stable isotope method and the corresponding TG 
was measured from control and Ppp1r3b∆hep mice under ad libitum fed conditions 
at 4 weeks on sucrose diet (n=6/genotype). (E) Palmitate synthesis and liver TG 
was measured from control and Ppp1r3b∆hep mice under overnight fasting-
refeeding for 6 hours at 4 weeks on sucrose diet (n=6/genotype).  All mice were 
adults (2-8months) and were age-matched within experiments. The data are 
expressed as the mean + S.E. Significance was determined in all panels by 
unpaired Student’s t-test (*p<0.05, **p<0.005, ***p<0.0001). (n.s), not significant. 
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Hepatic Ppp1r3b deletion causes elevation in plasma free fatty acids with 
increased expression of hepatic Cd36, a major fatty acid transporter in the 
liver. 
Next, I wanted to test whether the hepatic accumulation of triglycerides in 
Ppp1r3b∆hep mice is a consequence of elevation of free fatty acids. Under chronic 
high sucrose feeding, the increase in plasma NEFAs was sustained and even 
more significantly elevated in Ppp1r3b∆hep mice compared to the control group 
throughout the study (Fig. 17A).  There was also a significant upregulation in 
hepatic Cd36 mRNA levels (Fig. 17B) which is one of the important fatty acid 
transport proteins that mediates fatty acid uptake into the liver (124).  Moreover, 
it has been shown that hepatic Cd36 mRNA and protein expression is increased 
in diet-induced obesity conditions (125), and has been also shown to be 
upregulated in patients with NASH (126).   Collectively, these data indicate that 
elevation in plasma free fatty acids may drive an increase in hepatic triglycerides, 
possibly by hepatic fatty transporter facilitated increase in fatty acid uptake in 
Ppp1r3b∆hep mice. 
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Figure 17: Liver-specific deletion of Ppp1r3b promotes elevation in plasma 
free fatty acids, with increased hepatic Cd36 expression, a major fatty acid 
transporter in the liver 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Liver-specific deletion of Ppp1r3b promotes elevation in plasma 
free fatty acids, with increased hepatic Cd36 expression, a major fatty acid 
transporter in the liver (A) Non-esterified free fatty acids (NEFA) were 
measured in four-hour fasted plasma collected from control  and Ppp1r3b∆hep 
mice at 12 weeks on sucrose diet (n=5-7/genotype). (B) Hepatic transcript levels 
of Cd36 gene which mediates free fatty acid uptake in the liver (n=5-
7/genotype)). Four-hour fasted livers from control and Ppp1r3b∆hep mice at 12 
weeks on sucrose diet were used for these analyses.  All mice were adults (2-8 
months) and were age-matched within experiments. The data are expressed as 
the mean + S.E. Significance was determined in all panels by unpaired Student’s 
t-test (*p<0.05, **p<0.005, ***p<0.0001). (n.s), not significant.  
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Liver-specific Ppp1r3b knockout mice have increased body weight gain, 
adiposity with adipocyte hypertrophy, and elevated plasma leptin and 
NEFA levels upon chronic high sucrose diet.  
Ppp1r3b∆hep mice fed sucrose diet for 12 weeks, had elevated body weight 
gain and elevated white adipose tissue mass at 12 weeks on diet (Fig 18A, 18B).  
Adipocytes appeared larger in size in Ppp1r3b∆hep mice, compared to the control 
group (Fig 18C).  Next, I accessed plasma leptin levels as leptin is associated 
with increased adipocyte mass (127).   Consistent with the morphology, there 
was an increase in plasma leptin by about 3 fold in Ppp1r3b∆hep mice compared 
to the control group (Fig. 18D). These data indicate that liver specific deletion of 
Ppp1r3b likely promotes adipose tissue expansion, elevation in plasma leptin and 
subsequently hydrolysis of TG stores to release free fatty acids. These free fatty 
acids are then released into the plasma and are subsequently delivered to the 
liver. 
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Figure 18: Hepatic Ppp1r3b deletion sensitizes mice to chronic 
carbohydrate overload   
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Figure 18: Hepatic Ppp1r3b deletion sensitizes mice to chronic 
carbohydrate overload  (A) Body weight and percent of body weight gain in 
control and Ppp1r3b∆hep mice at 12 weeks on sucrose diet (n=5/genotype). (B) 
Percentage of weight of liver and white adipose tissue relative to body weights in 
four-hour fasted control and Ppp1r3b∆hep mice at 12 weeks on sucrose diet 
(n=5/genotype). (C) H&E staining of WAT sections from four-hour fasted control 
and Ppp1r3b∆hep mice at 12 weeks on sucrose diet shows increased adipocyte 
cell size (n=3-4/genotype). Quantification of adipocyte cell area and diameter 
was performed using Adiposoft ImageJ software. Values are reported in pixels. 
(C) Plasma leptin levels were measured in four-hour fasted plasma from control 
and Ppp1r3b∆hep mice at 12 weeks on sucrose diet (n=5-7/genotype).  Four-hour 
fasted white adipose tissue (WAT) lysates from control and Ppp1r3b∆hep mice at 
12 weeks on sucrose diet were used for these analyses. All mice were adults (2-
8 months) and were age-matched within experiments. The data are expressed as 
the mean + S.E. Significance was determined in all panels by unpaired Student’s 
t-test (*p<0.05, **p<0.005, ***p<0.0001). (n.s), not significant.  
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Mice overexpressing Ppp1r3b in liver are resistant to the dietary effects of 
chronic carbohydrate overload. 
I wanted to determine whether overexpressing Ppp1r3b can protect from 
HSD induced metabolic perturbations.  There were no difference in body weights 
and adipose tissue mass between both AAV-Null and AAV-Ppp1r3b mice (Fig. 
19A, 19B).  Moreover, the liver mass was increased as a consequence of 
increased glycogen storage (128).  Adipocytes appeared smaller in size by 
morphological analysis (Fig. 19C), and the elevation in plasma free fatty acids 
that was associated with deletion of Ppp1r3b in the liver was significantly 
reduced in mice overexpressing Ppp1r3b (Fig.19D) .  These data show that 
enhancing the expression of hepatic Ppp1r3b attenuates the metabolic 
impairment in adipose tissue that resulted from the deletion of this gene in the 
liver. 
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Figure 19: Mice overexpressing Ppp1r3b are protected from metabolic 
perturbations in white adipose tissue, resulting in normalization of plasma 
free fatty acids in chronic sucrose diet feeding state   
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Figure 19: Mice overexpressing Ppp1r3b are protected from metabolic 
perturbations in white adipose tissue, resulting in normalization of plasma 
free fatty acids in chronic sucrose diet feeding state  (A) Body weight and 
percent of body weight gain in AAV-Null and AAV-Ppp1r3b mice at 12 weeks on 
sucrose diet (n=8/group). (B) Percentage of mass of liver and white adipose 
tissue relative to body weights AAV-Null and AAV-Ppp1r3b mice at 12 weeks on 
sucrose diet (n=8/group). (C) H&E staining of adipose tissue sections from four-
hour fasted AAV-Null and AAV-Ppp1r3b mice at 12 weeks on sucrose diet shows 
modest decrease in adipocyte cell size (n=3-4/group). Quantification of adipocyte 
cell area and diameter was performed using Adiposoft ImageJ software. Values 
are reported in arbitrary units referred to as pixels. (D)  Non-esterified free fatty 
acids (NEFA) were measured in four-hour fasted plasma collected from AAV-Null 
and AAV-Ppp1r3b mice at 12 weeks on sucrose diet (n=8/group).  Mice were 
injected with AAV at 12 weeks of age and were subjected to sucrose diet and 
tissue lysates were analyzed at 12 weeks post injection and diet. The data are 
expressed as the mean + S.E. Significance was determined in all panels by 
unpaired Student’s t-test (*p<0.05, **p<0.005, ***p<0.0001). (n.s), not significant. 
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Deletion of Ppp1r3b in the liver promotes increased fatty acid utilization 
under chronic sucrose diet feeding.   
 Next, I wanted to examine the mitochondrial fatty acid β-oxidation 
pathway, which is a primary process that promotes consumption of fatty acids to 
generate energy in the form of ATP. In hepatic steatotic states, this pathway is 
frequently deregulated  (129).  Peroxisomal proliferator activated receptor alpha 
(PPARα), is a key transcription factor that mediates activation of target genes 
involved in the fatty acid oxidation pathway (130) (131), We conducted 
microarray analysis from livers isolated from control and Ppp1r3b∆hep mice from 
12 weeks high sucrose diet study (Fig. 20A).   There was significant upregulation 
in expression levels of Pparα target genes. I further validated several of these 
candidate genes that were likely altered based on the microarray, by real-time 
PCR and found that several genes, including Fgf21, a well-known PPARα target 
gene was upregulated (Fig. 20B).  Acly and Pklr were also upregulated, 
consistent with the increase in glycolytic pathway genes studied in Chapter 3.  
Interestingly, several bile acid synthesis genes, such as Cyp7b1 and Cyp27a1 
were downregulated. These data suggest that PPARα-dependent fatty acid 
oxidation pathway in Ppp1r3b∆hep mice likely remains functional and perhaps may 
even be augmented compared to the control group under chronic sucrose 
feeding. This is also consistent with the upregulation in ketone bodies detected in 
Ppp1r3b∆hep mice under long-term fasting studied in Chapter 3.   
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Figure 20: Ppp1r3bΔhep mice have increased transcription of PPARα target 
genes as identified by Ingenuity Pathway Analysis 
 
Figure 20: Ppp1r3bΔhep mice have increased transcription of PPARα target 
genes as identified by Ingenuity Pathway Analysis A) Ingenuity pathway 
analysis (IPA) of the set of differentially regulated genes (>1.5 absolute fold 
change in Ppp1r3bΔhep mice compared with Fl/Fl control mice (n=5/group) as 
obtained from Agilent microarray analysis of liver total RNA from mice on 12 
weeks on high sucrose diet (B) Some of these microarray genes were validated 
by real-time quantitative PCR in mice livers from this study. Significance was 
determined in all panels by unpaired Student’s t-test (*p<0.05, **p<0.005, 
***p<0.0001). (n.s), not significant. 
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Hepatic deletion of Ppp1r3b modestly increases VLDL-triglyceride 
secretion by the liver under chronic sucrose diet feeding at 4 weeks.  
The hepatic VLDL-triglyceride secretion pathway removes excess 
triglycerides from the liver in the form of VLDL particles, and this process is often 
impaired in hepatic steatotic states (129).  This process is sequential; with the 
primary stage that requires VLDL -particle assembly of TG with the 
apolipoprotein B, mediated by a key enzyme microsomal triglyceride transfer 
protein (MTP), encoded by the gene Mttp (132,133).  MTP plays a crucial role in 
lipidation and proper VLDL particle assembly in the lumen of endoplasmic 
reticulum (ER). There was a modest increase in VLDL-TG secretion in 
Ppp1r3b∆hep mice compared to the control group at 4-weeks on high sucrose diet, 
which was primarily mediated by the increase in plasma triglycerides obtained 
from the last time point under the experimental conditions (Fig. 21A). By gene 
expression, the levels of Mttp were however not different between the two groups 
on 12 weeks on high sucrose diet (Fig. 21B) suggesting that impairment in TG 
secretion by the liver does not underlie the phenotype of increased hepatic 
triglycerides in Ppp1r3b∆hep mice. 
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Figure 21: Liver-specific deletion of Ppp1r3b results in moderately 
increased hepatic VLDL-TG secretion under chronic sucrose diet at 4 
weeks 
Figure 21: Liver-specific deletion of Ppp1r3b results in moderately 
increased hepatic VLDL-TG secretion under chronic sucrose diet at 4 
weeks (A) VLDL-TG secretion was measured in four-hour fasted control and 
Ppp1r3b∆hep mice at 4-weeks on sucrose diet (n=4-6/genotype).  Values are 
reported as plasma TG levels and area under the curve (AUC) is expressed as 
arbitrary units.  .  (B) Hepatic transcript level of Mttp gene which mediates 
hepatic VLDL-TG secretion pathway (n=5-7/genotype). Four-hour fasted livers 
from control and Ppp1r3b∆hep mice at 12 weeks on sucrose diet were used for 
these analyses.  All mice were adults (2-8 months) and were age-matched within 
experiments. The data are expressed as the mean + S.E. Significance was 
determined in all panels by unpaired Student’s t-test (*p<0.05, **p<0.005, 
***p<0.0001). (n.s), not significant. 
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Hepatic Ppp1r3b deletion results in hyperinsulinemia, as well as attenuated 
insulin signaling in the liver and the mice develop systemic insulin 
resistance upon high sucrose diet feeding.  
Hepatic accumulation of lipids is a major phenotype associated with 
defective hepatic insulin signaling, which leads to hepatic insulin resistance in 
mammals. In humans and animal models, this has been extensively studied 
(134) (135) (136) (137).  In Ppp1r3b∆hep mice, I wanted to determine whether 
deletion of Ppp1r3b in the liver promotes defect in hepatic insulin signaling. Since 
insulin primarily activates PI3K/AKT and promotes glycogen synthesis by 
indirectly inhibiting GSK3 activity through phosphorylation and deactivation, we 
investigated this effect in Ppp1r3b∆hep mice.  First, I examined protein expression 
of AKT and GSK3, with their corresponding phosphorylated states in livers from 
6-month old mice on standard chow diet. There was a significant down regulation 
of the phosphorylated form of AKT relative to the total AKT levels, suggesting 
decreased activity, and a significant down regulation in the AKT-mediated 
inhibitory phosphorylation of Serine 9 on GSK3 in Ppp1r3b∆hep mice, indicating 
over-activation of GSK3β(Fig. 22A, 22B). These data indicate a defect in insulin 
signaling upon deletion of Ppp1r3b in the liver.  Next, I validated this finding in 
chronic sucrose diet feeding study, and first measured the plasma insulin levels 
in these mice.  There was a significant elevation in 4-hour fasted plasma insulin 
levels in Ppp1r3b∆hep mice compared to the control group at 12 weeks on HSD 
diet (Fig. 23A). Plasma insulin was also elevated in Ppp1r3b∆hep mice that were 
overnight fasted and refed diet for 6 hours at 4 weeks on HSD diet (Fig. 23B).  
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Phosphorylation of Serine 9 on GSK3β was downregulated, suggesting that 
GSK3β remains activated as a result of attenuated insulin signaling, consistent 
with data on chow diet (Fig. 23C).   
I performed an insulin tolerance test (ITT) in mice at 11 weeks on high 
sucrose diet, to determine the insulin-stimulated glucose disposal in tissues, 
which reflects the systemic response to exogenous insulin supplementation. 
There was also a robust impairment in the insulin stimulated glucose clearance in 
Ppp1r3b∆hep mice, suggesting that these mice become severely insulin resistant 
in response to chronic sucrose feeding compared to the control group (Fig. 23D) 
unlike Ppp1r3b∆hep mice fed standard chow diet, which remained insulin-sensitive 
at 4 months of age (Fig. 24A, 24B). Perhaps, older chow-fed Ppp1r3b∆hep mice 
become insulin resistant over time (not tested), and this phenotype is accelerated 
when provided sucrose-rich diet.  Taken together, these data indicate that 
deficiency of Ppp1r3b in the liver significantly promotes carbohydrate diet-
induced impairment in both the hepatic insulin signaling and systemic insulin 
response, making them susceptible to development of insulin resistance. 
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Figure 22: Ppp1r3b∆hep mice have attenuated hepatic insulin signaling on 
standard chow diet at 6 months of age  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Ppp1r3b∆hep mice have attenuated hepatic insulin signaling on 
standard chow diet at 6 months of age (A) Protein expression of P-AKT, total 
AKT, P-GSK3β,  total GSK3β and total GS were measured in liver lysates from 
ad libitum chow-fed control and Ppp1r3b∆hep mice (n=3-5/genotype). (B) 
Densitometry analysis was performed and ratios of P-AKT to total AKT, and P-
GSK3β to total GSK3β was calculated and reported.  Results were replicated in 
at least two independent experiments. All mice were adults (2-8 months) and 
were age-matched within experiments. The data are expressed as the mean + 
S.E. Significance was determined in all panels by unpaired Student’s t-test 
(*p<0.05, **p<0.005, ***p<0.0001). (n.s), not significant. 
 
 
104 
  
 
Figure 23: Liver-specific deletion of Ppp1r3b promotes impairment in 
insulin signaling in the liver, with increased susceptibility to development 
of hyperinsulinemia and systemic insulin resistance  
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Figure 23: Liver-specific deletion of Ppp1r3b promotes impairment in 
insulin signaling in the liver, with increased susceptibility to development 
of hyperinsulinemia and systemic insulin resistance (A) Plasma Insulin 
levels were measured in four-hour fasted plasma from control and Ppp1r3b∆hep 
mice at 12 weeks on sucrose diet (n=4/genotype). (B) Plasma insulin in mice 
refed HSD from control and Ppp1r3b∆hep mice at 4 weeks on sucrose diet (n= 5-
7/genotype). (C)Protein expression and densitometry analysis of P-GSKβ, and 
total GSK3β in liver lysates from four-hour fasted control and Ppp1r3b∆hep mice at 
12 weeks on sucrose diet (n=5/genotype). Four-hour fasted livers from control 
and Ppp1r3b∆hep mice at 12 weeks on sucrose diet were used for these analyses.  
(D) Insulin response in peripheral tissues as measured by insulin tolerance test 
(ITT) in 6-hour fasted control and Ppp1r3b∆hep mice at 11 weeks on sucrose diet 
(n=5-7/genotype). Values are reported as percentage of basal glucose levels and 
area under the curve (AUC) is expressed as arbitrary units.   All mice were adults 
(2-8 months) and were age-matched within experiments. The data are expressed 
as the mean + S.E. Significance was determined in all panels by unpaired 
Student’s t-test (*p<0.05, **p<0.005, ***p<0.0001). (n.s), not significant. 
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Figure 24: Plasma insulin and insulin response in 3-4month old Ppp1r3bΔhep 
mice on standard chow diet  
Figure 24: Plasma insulin and insulin response in 3-4month old Ppp1r3bΔhep 
mice on standard chow diet (A) Plasma Insulin levels were measured from 
control and Ppp1r3b∆hep mice under standard chow fed diet (n=5-8/genotype). (B) 
Insulin response in peripheral tissues as measured by insulin tolerance test (ITT) 
in 6-hour fasted control and Ppp1r3bΔhep mice on chow diet (n=6-7/genotype). 
Values are reported as percentage of basal glucose levels and area under the 
curve (AUC) is expressed as arbitrary units. All mice were adults (2-8 months) 
and were age-matched within experiments. The data are expressed as the mean 
+ S.E. Significance was determined in all panels by unpaired Student’s t-test 
(*p<0.05, **p<0.005, ***p<0.0001). (n.s), not significant. 
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Hepatic deletion of Ppp1r3b results in upregulation of the inflammatory 
cytokine Interleukin-6 (IL-6) in liver under chronic sucrose diet feeding. 
The development from accumulation of neutral lipids to state of 
inflammation is a hallmark of the progression in the pathophysiology of Non-
alcoholic fatty liver disease (NAFLD) and is marked by rise in inflammatory 
cytokines in the liver (138).  Since Ppp1r3b∆hep mice have progressive 
accumulation of triglycerides in the liver and defective insulin signaling that could 
promote susceptibility to lipotoxicity, we wanted to ask next if there were any 
alterations in the markers of inflammation in livers from Ppp1r3b∆hep mice fed 
chronic sucrose rich diet.  By gene expression, there was a significant increase in 
interleukin-6 (IL-6) in livers from Ppp1r3b∆hep mice (Fig. 25). It has been 
previously shown that hepatic expression of interleukin 6 (IL-6) is significantly 
elevated in patients with NAFLD (139), (140). Moreover, there is a positive 
correlation with liver IL-6 expression with plasma IL-6 levels and degree of insulin 
resistance(139), (141). Although levels of plasma IL-6 were not measured in 
these mice, this data suggests that chronic sucrose diet feeding promotes 
inflammation in Ppp1r3b∆hep mice, consistent with the insulin resistance observed 
in this mouse model.  
 
 
108 
  
 
Figure 25: Upregulation of inflammatory cytokine, IL-6 in Ppp1r3b∆hep mice 
liver under chronic sucrose diet feeding  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: Upregulation of inflammatory cytokine, IL-6 in Ppp1r3b∆hep mice 
liver. Hepatic transcript levels of Interleukin 6 (IL-6), which is a secreted 
adipocytokine that is also a marker of inflammatory response (n=5-7/genotype). 
Four-hour fasted liver lysates from control and Ppp1r3b∆hep mice at 12 weeks on 
sucrose diet were used for this analysis. All mice were adults (2-8 months) and 
were age-matched within experiments. The data are expressed as the mean + 
S.E. Significance was determined in all panels by unpaired Student’s t-test 
(*p<0.05, **p<0.005, ***p<0.0001). (n.s), not significant. 
 
 
109 
  
 
Deletion of Ppp1r3b in liver promotes systemic glucose intolerance under 
chronic high sucrose feeding 
Under chronic sucrose diet, Ppp1r3b∆hep mice became severely glucose 
intolerant, as early as three weeks on the diet, and this effect was sustained 
throughout the study (Fig. 26A, 26B, 26C).  Although not directly tested in this 
study, impaired glucose disposal by peripheral tissues such as  adipose tissue 
and skeletal muscle, is also a consequence of systemic insulin resistance, which 
could likely also contribute to this effect. Further studies to address glucose 
turnover in these tissues would be important to corroborate this finding.  
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Figure 26: Liver Ppp1r3b deletion promotes impairment in glucose 
tolerance under chronic high sucrose diet feeding state 
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Figure 26: Liver Ppp1r3b deletion promotes impairment in glucose 
tolerance under chronic high sucrose diet feeding state (A) Glucose disposal 
capacity is accessed by measuring plasma glucose concentrations during the 
intraperitoneal  glucose tolerance test (IPGTT – 2g/kg) in overnight fasted control 
and Ppp1r3b∆hep mice fed sucrose diet at 3 weeks (n=5-7/genotype). (B) GTT in 
overnight fasted control and Ppp1r3b∆hep mice on sucrose diet at 6 weeks (n=5-
7/genotype). (C) GTT in control and Ppp1r3b∆hep mice on sucrose diet at 8 weeks 
(n=5-7/genotype). Values are reported as glucose levels and area under the 
curve (AUC) is expressed as arbitrary units.  All mice were adults (2-8 months) 
and were age-matched within experiments. The data are expressed as the mean 
+ S.E. Significance was determined in all panels by unpaired Student’s t-test 
(*p<0.05, **p<0.005, ***p<0.0001). (n.s), not significant. 
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Mice overexpressing hepatic Ppp1r3b have restored glucose tolerance and 
insulin sensitivity under chronic high sucrose feeding when compared to 
Null AAV OE. 
While Ppp1r3b∆hep mice became glucose intolerant, mice overexpressing 
hepatic Ppp1r3b did not exhibit glucose intolerance, and did not become insulin 
resistant compared to the AAV-Null group (Fig. 27A, 27B) even under chronic 
sucrose diet feeding. These data indicate that enhancing glycogen storage in the 
liver by overexpressing Ppp1r3b attenuates the impairment in both the hepatic 
and whole-body glucose disposal capacity and perhaps the systemic insulin 
response by the peripheral tissues also remain preserved.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
113 
  
 
Figure 27: Mice overexpressing hepatic Ppp1r3b remained glucose and 
insulin sensitive compared to Null AAV OE mice under chronic sucrose 
diet feeding state 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: Mice overexpressing hepatic Ppp1r3b remained glucose and 
insulin sensitive compared to Null AAV OE mice under chronic sucrose 
diet feeding state (A) Glucose disposal capacity is measured by glucose 
tolerance test (GTT) in overnight fasted AAV-Null and AAV-Ppp1r3b mice on 
sucrose diet at 11 weeks (n=8/group).  Values are reported as glucose levels and 
area under the curve (AUC) is expressed as arbitrary units. (B) Insulin response 
in peripheral tissues as measured by insulin tolerance test (ITT-insulin dose -
0.75U/kg) in 6-hour fasted AAV-Null and AAV-Ppp1r3b mice at 11 weeks on 
sucrose diet (n=8/group). Values are reported as percentage of basal glucose 
levels and area under the curve (AUC) is expressed as arbitrary units. Mice were 
injected with AAV at 12 weeks of age and were subjected to sucrose diet and 
tissue lysates were analyzed at 12 weeks post injection and diet. The data are 
expressed as the mean + S.E. Significance was determined in all panels by 
unpaired Student’s t-test (*p<0.05, **p<0.005, ***p<0.0001). (n.s), not significant. 
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Deletion of Ppp1r3b in the liver leads to selective plasma dyslipidemia 
under chronic high sucrose diet feeding state. 
Since the high sucrose diet potentiated the phenotypes of the other 
metabolic traits that are associated with Ppp1r3b as described above, I wanted to 
characterize the effect on plasma lipids in this mouse model.  I found that in mice 
with hepatic deletion of Ppp1r3b, there was a significant elevation in plasma 
total-cholesterol, HDL-cholesterol and phospholipids, with approximately 23% 
higher levels in each of these plasma lipid components, consistent with the 
directionality with human GWAS association, indicating that the deletion of this 
gene in the liver raises plasma lipids.  Moreover, in sucrose diet experiments, I 
also observed an elevation in non-HDL cholesterol by approximately 40% in 
Ppp1r3b∆hep mice compared to the control group which was not observed on 
standard chow diet. And consistent with the human GWAS data, there was no 
effect on plasma triglycerides (Fig. 28A). 
To further characterize the cholesterol distribution in plasma lipoprotein 
subspecies, I pooled the plasma from mice from each group and subjected it to 
fast protein liquid chromatography (FPLC), which separates lipoproteins based 
on size and density. There was a robust leftward shift of the HDL-cholesterol 
peak in fractions isolated from Ppp1r3b∆hep mice compared to the fractions from 
the control group, suggesting that the size of the HDL lipid fractions is larger in 
Ppp1r3b∆hep mice compared to the control group (Fig. 28B). Then, I also analyzed 
the fractions for the apolipoproteins (ApoB, ApoE and ApoA1) that are primarily 
associated with VLDL, LDL and HDL particles. ApoB lipoproteins are commonly 
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associated with VLDL and LDL lipid particles, while ApoE is associated with all 
VLDL, LDL and HDL, whereas ApoA1 is exclusively associated with the HDL 
particles (142-144).  I analyzed the content of each of these corresponding 
lipoproteins in the transitory region where the FPLC fractions are characterized 
between non-HDL and HDL peaks, and where there was the largest difference 
observed between the two groups of mice (fractions #21-35).  Based on the 
analysis, it appeared that within these fractions, there was a mixture of two 
separate populations of lipid particles, corresponding to smaller dense LDL and 
larger HDL particles, as observed by the increase in ApoB content in fraction 21-
30, and ApoE and ApoA1 content in fractions 21-30, and 26-30 respectively in 
plasma from Ppp1r3b∆hep mice (Fig. 28C). Chronic sucrose diet produced an 
effect on non-HDL lipid species in Ppp1r3b∆hep mice, consistent with human 
GWAS signal, which was not previously detected on chow diet, and this elevation 
in cholesterol in non-HDL fractions is likely a result of increased packaging into 
small-dense LDL particles.  These data suggest that in the absence of Ppp1r3b 
in the liver, there is a striking impact on plasma lipids, promoting dyslipidemia by 
altering the amount and the composition of the lipid particles. Further studies 
characterizing lipoprotein metabolism in Ppp1r3b∆hep mice should focus on this 
important phenotype in greater detail.   
 
 
116 
  
 
Figure 28: Liver-specific deletion of Ppp1r3b promotes selective 
dyslipidemia with alterations in the composition of the plasma lipoprotein 
profile  
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Figure 28: Liver-specific deletion of Ppp1r3b promotes selective 
dyslipidemia with alterations in the composition of the plasma lipoprotein 
profile (A) Plasma lipids (including total cholesterol, HDL-cholesterol, non-HDL-
cholesterol, triglycerides, and phospholipids) were measured in four-hour fasted 
plasma collected from control and Ppp1r3b∆hep mice at 12weeks on sucrose diet 
(n=5-7/genotype). (B) FPLC analysis of lipoprotein distribution in plasma from 
control and Ppp1r3b∆hep mice at 12weeks on sucrose diet (n=5-7/genotype). 
Plasma samples were pooled for each genotype and were injected onto 
Superose-6-columns and separated into 0.5mL fractions as described in 
Materials and Methods. Cholesterol levels were evaluated for each sample and 
plotted. (C) Western blot analysis of ApoB, ApoE and ApoA1 in FPLC 
fractions#21-35 from control and Ppp1r3b∆hep mice at 12weeks on sucrose diet 
(n=5-7/genotype). All mice were adults (2-8 months) and were age-matched 
within experiments. The data are expressed as the mean + S.E. Significance was 
determined in all panels by unpaired Student’s t-test (*p<0.05, **p<0.005, 
***p<0.0001). (n.s), not significant. 
B 
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Hepatic overexpression of Ppp1r3b lowers total cholesterol, HDL-
cholesterol, and plasma phospholipids, and improves the lipoprotein 
profile under chronic sucrose diet feeding 
Under chronic high sucrose feeding at 12 weeks, Ppp1r3b∆hep mice 
exhibited selective dyslipidemia marked by increased levels of total cholesterol, 
HDL-cholesterol and phospholipids, without an effect on plasma triglycerides, in 
consistent with the directionality of these traits for this locus from the human 
genome wide association studies.  To further validate these findings, I studied 
the plasma lipids in mice overexpressing Ppp1r3b, which should presumably 
depict the opposite phenotypes.  In agreement with the human genetic 
association and the previous data obtained, we detected a reduction in plasma 
total cholesterol, HDL-cholesterol and phospholipids in mice overexpressing 
Ppp1r3b by 24%, 27% and 21% respectively compared to the control group (Fig. 
29A).  With respect to the plasma lipoprotein distribution, there was modest, but 
distinct shift in the HDL peak towards the right compared to the control group 
(Fig. 29B), suggesting that there was normalization in the cholesterol distribution 
in HDL lipid particles and their composition that  appeared to be altered in 
plasma from mice with hepatic deletion of Ppp1r3b.  Although not tested, it would 
be interesting to study the composition of lipid particles from plasma from these 
mice.  Taken together, these data suggest that overexpression of hepatic 
Ppp1r3b promotes decrease in plasma lipids, likely affecting the overall 
lipoprotein metabolism; however future studies would be required to parse the 
mechanisms underlying these findings.   
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Figure 29: Mice overexpressing hepatic Ppp1r3b had improved plasma lipid 
profile compared to AAV OE under chronic carbohydrate overload  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: Mice overexpressing hepatic Ppp1r3b had improved plasma lipid 
profile compared to AAV OE under chronic carbohydrate overload (A) 
Plasma lipids were measured in four-hour fasted plasma collected from AAV-Null 
and AAV-Ppp1r3b mice at 12 weeks on sucrose diet (n=8/group).  (B) FPLC of 
lipoprotein distribution in plasma from AAV-Null and AAV-Ppp1r3b mice at 12 
weeks on sucrose diet (n=8/group).  Plasma samples were pooled for each group 
and were injected onto Superose-6-columns and separated into 0.5mL fractions 
as described in Materials and Methods. Cholesterol levels were evaluated for 
each sample and plotted.  Mice were injected with AAV at 12 weeks of age and 
were subjected to sucrose diet and plasma samples were analyzed at 12 weeks 
post injection and diet. The data are expressed as the mean + S.E. Significance 
was determined in all panels by unpaired Student’s t-test (*p<0.05, **p<0.005, 
***p<0.0001). (n.s), not significant. 
 
 
120 
  
 
Table 3: Chapter 4  
Oligonucleotides used for Gene Expression Analysis by RT-PCR 
 
Name Gene 
Symbol 
Primer Sequence 
Sterol-regulatory binding 
protein 1 (SREBP1) 
Srebf1 5’-GGAGCCATGGATTGCACATT-3’ 
5’-GCTTCCAGAGAGGAGCCCAG-3’ 
Carbohydrate responsive 
element binding protein 
(ChREBP) 
Mlxipl 5’-AGATGGAGAACCGACGTATCA’3’ 
5’-ACTGAGCGTGCTGACAAGTC-3’ 
Acetyl-CoA Carboxylase-
alpha 
Acaca 5’-GATGAACCATCTCCGTTGGC-3’ 
5’- GACCCAATTATGAATCGGGAGTG-3’ 
Fatty 
acid synthase 
Fasn 5’-AGGGGTCGACCTGGTCCTCA-3’ 
5’-GCCATGCCCAGAGGGTGGTT-3’ 
Stearoyl-CoA Desaturase Scd1 5’-TTCTTGCGATACACTCTGGTGC-3’ 
5’-CGGGATTGAATGTTCTTGTCGT-3’ 
Fatty 
acid elongase 6 
Elovl6 5’-GAAAAGCAGTTCAACGAGAACG-3’ 
5’-AGATGCCGACCACCAAAGATA-3’ 
Microsomal Trigylceride 
Transfer Protein 
Mttp 5’-CTCTTGGCAGTGCTTTTTCTCT-3’ 
5’-GAGCTTGTATAGCCGCTCATT-3’ 
Fatty 
acid  translocase 
Cd36/FAT 5’-ATGACGTGGCAAAGAACAGC-3’ 
5’-GAAGGCTCAAAGATGCCTCC-3’ 
Interleukin-6 IL-6 5'-CTGCAAGAGACTTCCATCCAGTT-3' 
5'-AGGGAAGGCCGTGGTTGT-3’ 
ATP Citrate Lyase Acly 5’-CAGCCAAGGCAATTTCAGAGC-3’ 
5’-CTCGACGTTTGATTAACTGGTCT-3’ 
Liver Pyruvate Kinase 
 (L-PK) 
Pklr 5’-TCAAGGCAGGGATGAACATTG-3’ 
5’-CACGGGTCTGTAGCTGAGTG-3’ 
Peroxisomal proliferator 
activated receptor alpha 
PPARα 5’-AGAGCCCCATCTGTCCTCTC-3’ 
5’-ACTGGTAGTCTGCAAAACCAAA-3’ 
Carnitine 
palmitoyltransferase 1a 
Cpt1a 5’-CTCCGCCTGAGCCATGAAG-3’ 
5’-CACCAGTGATGATGCCATTCT-3’ 
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Cytochrome P450, family 
4, subfamily a, polypeptide 
14  
Cyp4a14 5’-TTTAGCCCTACAAGGTACTTGGA-3’ 
5’-GCAGCCACTGCCTTCGTAA-3’ 
Cytochrome P450, family 
7, subfamily b, polypeptide 
1 
Cyp7b1 5’-GGAGCCACGACCCTAGATG-3’ 
5’-TGCCAAGATAAGGAAGCCAAC-3’ 
Fibroblast growth factor 21 Fgf21 5’-CTGCTGGGGGTCTACCAAG-3’ 
5’-CTGCGCCTACCACTGTTCC-3’ 
β-actin Actb 5’-TTGGGTATGGAATCCTGTGG-3’ 
5’-CTTCTGCATCCTGTCAGCAA-3’ 
18S 18s 5’-CTTAGAGGGACAAGTGGCG-3’ 
5’-ACGCTGAGCCAGTCAGTGTA-3’ 
 
.    
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DISCUSSION 
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver disorders 
in which excess fat accumulates in the liver unrelated to chronic alcohol 
ingestion. NAFLD is classified into simple steatosis and nonalcoholic 
steatohepatitis (NASH).  NASH is characterized by combination of steatosis with 
intralobular inflammation and hepatocellular ballooning, which is often 
accompanied by fibrosis. A subset of NASH patients develops liver cirrhosis and 
hepatocellular carcinoma (HCC) (73,100).  NAFLD is sometimes characterized 
as the hepatic manifestation of metabolic syndrome, and its prevalence has been 
increasing worldwide over the recent decades in parallel with increasing rates of 
obesity and Type 2 diabetes (70). NAFLD/NASH is currently regarded as the 
most common chronic liver disease worldwide, with independently correlating 
with other chronic diseases including CVD and CKD. It is estimated that about 
20% of adults have NAFLD and 2-3% of adults have NASH.  Furthermore, 
genetic variations within diverse populations also contribute to the differences in 
distribution of prevalence rates of NAFLD among individuals.  For example, 
incidence rates of NAFLD in Hispanic Americans are approximately 20-30% 
higher than European and/or African American populations (145). 
Pathogenesis of NAFLD/NASH is a complex phenomenon with 
combination of different various metabolic factors contributing to the development 
of the disease. Fat accumulation in the liver is closely associated with metabolic 
derangements that relate to central obesity and insulin resistance. Hepatic 
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steatosis occurs when the rate of import and of synthesis of fatty acids by 
hepatocytes exceeds the rate of export and/or catabolism.  Consequently, the 
following four mechanisms are possible causes of lipid accumulation in the liver: 
1) increased uptake and deposition of fatty acids into hepatocytes, due to excess 
dietary intake or release from adipose tissue; 2) increased de novo hepatic fatty 
acid and triglyceride synthesis; 3) reduced very low-density lipoprotein (VLDL) 
synthesis and triglyceride export secretion and 4) failure of removal of fatty acids 
due to impaired hepatic mitochondrial β-oxidation. 
Despite its widespread occurrence, the pathogenesis of NAFLD/NASH 
has not been completely elucidated, and treatments for it other than lifestyle 
modification by diet and exercise have not been established.  Several limitations 
for studying NAFLD/NASH in humans include the longevity of studies as the 
progression of NAFLD/NASH occurs over a period of decades. Additionally, 
ethical limitations restricting drug administration and/or collection of liver 
specimens from patients preclude the progression of such type of research in 
humans. 
In this study, I specifically investigated the in vivo function of Ppp1r3b in 
hepatic and plasma lipid metabolism using loss of function and gain of function 
mouse models of Ppp1r3b in a liver-specific manner, using a specialized diet 
containing high sucrose content (66%) to study the effects on the associated 
metabolic traits. We reasoned that since Ppp1r3b is an important regulator of 
glycogen metabolism, that challenging the mice with increased sucrose content, 
would exacerbate the phenotypes and bring about the importance of its function 
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in this manner. Additionally, high sucrose type diet is commonly used to induce 
insulin resistance, glucose intolerance and diet- induced obesity in animal 
models (146,147), as sucrose is a dietary source of fructose, which has become 
an important and pervasive ingredient of Western diets, with an exponential rise 
in world per capita daily fructose intake over the last decade(148). Together with 
the increase in fructose consumption in the diet over the last several decades, 
there has been a proportional increase in the incidence of obesity and 
development of metabolic syndrome. Therefore, using high sucrose diet reflects 
the current composition of diet consumed by individuals in Westernized societies, 
and is also a suitable dietary stimulation for studying the development of hepatic 
steatosis and/or NAFLD and NASH. 
Consistent with my previous study demonstrating that Ppp1r3b is a critical 
mediator of hepatic glycogen synthesis, I first established that even under the 
context of high sucrose diet feeding, these liver specific Ppp1r3b knockout mice 
(Ppp1r3b∆hep mice) were not able to synthesize and store hepatic glycogen. 
Consequently, lack of glucose storage into hepatic glycogen led to shunting of 
energy into increased storage into hepatic triglycerides in Ppp1r3b∆hep mice, with 
visible appearance of microvesicular type lipid droplets in hepatocytes. This 
phenotype is in agreement with other animal models that harbor dysregulation in 
hepatic glycogen synthesis (37), (95), indicating that derangement in 
carbohydrate homeostasis in the liver has a profound impact on fat metabolism. 
To study the mechanisms underlying the accumulation of hepatic triglycerides in 
Ppp1r3b∆hep mice, I characterized the effects on four major routes through which 
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imbalance in fatty acid accumulation is obtained in the liver. First, I studied the 
effect on de novo lipogenesis pathway, through which glucose is primarily 
converted into acetyl-CoA , which is a major precursor for fatty acid synthesis 
(54,123). Under chronic (12-week) sucrose diet feeding, a substantial elevation in 
the expression of lipogenic genes and a significant upregulation of fatty acid 
synthase protein levels in Ppp1r3b∆hep mice suggest that perhaps upon uptake in 
the liver, glucose is driven into the glycolytic and lipogenic pathway rather than 
glycogenosis to serve as a substrate for fatty acid and subsequently triglyceride 
synthesis in hepatocytes.   Conversely, under shorter-term sucrose feeding for 
four weeks, the upregulation in DNL pathway in Ppp1r3b∆hep mice was not 
detected, suggesting that perhaps this phenomenon is only observed under 
chronic over-nutrition, and genetic deficiency of Ppp1r3b combined with a shorter 
exposure to sucrose diet, serves as an initial stage for the development of 
steatosis to occur (149) and requires prolonged dietary exposure to detect any 
tangible perturbation in this pathway.  
The next mechanisms we explored in Ppp1r3b∆hep mice were the fatty acid 
TG export through VLDL-TG secretion by the liver, and the fatty acid β-oxidation 
which utilizes fatty acids for energy output, therefore eliminating their 
accumulation in the liver.  Under chronic sucrose diet feeding, there was no 
reduction in VLDL-TG secretion at short-term four week high sucrose diet feeding 
in Ppp1r3b∆hep mice.  In contrast, liver microarray analysis showed that there was 
an upregulation of various target genes involved in PPARα pathway, which is a 
major transcription factor that promotes fatty acid oxidation.  Perhaps, fatty 
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oxidation pathway is still functional in Ppp1r3b∆hep mice, suggesting that under 
shorter term sucrose diet challenge, it could compensate by consumption of 
newly synthesized fatty acids for energy production, and hence the effect on de 
novo lipogenesis is masked under this setting.  Long term chronic sucrose 
feeding, brings out this effect, possibly as a result of elevated synthesis and 
storage into fatty acids that overcomes the rate of its consumption, as this 
pathway is saturated and cannot fully utilize the increased supply of fatty acids 
derived from carbohydrate overload. The limitation of this study was that these 
processes were not comprehensively studied under different nutritional states 
and dietary exposure, therefore the effect of these pathways in the context of the 
hepatic deletion of Ppp1r3b remains to be elucidated.  Further extensive studies 
of these mechanisms would be essential to effectively conclude if these 
processes are affected in this animal model. 
Alterations in lipid metabolism during states of glycogen depletion have 
been observed in several clinical models. Severe liver glycogen depletion in 
patients with rare mutations in the glycogen synthase gene can result in 
elevations in fasting ketone bodies and free fatty acids, a condition known as 
glycogen storage disease type 0 (96,97,150,151).  In agreement with these 
studies, one phenotype that was consistently observed in Ppp1r3b∆hep mice was 
elevation in plasma free fatty acids and this effect was sustained even under 
chronic high sucrose diet feeding. Accordingly, there was evidence of body 
weight gain driven by increased amount of adipose tissue weight, with 
enlargement in adipocytes, and elevation in plasma leptin levels in Ppp1r3b∆hep 
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mice.  Adipocytes secrete adipocytokines such as leptin in response to hormonal 
signaling through insulin, and circulating leptin levels increase in proportion to the 
size of fat depots (127). Moreover, expression of leptin is increased in chronic 
over-nutritional conditions and in patients with higher BMI (152). Furthermore, 
leptin also positively drives lipolysis through the action of sympathetic nerve 
fibers that innervate adipose tissue, by directly mediating activation of hormone 
sensitive lipase (HSL) to mediate TG hydrolysis (153). These metabolic 
alterations are consistent with diet-induced obesity states as seen in other animal 
models (154).  Hyperleptinemia is frequently observed in obese individuals and 
animals (155,156),  Moreover, leptin promotes hydrolysis of triglycerides stores in 
white adipose tissue through sympathetic innervation (157), and endogenous 
leptin action is thought to be retained in diet-induced obesity mice (158).  Taken 
together, these data demonstrate that hepatic deletion of Ppp1r3b promotes 
increased lipolysis of triglyceride stores from adipose tissue as an adaptive 
response towards utilization of fat as a primary fuel source for energy production. 
The development of glucose intolerance and hepatic insulin resistance in 
Ppp1r3b∆hep mice under chronic high sucrose diet feeding is likely a consequence 
of combinatorial effect of multiple metabolic factors that contribute to its 
progression.  First, in Ppp1r3b∆hep mice, glycogen as well as glycogen synthase 
activity are significantly reduced in the liver, suggesting that decreased storage of 
glucose into liver prompts a progressive impairment of its glucose disposal 
capacity, resulting in postprandial hyperglycemia and glucose intolerance(159).  
Second, the defect in hepatic glycogen synthesis and reduced liver glycogen 
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content itself has implications on insulin resistance (75,160) as insulin stimulation 
of this pathway is diminished; therefore glucose handling (i.e. glucose uptake and 
utilization) by the liver is severely disturbed in these mice.  Although not explored 
in this study, it is also likely that there could be impairment in glucose uptake and 
insulin signaling in skeletal muscle and adipose tissue in Ppp1r3b∆hep mice, that 
potentiates these phenotypes.  Third, the consequence in elevation of plasma 
free fatty acids is corroborated by increased expression of hepatic FAT/Cd36, 
which is one of the major fatty acid transporters in liver that promotes uptake of 
fatty acids from plasma compartment.  Elevated levels of hepatic Cd36 have 
been linked to diet-induced obesity, and insulin resistance(125,126).  Therefore, 
increased flux of free fatty acids into the liver in Ppp1r3b∆hep mice would likely 
contribute to increased hepatic free fatty acid and triglyceride pool, leading to 
insulin resistance.  The contribution of fatty acids synthesized from the lipogenic 
pathway could also possibly mediate its accumulation, which is controlled by two 
major transcription factors, ChREBP and SREBP1 through glucose and insulin 
respectively (50). Although the mRNA levels of ChREBP and SREBP1 
themselves did not change, target genes including Acaca, Fas, Scd1 and Elovl6 
were all upregulated, suggesting that perhaps activation and nuclear 
translocation of ChREBP and SREBP1 may drive activation of these target 
genes (51,108,161).   Moreover, inactivation of SREBP1 gene in livers of ob/ob 
mice, a genetic model of leptin deficiency that develops obesity and hepatic 
steatosis, results in approximately 50% reduction in hepatic triglycerides (162). 
Similarly, deletion of ChREBP in ob/ob mice results in decreased hepatic 
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steatosis and obesity, and ameliorates glucose intolerance and insulin 
resistance(163).  Hence, synergistic action of these transcription factors is 
required for regulation of lipogenesis in liver.  Further molecular studies to probe 
the mechanistic association of these transcription factors with the activation of 
their target genes would be of important relevance in this animal model. 
Additionally, hepatic insulin signaling is attenuated in Ppp1r3b∆hep mice, 
with impaired activation of AKT and inactivation of glycogen synthase kinase 3 
(GSK3) in high sucrose-fed mice.  Elevated activity of GSK3 has been 
associated with the pathogenesis of insulin resistance both in liver and skeletal 
muscle (164-166).  Although the activation in upstream insulin signaling proteins, 
such as the phosphorylation of insulin receptor substrates (IRS1 and IRS2) and 
tyrosine phosphorylation of insulin receptor was not tested in this study, it is 
highly likely that there could also be attenuation in their activation status in 
Ppp1r3b∆hep mice. 
Lastly, the cellular mechanisms responsible for fatty acid induced insulin 
resistance are not fully understood, however it is speculated that several fatty 
acid derived lipid intermediates such as diacylglycerol (DAG), long chain fatty 
acyl-CoA, ceramide, lysophosphatidic acid (LPA) and phosphatidic acid (PA), 
rather than the TAG itself, are important for the development of insulin 
resistance.  It has been proposed that when excessive DAG is formed, protein 
kinase C epsilon (PKCε) is activated, which subsequently diminishes 
phosphatidylinositol 3-kinase (PI3K) and Akt activation.  In this regard, mice 
lacking glycerol-3-phosphate acyltransferase (GPAT1), which is a key enzyme 
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that mediates glycerolipid synthesis, have reduced DAG and TAG, and are 
protected from high-fat diet-induced hepatic insulin resistance, possibly as a 
result of low DAG-mediated PKCε activation (167).  In addition to DAG, 
glycerolipid intermediates, such as LPA and PA can also alter signaling 
pathways, resulting in metabolic perturbations leading to induction of fatty liver 
(168,169).  Hepatic ceramides are a bioactive lipid species implicated in 
promoting insulin resistance, likely through promoting elevation in sphingolipid 
species which oppose insulin action, and lead to accumulation of medium long-
chain acylcarnitines, associated with oxidative stress and decreased fatty acid 
oxidation (170,171).  Although these parameters were not tested in the current 
study, characterizing the alterations in these lipid metabolites in Ppp1r3b∆hep mice 
would be highly relevant to elucidate the pathophysiology of hepatic steatosis 
and insulin resistance in this animal model.  
Another potential proposition for the development of systemic insulin 
resistance in Ppp1r3b∆hep mice could be the elevation in chronic inflammation. 
Growing evidence links a chronic, sub-acute inflammatory state to the 
development of obesity and the coexisting conditions of insulin resistance.  
Researchers have consistently found elevation in markers of inflammatory 
responses, and it has been shown that pro-inflammatory cytokines can cause 
insulin resistance, while anti-inflammatory therapies can reverse the effect, 
suggesting that inflammation may directly be involved in its pathogenesis (172).  
Inflammatory markers that are synthesized in the liver include C-Reactive Protein 
(CRP), Plasminogen activator inhibitor-1 (PAI-1), fibrinogen, and Interleukin 6 (IL-
 
 
131 
  
 
6), suggesting that sub-acute inflammation in the liver secondary to steatosis 
might be involved in the development of insulin resistance (138,172). 
Upregulation in hepatic expression of IL-6 in Ppp1r3b∆hep mice under chronic 
high-sucrose diet feeding indicates that elevated inflammatory pathway could 
likely be promoting the progression to insulin resistance secondary to the hepatic 
fatty acid accumulation found in this mouse model. 
A final phenotype that I explored in this mouse model was the effect on 
plasma lipids, as PPP1R3B genetic locus was also linked to total cholesterol, 
HDL-C and LDL-C in human GWAS studies (15,17).  In liver specific-Ppp1r3b 
knockout mice fed high sucrose diet, a significant elevation in plasma HDL-C, 
LDL-C and total cholesterol levels, and a concomitant change in the composition 
in these lipid species, indicates that perhaps consequence of glycogen storage 
deficiency, does promote defect in lipid metabolism, giving rise to plasma lipid 
abnormalities. These concepts have also been explored in glycogen storage 
disorders, such as GSD1, in which patients with a defect in the enzyme Glucose-
6-Phosphatase (G6PC).  These patients have inability in mobilizing their hepatic 
glycogen stores, and also have hepatic steatosis as a consequence, with 
abnormally high plasma lipids, including VLDL-C and LDL-C, with a delayed 
clearance of these species (173,174). Dyslipidemia is also frequently observed in 
patients with hepatic steatosis and NAFLD, and is typically characterized by 
elevated plasma triglycerides and LDL-C and decreased HDL-C (175,176). This 
atherogenic dyslipidemia may confer increased risk to the development of 
cardiovascular disease.  In regards to HDL-cholesterol, it is now largely accepted 
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that its functionality is more important than its quantity in conferring 
atheroprotection (177). In that regard, although HDL exerts multiple beneficial 
actions (178), in the presence of inflammation, oxidative stress and/or 
dysglycemia, HDL may be transformed into dysfunctional molecules exerting pro-
atherogenic effects (179,180).  Perhaps, the changes in plasma lipid composition 
in HDL fractions observed in Ppp1r3b∆hep mice could reflect this possibility.  And 
further, although there were no differences detected in plasma triglycerides in 
Ppp1r3b∆hep mice, it is highly possible that the defect in hepatic Ppp1r3b could 
promote rapid remodeling of these lipid species, that this effect could be not be 
seen under steady state conditions.  More comprehensive studies utilizing tracer 
methods to characterize the dynamic properties of these lipid species would be 
essential in further studying the alterations in plasma lipid metabolism in this 
mouse model.   Furthermore, crossing Ppp1r3b∆hep mice with other mice strains, 
such as LDL-receptor and/or ApoE knockout mice, which are typically used for 
atherogenic  studies (181,182) would be of great interest to further probe this 
phenotype and to study the effect of the deletion of Ppp1r3b in the development 
of cardiovascular disease. 
Lastly, using the mouse model of acutely overexpressing Ppp1r3b in liver 
in C57BL/6J wildtype mice was an important tool for validating these phenotypes 
in a reciprocal manner.  In mice overexpressing liver Ppp1r3b, we showed that 
hepatic fat accumulation was attenuated under chronic sucrose diet feeding, as a 
result of enhanced hepatic glycogen storage. This phenomenon has been 
reported in a recent study, suggesting that elevation in liver glycogen content has 
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been shown to attenuate hepatic steatosis in diet-induced obese mice (89). The 
authors concluded that this could be mediated through reduced food intake and 
appetite in these mice. In my study, although I did not test this parameter, it is 
possible that in mice overexpressing liver Ppp1r3b, this could be also be 
mediated as hepatic glycogen content has been linked to liver-brain-adipose 
neural axis(183).   In conditions of liver glycogen shortage, such as in liver 
Ppp1r3b∆hep mice, this activation in neurocircuitry, results in energy shift from 
carbohydrate to fat consumption.  Further studies would be essential to explore 
this phenotype in comprehensive detail. 
The reversal in glucose intolerance, insulin resistance, with reduction in 
plasma free fatty acids, and attenuation in adipocyte physiology in mice 
overexpressing liver Ppp1r3b under chronic sucrose diet feeding indicates that 
enhancing hepatic glycogen storage greatly improves the metabolic profile of 
these mice. And lastly, the fact that mice overexpressing liver Ppp1r3b, have 
reduced plasma total cholesterol, HDL-cholesterol, and phospholipids, also 
suggests that improving hepatic glycogen storage could confer improved lipid 
profile, which could be of major interest to the understanding of the development 
and potential protection towards cardiovascular disease.  Further detailed studies 
in variations on this animal model will be essential to characterize this effect. 
Taken together, the two mouse models (Ppp1r3b∆hep mice and mice 
overexpressing liver Ppp1r3b) represent interesting new research tools to study 
the pathophysiology of insulin resistance and associated metabolic disorders 
including dyslipidemia, NAFLD and Type 2 Diabetes. Glycogen synthesis is 
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typically diminished in patients with Type 2 Diabetes, and may represent a critical 
event in the development of the disease (61).  In Ppp1r3b∆hep mice, attenuation in 
liver glycogen synthesis results in pronounced impairment in insulin signaling, 
leading to systemic insulin resistance, under dietary manipulation. Derangement 
in hepatic glycogen metabolism is associated with altered lipid metabolism, 
through redirection of fuel substrates into lipid.  Enhancement of hepatic 
glycogen storage pathway as shown in mice overexpressing liver Ppp1r3b 
greatly improves these metabolic perturbations. The data presented here 
demonstrate that adaptor proteins such as Ppp1r3b play a key permissive role in 
mediating insulin action in a physiological context, and that improvement in 
hepatic glycogen content through this measure could be a potential target for 
pharmacological manipulation of diabetes and obesity. 
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CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
4.1 Metabolic disease, NAFLD, and PPP1R3B  
The incidence of obesity and Type 2 diabetes both in adults and children 
has reached epidemic proportions worldwide in the last several years. More than 
two thirds of adults are overweight, and more than one-third of adolescent 
children are obese by the age of 19 in the United States (72,184). Non-alcoholic 
fatty liver disease (NAFLD) has become a major issue associated with these 
metabolic disorders, representing over 75% of chronic liver diseases (184). 
NAFLD is prevalent in patients of all ages, and it has been reported in children as 
young as 2 years of age (185).  Epidemiological studies in United States and 
other countries have shown that the prevalence of this disease has nearly 
doubled over the last twenty years, and this increase is even more pronounced in 
adolescent populations, where the incidence have increased significantly (186-
188).  Various ethnic populations are more at risk for developing NAFLD, likely 
due to genetic variations, leading to increased predisposition (145,186).  Despite 
the increased prevalence of the disease, the mechanisms underlying the 
pathophysiology of the development of NAFLD have not been fully elucidated. 
There is a growing interest and effort among researchers and clinicians to 
understand the pathogenesis of this disease in more depth, with the aim of 
improving future diagnostic, preventative, and therapeutic options for the 
management of NAFLD.  
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NAFLD is characterized as a spectrum of histopathological stages in the 
liver ranging from simple steatosis to non-alcoholic steatohepatitis (NASH). 
Steatosis is first hallmark of NAFLD, and is characterized by excessive fat 
accumulation in the liver, not attributable to alcohol consumption.  Steatosis is 
defined as the presence of hepatic lipid levels above the 95th percentile for 
healthy individuals (>55mg/g liver)(73), or found in greater than 5% of 
hepatocytes by histopathology (189). Although hepatic steatosis alone is not 
classically considered harmful, it is now considered as one of the major factors 
that promote susceptibility to progressive injury, along with oxidative 
hepatocellular damage, and inflammation leading to non-alcoholic steatohepatitis 
(NASH), fibrosis, cirrhosis, and hepatocellular carcinoma in a small subset of 
patients(104).  Moreover, the development of hepatic steatosis itself parallels the 
occurrence of insulin resistance; however this correlation does not define a 
causal relationship. It remains unclear whether insulin resistance or excessive fat 
accumulation develops first, and whether fatty liver invariably leads to insulin 
resistance.  Peripheral as well as whole-body insulin resistance may cause fatty 
liver by elevation in plasma free fatty acids, glucose and insulin which stimulates 
lipid synthesis and impair β-oxidation in the liver.  
The liver is a central organ in the body that orchestrates important 
metabolic functions that comprise of 1) storage and utilization of carbohydrates 
and neutral lipids, 2) hepatic glucose production to provide energy source under 
prolonged fasting state to peripheral tissues 3) utilization of fatty acids as energy 
source, and 4) export of fatty acids and cholesterol for delivery of these species 
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to peripheral tissues for structural and energy support. Systemic homeostasis of 
these major macronutrients is important for sustained health and survival.  
Therefore, perturbations in these liver-mediated nutrient homeostatic processes 
can lead to increased susceptibility to metabolic diseases. In NAFLD, hepatic 
triglyceride (TG) accumulation is a major factor that drives its development, with 
underlying causes linked to genetics and multifactorial alterations in diet, and 
endocrine mediated hormonal regulation of normal organ functions in liver, 
adipose tissue, skeletal muscle, and the immune system. More specifically, 
accumulation of triglycerides in the liver is a consequence of dysregulation in the 
catabolic and anabolic processes that maintain its steady-state equilibrium.  
These mechanisms include: 1) Synthesis of TG from dietary glucose, 2) 
Increased flux of free fatty acids derived from adipose tissue, which contribute to 
production and storage of TG, 3) Utilization of FFA into mitochondrial β-oxidation 
processes to generate energy, and 4) its export by the liver in the form of VLDL 
particles.  Imbalance in hepatic TG occurs when the rate at which it is 
synthesized and stored exceeds the rate at which it is consumed and/or 
exported.   
Variations in the prevalence of NAFLD among different ethnic populations 
could be in part explained by genetic differences within these individuals, which 
render them more susceptible to developing the disease. Previous 
epidemiological studies have shown that genetic factors account for one of the 
major components for the development of NAFLD (145,186,190,191).  In United 
States alone, Hispanics have the highest prevalence of the disease, with 45% 
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incidence rate compared to 33% among non-Hispanic whites and 24% among 
African Americans (103,192). Recent efforts to elucidate these genetic 
differences through large-scale genome wide studies (GWAS) in humans have 
identified several variants near candidate genes that suggest their potential roles 
in the increased predisposition in certain populations towards the development of 
the disease.  Single nucleotide polymorphisms (SNPs) near, one such genetic 
locus, PPP1R3B were found to be associated with hepatic steatosis among 
European and Hispanic Americans (16,17).   In addition to association with 
hepatic steatosis, PPP1R3B was also linked with multiple other metabolic traits 
including plasma glucose, insulin, lactate, lipids and alkaline phosphatase (ALP) 
levels (15,18,19,21).  And more importantly, the identification of PPP1R3B as an 
expression quantitative trait locus (eQTL)(15), specifically in liver, correlated with 
these associations, further strengthening our speculation that modulation of 
PPP1R3B  expression could potentially promote these metabolic effects 
observed in humans, and prompted us to further functionally validate these 
associations in a mammalian system.     
The aim of my dissertation was to study these GWAS-associated 
metabolic implications of PPP1R3B. The studies described in this dissertation 
were conducted to explore the functional consequences of these metabolic 
associations with PPP1R3B in further detail, by utilization of liver-specific 
Ppp1r3b loss-of function and gain-of-function mouse models.  In this chapter, I 
briefly discuss the major findings of this work and discuss its overarching 
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implications for future research.  A detailed discussion of the data has been 
provided in the previous chapters.  
4.2 Summary of major findings 
The major goal of this dissertation work was to characterize the functional 
role of hepatic PPP1R3B with respect to dictating the metabolic traits that were 
associated with polymorphisms near this genetic locus in humans. To this end, 
the major focus was to characterize novel mouse models of liver-specific 
Ppp1r3b loss-of function and gain-of-function systems, to determine effects  on 
plasma glucose and lipid homeostasis and development of NAFLD upon chow 
feeding as well as in a novel high sucrose diet feeding model to induce insulin 
resistance. I further probed the underlying mechanisms of the actions of Ppp1r3b 
in mediating carbohydrate and lipid partitioning and optimal fuel selection to 
maintain systemic nutrient homeostasis.  My work suggests that hepatic Ppp1r3b 
is a critical regulator of liver glycogen metabolism through modulation of 
glycogen synthase as well as glycogen phosphorylase activities, and 
consequently, plays an important role in regulating macronutrient homeostasis in 
the liver, plasma and periphery, and in the development of systemic insulin 
resistance under dietary manipulations.   
In Chapter 2, I elucidated the functional consequence of hepatic 
PPP1R3B on hepatic glycogen metabolism, and implications in whole body 
glucose homeostasis.  The major findings of this study were the following: 1) 
Liver-specific Ppp1r3b knockout mice (Ppp1r3b∆hep mice) had significantly 
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reduced steady-state hepatic glycogen levels under feeding and acute fasting 
states resulting in mild hypoglycemia.  2) In addition to the depletion in hepatic 
glycogen content, the dephosphorylation and activation of hepatic glycogen 
synthase (GS), a key enzyme involved in glycogen synthesis, was severely 
impaired. 3) Physiological consequences of reduced hepatic glycogen stores led 
to shunting of carbon source from dietary glucose into glycolysis pathway under 
ad libitum fed state, with increased expression of major glycolytic enzymes in the 
liver and resultant elevation in plasma lactate in Ppp1r3b∆hep mice.  4) Under 
prolonged fasting states, there was an early onset of expression of genes 
involved in the gluconeogenesis pathway in the liver, with increased utilization of 
non-carbohydrate sources such as pyruvate to maintain plasma glucose, 
indicating that liver gluconeogenesis thereby compensates for the lack of hepatic 
glycogen content and presumably glycogenolysis to maintain blood glucose in 
Ppp1r3b∆hep mice, 5) and there was significant elevation in plasma ketone bodies 
in Ppp1r3b∆hep mice under prolonged fasting state.  6) In a reciprocal manner, 
overexpressing Ppp1r3b in the liver enhances hepatic glycogen synthesis 
through efficient de-phosphorylation (i.e. activation) of GS, as well as storage 
presumably through inactivation of GP, and reverses these metabolic 
perturbations, including protection from formation of ketone bodies under 
prolonged fasting detected in Ppp1r3b∆hep mice. These findings indicate that 
hepatic Ppp1r3b is a critical regulator of hepatic glycogen stores and whole-body 
energy homeostasis.  
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In addition to glucose, liver is a major regulatory organ for de-novo 
synthesis of fatty acids or lipogenesis (DNL) and lipid-lipoprotein metabolism. 
Fatty acids in the liver are used for esterification and storage into triglycerides 
(TG) and are provided by three major sources: de-novo synthesis within liver, 
diet, and peripherally derived: adipose tissue lipolysis being the major contributor 
to plasma free fatty acid content upon fasting due to insulin mediated de-
repression of lipolysis.  In the fed state, dietary fats in the form of TG are 
transported by chylomicrons into the lymphatics. Because of their larger size, TG 
particles cannot be directly absorbed across the intestinal epithelium, therefore 
they are further hydrolyzed by lipases, such as lipoprotein lipases (LPL), are 
reassembled and secreted into the systemic circulation and are subsequently 
delivered to the peripheral tissues.  Another source of fatty acids in the liver is 
their derivation from dietary glucose. Glucose serves as a substrate that can be 
further metabolized for DNL.  Upon uptake by hepatocytes, glucose is 
phosphorylated into Glucose-6-phosphate (G6P) which can be polymerized into 
glycogen for energy storage, or metabolized further through the glycolysis 
pathway to generate pyruvate and lactate. Pyruvate is further converted into 
acetyl-coA, which is a major precursor for de novo lipogenesis. Acetyl-coA can 
subsequently be converted into malonyl-CoA, which is a rate-limiting step that 
commits its fate towards synthesis into fatty acids. Intracellular glucose can 
activate both direct and indirect mechanisms that regulate the synthesis of fatty 
acids.  The indirect pathway is mediated by insulin, which is a primary hormone 
that regulates DNL through activation of a transcription factor, sterol-regulatory 
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element-binding protein 1 (SREBP1) (49). Insulin promotes site-1 and 2 protease 
mediated cleavage of inactivated form of SREBP in the ER. Activated SREBP 
translocates from the cytosol into the nucleus, and stimulates the expression of 
genes involved in the lipogenesis pathway, which include Acetyl-coA carboxylase 
(ACC), fatty acid synthase (FAS), stearoyl-coA desaturase (SCD1), fatty acid 
elongase (ELOVL6) and mitochondrial glycerol 3-phosphate acyltransferase 
(GPAT) (49).  Intracellular glucose can also directly stimulate lipogenesis by 
activating the transcription factor carbohydrate response element binding protein 
(ChREBP). G6P and another intermediate metabolite in the Pentose Phosphate 
Pathway, Xylose-5-Phospate (X5P) have been identified as allosteric regulators 
of ChREBP (46,51,193).  ChREBP increases de novo synthesis of free fatty 
acids through the regulation of enzymes including pyruvate kinase (L-PK), FAS, 
and ACC.  The coordinated actions of these major transcription factors lead to 
the glucose-derived regulation of FA synthesis.   
In the fasting state, insulin and glucose levels drop, therefore lipogenesis 
may not serve as a primary route for derivation of fatty acids.  Conversely, rise in 
another set of hormones that include glucagon and epinephrine promote 
increase in activities of several lipases in adipose tissue including hormone 
sensitive lipase (HSL) and adipose TG lipase (ATGL). These lipases mediate 
hydrolysis of triglycerides and promote increase in plasma free fatty acids.  
Plasma free fatty acids can then be taken up by the liver and are processed in 
three ways: 1) utilization by the β-oxidation pathway for energy production 2) re-
esterification and storage as triglycerides in intracellular lipid droplets in 
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hepatocytes, or 3) or assembly into the core of apoB100 containing pre-VLDL 
particles in the lumen of the ER mediated by the actions of microsomal 
triglyceride transfer protein (MTTP), and subsequent export in the form of VLDL-
TG particles.  Fatty acids can also be incorporated to synthesize cholesterol and 
phospholipids in addition to VLDL.    
In Chapter 3, I delved into characterizing the role of hepatic Ppp1r3b in 
fatty acid synthesis, storage into triglycerides and its metabolism, specifically 
addressing its association with hepatic steatosis and plasma lipids from human 
GWAS studies.  As described earlier, ectopic accumulation of hepatic 
triglycerides gives rise to steatosis and is a result of an imbalance in fatty acid 
synthesis, utilization and secretion. A defect in four major routes in the liver could 
contribute to this clinical pathology. These include: 1) Increased free fatty acid 
uptake in the liver derived from adipose tissue derived plasma free fatty acids, 2) 
Increased synthesis of fatty acid synthesis from dietary glucose, 3) Impaired 
VLDL-TG secretion due to alterations in its assembly and/or secretion processes 
by the liver, and 4) decreased capacity to utilize fatty acids for β-oxidation 
pathway.  
High sucrose diet feeding was used as the model to stimulate a diet 
induced obesity state, and to study the metabolic phenotypes in Ppp1r3b∆hep 
mice. The major findings with respect to alterations in hepatic fat from this study 
are as following: 1) There was a significant increase in lipogenic gene 
expression, with a concomitant increase in FAS protein levels in Ppp1r3b∆hep 
mice livers. 2) There was no major difference observed in VLDL-TG secretion or 
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in expression of hepatic Mttp in Ppp1r3b∆hep mice livers. 3) Liver microarray 
analyses revealed gene expression pattern consistent with PPARα activation in 
Ppp1r3b∆hep mice, indicating that oxidation of fat could contribute as a 
compensatory mechanism to be utilized as a fuel source in the absence of 
intracellular glucose storage.  This finding is further corroborated by increased 
formation of ketone bodies observed in Ppp1r3b∆hep mice under prolonged fasting 
state.  4) Lastly, one major phenotype that was consistently observed in 
Ppp1r3b∆hep mice was an elevation in plasma free fatty acids under both chow 
and high sucrose diet.  Further molecular studies classifying the intracellular fate 
of fatty acids towards β- oxidation vs. storage and re-secretion as VLDL-TG from 
primary hepatocytes isolated from Ppp1r3b∆hep mice would be of significant 
importance to support the conclusion that increased FFA uptake and diminished 
oxidation capacity results in their storage as hepatic TGs. It has been previously 
shown that plasma free fatty acids are elevated in large, well-characterized 
populations of individuals with obesity, insulin resistance, NAFLD and Type 2 
Diabetes (194-196).   
Another major finding from my study was that under chronic sucrose 
feeding state, Ppp1r3b∆hep mice became severely glucose intolerant and insulin 
resistant. These mice also had elevated plasma insulin levels upon 12 weeks on 
high sucrose diet. There was also evidence of a potential defect in hepatic insulin 
signaling in in Ppp1r3b∆hep mice, with a decrease in deactivation of Glycogen 
Synthase Kinase 3 (GSK3) generally mediated by the major insulin-responsive 
kinase, AKT. Further comprehensive analysis of other insulin signaling proteins, 
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such as activation of upstream insulin receptor (IR), insulin receptor substrates 
(IRS1, and IRS2) and insulin signaling in other tissues such as white adipose 
tissue (WAT) and skeletal muscle would be of significant importance to support 
this conclusion. Data supporting insulin resistance in extrahepatic tissues was 
generated in white adipose tissue isolated from Ppp1r3b∆hep mice.  I showed that 
there was an increase in the WAT organ weight, which led to a rise in body 
weight gain under chronic sucrose feeding for 12 weeks. Further characterization 
of the adipocytes demonstrated that there was a possible increase in its cellular 
size in Ppp1r3b∆hep mice by morphological analysis. Plasma leptin levels were 
also significantly increased, consistent with the increased adipose tissue mass.  
Molecular studies showing increased cellular lipolysis in adipocytes isolated from 
Ppp1r3b∆hep mice would further corroborate this conclusion. Collectively, these 
findings indicate that hyperinsulinemia combined with defective hepatic and 
extrahepatic insulin signaling, likely leads to hepatic and systemic insulin 
resistance in these mice, paralleling ectopic fatty acid accumulation in liver. 
Although not tested in this research work, studying the intramyocellular lipid 
content in skeletal muscle would be highly relevant, supporting the conclusion of 
development of systemic insulin resistance in this mouse model.  
Hepatic insulin resistance is also associated with inflammation, which is a 
primary marker that defines the progression from steatosis to the state of non-
alcoholic steatohepatitis (NASH) in NAFLD patients (197). Commonly implicated 
inflammatory cytokines in this process are tumor necrosis fact alpha (TNFα), and 
Interleukin-6 (IL-6), both of which have been highly correlated to development of 
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insulin resistance, diabetes, and fatty liver in both animals and humans 
(71,139,140,198).   In this study, expression of IL-6 in liver was significantly 
increased in Ppp1r3b∆hep mice.  More specific studies revealing other markers of 
inflammation, with that of any evidence of oxidative liver damage would be of 
high relevance and importance to support this finding in this animal model.  
In Chapter 3, another major phenotype that I characterized in Ppp1r3b∆hep 
mice was an elevation in plasma lipids, which include: HDL, non-HDL, total 
cholesterol and phospholipids.  This finding was consistent with the human 
GWAS association of this locus, further validating our hypothesis that expression 
of PPP1R3B modulated plasma lipids.  It is well studied that hepatic 
steatosis/NAFLD and insulin resistance are often closely linked to dysregulation 
in plasma lipids, resulting in dyslipidemia, and are associated with increased risk 
for cardiovascular diseases (101,176).  In our mouse model, the elevation in 
these lipid species was also associated with a difference observed in the 
composition of these particles. This was supported by the elevation in 
appearance of different lipoproteins (ApoE, ApoA1, ApoB) in the lipid fractions in 
plasma from Ppp1r3b∆hep mice. Our interpretation of the data was that there is a 
potential difference in the size of these lipid particles in Ppp1r3b∆hep mice 
compared to the control group, perhaps suggestive of larger HDL or smaller LDL 
particles, which are known to be found in patients with NAFLD (180). The 
characterization of functional properties of these lipid species should be focused 
for further detailed studies, and would of significant importance for deeper 
understanding of the lipoprotein metabolism in this animal model.  
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In the reciprocal overexpression animal model of Ppp1r3b in the liver, the 
metabolic perturbations observed in Ppp1r3b∆hep mice were attenuated, resulting 
in amelioration of the phenotypes under chronic high sucrose diet feeding states.   
These findings include: 1) Reduced hepatic triglycerides, with ameliorated 
hepatic glycogen storage in mice overexpressing liver Ppp1r3b. 2) Reduced 
levels of plasma free fatty acids, with no differences in body weight gain and 
adipose tissue mass, and reduced adipocyte cell size in mice overexpressing 
liver Ppp1r3b, indicating that the enhancement of hepatic glycogen stores 
significantly improved the extrahepatic metabolic impairments that lead to 
dysregulated hepatic lipid metabolism, as observed in Ppp1r3b∆hep mice.  3) In 
these mice, there was also a reciprocal reduction in plasma lipids, with 
decreased levels of HDL cholesterol, total cholesterol and phospholipids 
compared to the control group. This was also associated with the reduced HDL 
peak size, which was modestly discernible from pooled plasma analysis by FPLC 
from Ppp1r3b∆hep mice.  4) These mice did not have impaired glucose tolerance 
and did not become insulin resistant, compared to control mice even under 
chronic high sucrose diet feeding, indicating that enhancing hepatic glycogen 
storage restored the systemic maintenance of glucose disposal, and functional 
insulin responses in hepatic and peripheral tissues.   Further detailed studies with 
respect to insulin signaling in tissues and whole- body glucose and lipid 
metabolism in these mice would greatly advance our understanding on the role of 
hepatic Ppp1r3b in orchestrating carbohydrate and lipid metabolism in mice.  
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A schematic model that brings together the role of PPP1R3B in hepatic glucose 
and lipid metabolism and its systemic effects is shown in Figure 30. 
To provide a broad overview of the role of hepatic Ppp1r3b in glucose and lipid 
metabolism, I propose a model below based on the current findings from my 
studies, with the anticipation that this work will be of future research interest for 
studying these pathways in greater depth.  
Figure 30: Proposed role of hepatic Ppp1r3b in carbohydrate and lipid 
metabolism (Based on this research work) 
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Figure 30: Proposed role of hepatic Ppp1r3b in carbohydrate and lipid metabolism: In liver Ppp1r3b 
deficient model, glucose derived from dietary uptake in hepatocytes, cannot efficiently be stored into glycogen. 
Carbons from glucose molecules are shunted towards the glycolysis pathway to generate two end products- 
Pyruvate and Lactate.  Lactate is secreted during ad-lib state, contributing to plasma lactate pool which can be 
re-uptaken to re-generate pyruvate that can be further metabolized to synthesize fatty acids and triglycerides, in 
de novo lipogenesis (DNL) pathway.  DNL is driven by two primary transcription factors, SREBP1 and ChREBP, 
regulated by insulin and glucose-6-phosphate respectively. Increased hepatic fat is a critical factor associated 
with NAFLD, and DNL is one of the major contributors to the hepatic fat source in Ppp1r3b
∆hep
 mice. In addition, 
mice become insulin resistant and glucose intolerant. Another contribution of hepatic FA in these mice is likely 
derived from increased plasma FA source from TG lipolysis in adipose tissue (due to insulin resistance), which 
are taken up by the in the liver (facilitated by CD36-transporter) and re-esterified into TG. Increased FA and 
insulin resistance also contributes to hepatic inflammation, as evident by increased IL-6 levels.  Increased TG 
availability in the liver drives alterations in assembly and secretion of VLDL, LDL and HDL/PL particles leading 
to changes in plasma lipids.     
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4.3 Remaining questions and future directions 
In conclusion, the work in this dissertation provides a functional 
characterization of hepatic Ppp1r3b and its role in hepatic glucose and lipid 
metabolism. I have established that our novel liver-specific loss and gain-of-
function Ppp1r3b mouse models, closely mirror the human genetics, and can be 
used to further probe in-depth mechanisms underlying the metabolic phenotypes 
that I report in this work.   
Several questions/gaps in knowledge still remain and could be addressed 
in future work. These questions include:  
1) What are the mechanistic implications of perturbations of fatty acid 
metabolism in liver in Ppp1r3b∆hep mice? From this work, I found that increased 
dietary glucose stimulation exacerbates hepatic fat accumulation, most likely 
through combination of activation of de novo lipogenesis and increased plasma 
free fatty acids. Mechanisms underlying increased plasma FFA release in 
Ppp1r3b∆hep mice need to be further explored in detail.  In vivo tracer studies 
should be performed to measure the rate of production of fatty acid synthesis and 
rate of esterification of fatty acids into triglycerides using various radio-labeled 
precursors (i.e- radiolabeled glucose for lipogenesis, and radiolabeled fatty acid 
(palmitate/oleate) for re-esterification), under chronic sucrose diet feeding to 
quantifiably measure lipogenesis and free fatty acid esterification respectively 
(199,200). Moreover, ex vivo experiments to address the cellular uptake of free 
fatty acids could be performed in primary hepatocytes in these mouse models 
(201), to further corroborate these phenotypes.  Likewise, the hepatic fatty acid 
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oxidation pathway, which was not fully explored in this work, could also be 
addressed using ex vivo experiments in primary hepatocytes (201).  Lastly, it has 
been shown that hepatic TG availability is a critical substrate-driven determinant 
of the assembly of apoB100 containing VLDL-TG particles in the liver.  In mouse 
models of insulin resistance, loss of responsiveness to insulin together with 
increased hepatic TG promotes increased VLDL-TG secretion in chronic states 
(202).  In Liver-insulin receptor KO mice (LIRKO), complete abrogation of hepatic 
insulin signaling resulted in increased apoB secretion (203). In Ppp1r3b∆hep mice 
under chronic sucrose feeding, although very modest increase were observed 
with respect to hepatic VLDL-TG secretion, the limitation of this study was that it 
was performed under shorter dietary exposure (4-weeks), and the relative ApoB 
secretion along with hepatic TG secretion was also not tested.  Perhaps, longer 
exposure to dietary glucose can potentiate this phenotype, as insulin resistance 
already manifests in these mice within 11 weeks on diet. Therefore, this pathway 
should be further addressed by in-vivo measurement of ApoB and TG secretion 
in these mice, using amino acid precursor labeling, such as [S35] methionine 
which is commonly used to access ApoB secretion (203,204).   
2) What are the mechanisms underlying metabolic perturbations in 
extrahepatic organs in Ppp1r3b∆hep mice?  From this work, it was shown that 
adipocyte morphology was altered with respect to the cellular size, and in 
addition, there was elevation in plasma free fatty acid levels in Ppp1r3b∆hep mice.  
The next logical experiment that remains to be addressed is to measure lipolysis 
from isolated adipocytes from control and Ppp1r3b∆hep mice, to test the 
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hypothesis that there is increased hydrolysis of triglycerides in Ppp1r3b∆hep mice, 
contributing to the increase in plasma fatty acid levels, further corroborating the 
finding from this work (205).  Additionally, since Ppp1r3b∆hep mice become insulin 
resistant, accessing insulin signaling in adipocytes would also be relevant to 
probe further mechanistic insight into how hepatic Ppp1r3b may play a role in 
driving insulin insensitivity in extrahepatic tissues, Likewise; similar studies could 
also be performed in skeletal muscle to access the severity of systemic insulin 
resistance in Ppp1r3b∆hep mice (68,206).  
3) Ppp1r3b∆hep mice become progressively more glucose intolerant over 
time under chronic sucrose diet feeding conditions. Conducting whole-body 
glucose utilization in combination with insulin clamp studies to characterize in 
vivo glucose uptake and turnover in different tissues such as liver, skeletal 
muscle and adipose tissue would also provide important insight into the 
metabolic mechanisms impaired in tissues underlying the insulin insensitivity in a 
more distinct and quantifiable manner (207). 
4) From this research work, dyslipidemia was identified as another major 
phenotype detected in Ppp1r3b∆hep mice. Mechanistic studies probing how 
lipoprotein metabolism is altered remains to be further characterized. Studies to 
illustrate the dynamic regulation of plasma lipoproteins in the context of 
deregulated hepatic carbohydrate and lipid homeostasis in Ppp1r3b∆hep mice 
would be significantly relevant, since particularly in insulin resistant states, such 
as patients with NAFLD and type 2 diabetes, frequently present with distinct lipid 
abnormalities, characterized by increased small dense LDL, and TG, with 
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reduced HDL and/or its abnormal functionality (175,180,208).  Of particular 
interest would be to study how the functionality of HDL is affected, since it serves 
as a protective lipid species, known to promote removal of cholesterol from 
plasma and extra-hepatic tissues, by transporting it to the liver for elimination into 
bile, in a process known as the reverse cholesterol transport(209). This pathway 
has been shown to be impaired in patients with NAFLD, due to defect in the 
capacity of HDL to recycle cellular and plasma cholesterol, largely mediated by 
inflammatory responses, dysglycemia and oxidative stress (176,179,180,210).  In 
Ppp1r3b∆hep mice, inflammation is present as detected by increased IL-6 
expression in liver, and there is a difference in composition of these lipid 
particles.  
In summary, we have shown through our studies that hepatic Ppp1r3b 
plays a crucial role in mediating carbohydrate and lipid fuel homeostasis in the 
liver, and genetic impairment in this pathway causes pathological conditions such 
as NAFLD. Further research will help elucidate interesting mechanistic insights 
into understanding the pathophysiology of such chronic liver diseases, with the 
hope to attain novel therapeutic targets for these metabolic disorders.  
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APPENDIX 
STUDY: 12-week High Fat Diet Study in control and Ppp1r3b liver-specific 
knockout (Ppp1r3bΔhep) mice 
Figure 1: Ppp1r3bΔhep mice maintained hepatic glycogen storage deficiency 
on 12 weeks of high fat diet 
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Figure 1: Ppp1r3bΔhep mice maintained hepatic glycogen storage deficiency 
on 12 weeks of high fat diet (A) Total body weights (n=7-10/genotype) (B) 
Percent of body weight gain (n=7-10/genotype) (C)  Liver glycogen levels (n=7-
10/genotype). (ND) Not detectable (D) Plasma glucose levels (n=7-10/genotype) 
(E) Protein expression of total GS, and P-GS (S641) (n=5/genotype).  Four-hour 
fasted livers from control and Ppp1r3b∆hep mice at 12 weeks on high fat diet 
(containing 45%kcal fat) were used for these analyses.  All mice were adults (2-8 
months) and were age-matched within experiments. The data are expressed as 
the mean + S.E. Significance was determined in all panels by unpaired Student’s 
t-test (*p<0.05, **p<0.005, ***p<0.0001). (n.s), not significant. 
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Figure 2: Liver TG in Ppp1r3b∆pp1 mice did not significantly change under 
chronic high fat diet feeding 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Liver TG in Ppp1r3b∆hep mice did not significantly change under 
chronic high fat diet feeding (A) Liver triglyceride levels (n=7-10/genotype) (B) 
Hepatic transcript levels of genes in the lipogenic pathway: Acaca, Fasn, and 
Scd1 (n=7-10/genotype) Four-hour fasted livers from control and Ppp1r3b∆hep 
mice at 12 weeks on high fat diet (containing 45%kcal fat) were used for these 
analyses.  All mice were adults (2-8 months) and were age-matched within 
experiments. The data are expressed as the mean + S.E. Significance was 
determined in all panels by unpaired Student’s t-test (*p<0.05, **p<0.005, 
***p<0.0001). (n.s), not significant.  
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Figure 3: Ppp1r3bΔhep mice have modest impairment in glucose and insulin 
tolerance compared to control group under high fat diet on 12 weeks 
Figure 3: Ppp1r3bΔhep mice have modest impairment in glucose and insulin 
tolerance compared to control group under high fat diet on 12 weeks (A) 
Glucose disposal capacity is measured by glucose tolerance test (GTT) in control 
and Ppp1r3b∆hep mice on 8 weeks on high fat diet (n=7-10/genotype). Values are 
reported as glucose levels and area under the curve (AUC) is expressed as 
arbitrary units.  (B)  Insulin response in peripheral tissues as measured by insulin 
tolerance test (ITT) in 6-hour fasted control and Ppp1r3b∆hep mice at 11 weeks on 
sucrose diet (n=7-10/genotype). Values are reported as percentage of basal 
glucose levels and area under the curve (AUC) is expressed as arbitrary units.   
All mice were adults (2-8 months) and were age-matched within experiments. 
The data are expressed as the mean + S.E. Significance was determined in all 
panels by unpaired Student’s t-test (*p<0.05, **p<0.005, ***p<0.0001). (n.s), not 
significant.  
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Figure 4: Ppp1r3bΔhep mice did not exhibit dyslipidemia compared to 
control group under chronic high fat diet feeding 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Ppp1r3bΔhep mice did not exhibit dyslipidemia compared to 
control group under chronic high fat diet feeding (A) Plasma lipids (including 
total cholesterol, HDL-cholesterol, non-HDL-cholesterol, triglycerides, and 
phospholipids) were measured in four-hour fasted plasma collected from control 
and Ppp1r3b∆hep mice at 12 weeks on high fat diet (n=7-10/genotype). (B)  Non-
esterified free fatty acids (NEFA) were measured in four-hour fasted plasma 
collected from control and Ppp1r3b∆hep mice at 12 weeks on high fat diet (n=7-
10/genotype). All mice were adults (2-8 months) and were age-matched within 
experiments. The data are expressed as the mean + S.E. Significance was 
determined in all panels by unpaired Student’s t-test (*p<0.05, **p<0.005, 
***p<0.0001). (n.s), not significant. 
 
 
158 
  
 
BIBLIOGRAPHY 
1. Visscher, Peter M., Brown, Matthew A., McCarthy, Mark I., and Yang, J. Five Years of 
GWAS Discovery. The American Journal of Human Genetics 90, 7-24 
2. Anderson, C. A., Boucher, G., Lees, C. W., Franke, A., D'Amato, M., Taylor, K. D., Lee, J. 
C., Goyette, P., Imielinski, M., Latiano, A., Lagace, C., Scott, R., Amininejad, L., 
Bumpstead, S., Baidoo, L., Baldassano, R. N., Barclay, M., Bayless, T. M., Brand, S., 
Buning, C., Colombel, J. F., Denson, L. A., De Vos, M., Dubinsky, M., Edwards, C., 
Ellinghaus, D., Fehrmann, R. S., Floyd, J. A., Florin, T., Franchimont, D., Franke, L., 
Georges, M., Glas, J., Glazer, N. L., Guthery, S. L., Haritunians, T., Hayward, N. K., Hugot, 
J. P., Jobin, G., Laukens, D., Lawrance, I., Lemann, M., Levine, A., Libioulle, C., Louis, E., 
McGovern, D. P., Milla, M., Montgomery, G. W., Morley, K. I., Mowat, C., Ng, A., 
Newman, W., Ophoff, R. A., Papi, L., Palmieri, O., Peyrin-Biroulet, L., Panes, J., Phillips, 
A., Prescott, N. J., Proctor, D. D., Roberts, R., Russell, R., Rutgeerts, P., Sanderson, J., 
Sans, M., Schumm, P., Seibold, F., Sharma, Y., Simms, L. A., Seielstad, M., Steinhart, A. 
H., Targan, S. R., van den Berg, L. H., Vatn, M., Verspaget, H., Walters, T., Wijmenga, C., 
Wilson, D. C., Westra, H. J., Xavier, R. J., Zhao, Z. Z., Ponsioen, C. Y., Andersen, V., 
Torkvist, L., Gazouli, M., Anagnou, N. P., Karlsen, T. H., Kupcinskas, L., Sventoraityte, J., 
Mansfield, J. C., Kugathasan, S., Silverberg, M. S., Halfvarson, J., Rotter, J. I., Mathew, C. 
G., Griffiths, A. M., Gearry, R., Ahmad, T., Brant, S. R., Chamaillard, M., Satsangi, J., Cho, 
J. H., Schreiber, S., Daly, M. J., Barrett, J. C., Parkes, M., Annese, V., Hakonarson, H., 
Radford-Smith, G., Duerr, R. H., Vermeire, S., Weersma, R. K., and Rioux, J. D. (2011) 
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of 
confirmed associations to 47. Nature genetics 43, 246-252 
3. Shu, X. O., Long, J., Cai, Q., Qi, L., Xiang, Y. B., Cho, Y. S., Tai, E. S., Li, X., Lin, X., Chow, W. 
H., Go, M. J., Seielstad, M., Bao, W., Li, H., Cornelis, M. C., Yu, K., Wen, W., Shi, J., Han, B. 
G., Sim, X. L., Liu, L., Qi, Q., Kim, H. L., Ng, D. P., Lee, J. Y., Kim, Y. J., Li, C., Gao, Y. T., 
Zheng, W., and Hu, F. B. (2010) Identification of new genetic risk variants for type 2 
diabetes. PLoS Genet 6, e1001127 
4. Speliotes, E. K., Willer, C. J., Berndt, S. I., Monda, K. L., Thorleifsson, G., Jackson, A. U., 
Lango Allen, H., Lindgren, C. M., Luan, J., Magi, R., Randall, J. C., Vedantam, S., Winkler, 
T. W., Qi, L., Workalemahu, T., Heid, I. M., Steinthorsdottir, V., Stringham, H. M., 
Weedon, M. N., Wheeler, E., Wood, A. R., Ferreira, T., Weyant, R. J., Segre, A. V., 
Estrada, K., Liang, L., Nemesh, J., Park, J. H., Gustafsson, S., Kilpelainen, T. O., Yang, J., 
Bouatia-Naji, N., Esko, T., Feitosa, M. F., Kutalik, Z., Mangino, M., Raychaudhuri, S., 
Scherag, A., Smith, A. V., Welch, R., Zhao, J. H., Aben, K. K., Absher, D. M., Amin, N., 
Dixon, A. L., Fisher, E., Glazer, N. L., Goddard, M. E., Heard-Costa, N. L., Hoesel, V., 
Hottenga, J. J., Johansson, A., Johnson, T., Ketkar, S., Lamina, C., Li, S., Moffatt, M. F., 
Myers, R. H., Narisu, N., Perry, J. R., Peters, M. J., Preuss, M., Ripatti, S., Rivadeneira, F., 
Sandholt, C., Scott, L. J., Timpson, N. J., Tyrer, J. P., van Wingerden, S., Watanabe, R. M., 
White, C. C., Wiklund, F., Barlassina, C., Chasman, D. I., Cooper, M. N., Jansson, J. O., 
Lawrence, R. W., Pellikka, N., Prokopenko, I., Shi, J., Thiering, E., Alavere, H., Alibrandi, 
M. T., Almgren, P., Arnold, A. M., Aspelund, T., Atwood, L. D., Balkau, B., Balmforth, A. J., 
Bennett, A. J., Ben-Shlomo, Y., Bergman, R. N., Bergmann, S., Biebermann, H., 
Blakemore, A. I., Boes, T., Bonnycastle, L. L., Bornstein, S. R., Brown, M. J., Buchanan, T. 
A., Busonero, F., Campbell, H., Cappuccio, F. P., Cavalcanti-Proenca, C., Chen, Y. D., 
 
 
159 
  
 
Chen, C. M., Chines, P. S., Clarke, R., Coin, L., Connell, J., Day, I. N., den Heijer, M., Duan, 
J., Ebrahim, S., Elliott, P., Elosua, R., Eiriksdottir, G., Erdos, M. R., Eriksson, J. G., Facheris, 
M. F., Felix, S. B., Fischer-Posovszky, P., Folsom, A. R., Friedrich, N., Freimer, N. B., Fu, 
M., Gaget, S., Gejman, P. V., Geus, E. J., Gieger, C., Gjesing, A. P., Goel, A., Goyette, P., 
Grallert, H., Grassler, J., Greenawalt, D. M., Groves, C. J., Gudnason, V., Guiducci, C., 
Hartikainen, A. L., Hassanali, N., Hall, A. S., Havulinna, A. S., Hayward, C., Heath, A. C., 
Hengstenberg, C., Hicks, A. A., Hinney, A., Hofman, A., Homuth, G., Hui, J., Igl, W., 
Iribarren, C., Isomaa, B., Jacobs, K. B., Jarick, I., Jewell, E., John, U., Jorgensen, T., 
Jousilahti, P., Jula, A., Kaakinen, M., Kajantie, E., Kaplan, L. M., Kathiresan, S., Kettunen, 
J., Kinnunen, L., Knowles, J. W., Kolcic, I., Konig, I. R., Koskinen, S., Kovacs, P., Kuusisto, J., 
Kraft, P., Kvaloy, K., Laitinen, J., Lantieri, O., Lanzani, C., Launer, L. J., Lecoeur, C., 
Lehtimaki, T., Lettre, G., Liu, J., Lokki, M. L., Lorentzon, M., Luben, R. N., Ludwig, B., 
Manunta, P., Marek, D., Marre, M., Martin, N. G., McArdle, W. L., McCarthy, A., 
McKnight, B., Meitinger, T., Melander, O., Meyre, D., Midthjell, K., Montgomery, G. W., 
Morken, M. A., Morris, A. P., Mulic, R., Ngwa, J. S., Nelis, M., Neville, M. J., Nyholt, D. R., 
O'Donnell, C. J., O'Rahilly, S., Ong, K. K., Oostra, B., Pare, G., Parker, A. N., Perola, M., 
Pichler, I., Pietilainen, K. H., Platou, C. G., Polasek, O., Pouta, A., Rafelt, S., Raitakari, O., 
Rayner, N. W., Ridderstrale, M., Rief, W., Ruokonen, A., Robertson, N. R., Rzehak, P., 
Salomaa, V., Sanders, A. R., Sandhu, M. S., Sanna, S., Saramies, J., Savolainen, M. J., 
Scherag, S., Schipf, S., Schreiber, S., Schunkert, H., Silander, K., Sinisalo, J., Siscovick, D. 
S., Smit, J. H., Soranzo, N., Sovio, U., Stephens, J., Surakka, I., Swift, A. J., Tammesoo, M. 
L., Tardif, J. C., Teder-Laving, M., Teslovich, T. M., Thompson, J. R., Thomson, B., Tonjes, 
A., Tuomi, T., van Meurs, J. B., van Ommen, G. J., Vatin, V., Viikari, J., Visvikis-Siest, S., 
Vitart, V., Vogel, C. I., Voight, B. F., Waite, L. L., Wallaschofski, H., Walters, G. B., Widen, 
E., Wiegand, S., Wild, S. H., Willemsen, G., Witte, D. R., Witteman, J. C., Xu, J., Zhang, Q., 
Zgaga, L., Ziegler, A., Zitting, P., Beilby, J. P., Farooqi, I. S., Hebebrand, J., Huikuri, H. V., 
James, A. L., Kahonen, M., Levinson, D. F., Macciardi, F., Nieminen, M. S., Ohlsson, C., 
Palmer, L. J., Ridker, P. M., Stumvoll, M., Beckmann, J. S., Boeing, H., Boerwinkle, E., 
Boomsma, D. I., Caulfield, M. J., Chanock, S. J., Collins, F. S., Cupples, L. A., Smith, G. D., 
Erdmann, J., Froguel, P., Gronberg, H., Gyllensten, U., Hall, P., Hansen, T., Harris, T. B., 
Hattersley, A. T., Hayes, R. B., Heinrich, J., Hu, F. B., Hveem, K., Illig, T., Jarvelin, M. R., 
Kaprio, J., Karpe, F., Khaw, K. T., Kiemeney, L. A., Krude, H., Laakso, M., Lawlor, D. A., 
Metspalu, A., Munroe, P. B., Ouwehand, W. H., Pedersen, O., Penninx, B. W., Peters, A., 
Pramstaller, P. P., Quertermous, T., Reinehr, T., Rissanen, A., Rudan, I., Samani, N. J., 
Schwarz, P. E., Shuldiner, A. R., Spector, T. D., Tuomilehto, J., Uda, M., Uitterlinden, A., 
Valle, T. T., Wabitsch, M., Waeber, G., Wareham, N. J., Watkins, H., Wilson, J. F., Wright, 
A. F., Zillikens, M. C., Chatterjee, N., McCarroll, S. A., Purcell, S., Schadt, E. E., Visscher, P. 
M., Assimes, T. L., Borecki, I. B., Deloukas, P., Fox, C. S., Groop, L. C., Haritunians, T., 
Hunter, D. J., Kaplan, R. C., Mohlke, K. L., O'Connell, J. R., Peltonen, L., Schlessinger, D., 
Strachan, D. P., van Duijn, C. M., Wichmann, H. E., Frayling, T. M., Thorsteinsdottir, U., 
Abecasis, G. R., Barroso, I., Boehnke, M., Stefansson, K., North, K. E., McCarthy, M. I., 
Hirschhorn, J. N., Ingelsson, E., and Loos, R. J. (2010) Association analyses of 249,796 
individuals reveal 18 new loci associated with body mass index. Nature genetics 42, 937-
948 
 
 
160 
  
 
5. Abecasis, G. R., Altshuler, D., Auton, A., Brooks, L. D., Durbin, R. M., Gibbs, R. A., Hurles, 
M. E., and McVean, G. A. (2010) A map of human genome variation from population-
scale sequencing. Nature 467, 1061-1073 
6. Stranger, B. E., Stahl, E. A., and Raj, T. (2011) Progress and Promise of Genome-Wide 
Association Studies for Human Complex Trait Genetics. Genetics 187, 367-383 
7. Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J. Y., Sackler, R. S., Haynes, C., Henning, A. K., 
SanGiovanni, J. P., Mane, S. M., Mayne, S. T., Bracken, M. B., Ferris, F. L., Ott, J., 
Barnstable, C., and Hoh, J. (2005) Complement factor H polymorphism in age-related 
macular degeneration. Science 308, 385-389 
8. Toomey, C. B., Kelly, U., Saban, D. R., and Bowes Rickman, C. (2015) Regulation of age-
related macular degeneration-like pathology by complement factor H. Proceedings of 
the National Academy of Sciences of the United States of America 112, E3040-E3049 
9. Schadt, E. E., Lamb, J., Yang, X., Zhu, J., Edwards, S., GuhaThakurta, D., Sieberts, S. K., 
Monks, S., Reitman, M., Zhang, C., Lum, P. Y., Leonardson, A., Thieringer, R., Metzger, J. 
M., Yang, L., Castle, J., Zhu, H., Kash, S. F., Drake, T. A., Sachs, A., and Lusis, A. J. (2005) 
An integrative genomics approach to infer causal associations between gene expression 
and disease. Nature genetics 37, 710-717 
10. Yang, X., Deignan, J. L., Qi, H., Zhu, J., Qian, S., Zhong, J., Torosyan, G., Majid, S., Falkard, 
B., Kleinhanz, R. R., Karlsson, J., Castellani, L. W., Mumick, S., Wang, K., Xie, T., Coon, M., 
Zhang, C., Estrada-Smith, D., Farber, C. R., Wang, S. S., van Nas, A., Ghazalpour, A., 
Zhang, B., MacNeil, D. J., Lamb, J. R., Dipple, K. M., Reitman, M. L., Mehrabian, M., Lum, 
P. Y., Schadt, E. E., Lusis, A. J., and Drake, T. A. (2009) Validation of candidate causal 
genes for obesity that affect shared metabolic pathways and networks. Nature genetics 
41, 415-423 
11. Loos, R. J., Lindgren, C. M., Li, S., Wheeler, E., Zhao, J. H., Prokopenko, I., Inouye, M., 
Freathy, R. M., Attwood, A. P., Beckmann, J. S., Berndt, S. I., Jacobs, K. B., Chanock, S. J., 
Hayes, R. B., Bergmann, S., Bennett, A. J., Bingham, S. A., Bochud, M., Brown, M., 
Cauchi, S., Connell, J. M., Cooper, C., Smith, G. D., Day, I., Dina, C., De, S., Dermitzakis, E. 
T., Doney, A. S., Elliott, K. S., Elliott, P., Evans, D. M., Sadaf Farooqi, I., Froguel, P., Ghori, 
J., Groves, C. J., Gwilliam, R., Hadley, D., Hall, A. S., Hattersley, A. T., Hebebrand, J., Heid, 
I. M., Lamina, C., Gieger, C., Illig, T., Meitinger, T., Wichmann, H. E., Herrera, B., Hinney, 
A., Hunt, S. E., Jarvelin, M. R., Johnson, T., Jolley, J. D., Karpe, F., Keniry, A., Khaw, K. T., 
Luben, R. N., Mangino, M., Marchini, J., McArdle, W. L., McGinnis, R., Meyre, D., 
Munroe, P. B., Morris, A. D., Ness, A. R., Neville, M. J., Nica, A. C., Ong, K. K., O'Rahilly, S., 
Owen, K. R., Palmer, C. N., Papadakis, K., Potter, S., Pouta, A., Qi, L., Randall, J. C., 
Rayner, N. W., Ring, S. M., Sandhu, M. S., Scherag, A., Sims, M. A., Song, K., Soranzo, N., 
Speliotes, E. K., Syddall, H. E., Teichmann, S. A., Timpson, N. J., Tobias, J. H., Uda, M., 
Vogel, C. I., Wallace, C., Waterworth, D. M., Weedon, M. N., Willer, C. J., Wraight, Yuan, 
X., Zeggini, E., Hirschhorn, J. N., Strachan, D. P., Ouwehand, W. H., Caulfield, M. J., 
Samani, N. J., Frayling, T. M., Vollenweider, P., Waeber, G., Mooser, V., Deloukas, P., 
McCarthy, M. I., Wareham, N. J., Barroso, I., Jacobs, K. B., Chanock, S. J., Hayes, R. B., 
Lamina, C., Gieger, C., Illig, T., Meitinger, T., Wichmann, H. E., Kraft, P., Hankinson, S. E., 
Hunter, D. J., Hu, F. B., Lyon, H. N., Voight, B. F., Ridderstrale, M., Groop, L., Scheet, P., 
Sanna, S., Abecasis, G. R., Albai, G., Nagaraja, R., Schlessinger, D., Jackson, A. U., 
Tuomilehto, J., Collins, F. S., Boehnke, M., and Mohlke, K. L. (2008) Common variants 
 
 
161 
  
 
near MC4R are associated with fat mass, weight and risk of obesity. Nature genetics 40, 
768-775 
12. van Vliet-Ostaptchouk, J. V., van Haeften, T. W., Landman, G. W. D., Reiling, E., Kleefstra, 
N., Bilo, H. J. G., Klungel, O. H., de Boer, A., van Diemen, C. C., Wijmenga, C., Boezen, H. 
M., Dekker, J. M., van 't Riet, E., Nijpels, G., Welschen, L. M. C., Zavrelova, H., Bruin, E. J., 
Elbers, C. C., Bauer, F., Onland-Moret, N. C., van der Schouw, Y. T., Grobbee, D. E., 
Spijkerman, A. M. W., van der A, D. L., Simonis-Bik, A. M., Eekhoff, E. M. W., Diamant, 
M., Kramer, M. H. H., Boomsma, D. I., de Geus, E. J., Willemsen, G., Slagboom, P. E., 
Hofker, M. H., and t Hart, L. M. (2012) Common Variants in the Type 2 Diabetes KCNQ1 
Gene Are Associated with Impairments in Insulin Secretion During Hyperglycaemic 
Glucose Clamp. PLoS ONE 7, e32148 
13. Yasuda, K., Miyake, K., Horikawa, Y., Hara, K., Osawa, H., Furuta, H., Hirota, Y., Mori, H., 
Jonsson, A., Sato, Y., Yamagata, K., Hinokio, Y., Wang, H. Y., Tanahashi, T., Nakamura, N., 
Oka, Y., Iwasaki, N., Iwamoto, Y., Yamada, Y., Seino, Y., Maegawa, H., Kashiwagi, A., 
Takeda, J., Maeda, E., Shin, H. D., Cho, Y. M., Park, K. S., Lee, H. K., Ng, M. C., Ma, R. C., 
So, W. Y., Chan, J. C., Lyssenko, V., Tuomi, T., Nilsson, P., Groop, L., Kamatani, N., Sekine, 
A., Nakamura, Y., Yamamoto, K., Yoshida, T., Tokunaga, K., Itakura, M., Makino, H., 
Nanjo, K., Kadowaki, T., and Kasuga, M. (2008) Variants in KCNQ1 are associated with 
susceptibility to type 2 diabetes mellitus. Nature genetics 40, 1092-1097 
14. Global Lipids Genetics, C. (2013) Discovery and refinement of loci associated with lipid 
levels. Nature genetics 45, 1274-1283 
15. Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, 
M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., Johansen, C. T., Fouchier, S. 
W., Isaacs, A., Peloso, G. M., Barbalic, M., Ricketts, S. L., Bis, J. C., Aulchenko, Y. S., 
Thorleifsson, G., Feitosa, M. F., Chambers, J., Orho-Melander, M., Melander, O., 
Johnson, T., Li, X., Guo, X., Li, M., Shin Cho, Y., Jin Go, M., Jin Kim, Y., Lee, J. Y., Park, T., 
Kim, K., Sim, X., Twee-Hee Ong, R., Croteau-Chonka, D. C., Lange, L. A., Smith, J. D., Song, 
K., Hua Zhao, J., Yuan, X., Luan, J., Lamina, C., Ziegler, A., Zhang, W., Zee, R. Y., Wright, A. 
F., Witteman, J. C., Wilson, J. F., Willemsen, G., Wichmann, H. E., Whitfield, J. B., 
Waterworth, D. M., Wareham, N. J., Waeber, G., Vollenweider, P., Voight, B. F., Vitart, 
V., Uitterlinden, A. G., Uda, M., Tuomilehto, J., Thompson, J. R., Tanaka, T., Surakka, I., 
Stringham, H. M., Spector, T. D., Soranzo, N., Smit, J. H., Sinisalo, J., Silander, K., 
Sijbrands, E. J., Scuteri, A., Scott, J., Schlessinger, D., Sanna, S., Salomaa, V., Saharinen, J., 
Sabatti, C., Ruokonen, A., Rudan, I., Rose, L. M., Roberts, R., Rieder, M., Psaty, B. M., 
Pramstaller, P. P., Pichler, I., Perola, M., Penninx, B. W., Pedersen, N. L., Pattaro, C., 
Parker, A. N., Pare, G., Oostra, B. A., O'Donnell, C. J., Nieminen, M. S., Nickerson, D. A., 
Montgomery, G. W., Meitinger, T., McPherson, R., McCarthy, M. I., McArdle, W., 
Masson, D., Martin, N. G., Marroni, F., Mangino, M., Magnusson, P. K., Lucas, G., Luben, 
R., Loos, R. J., Lokki, M. L., Lettre, G., Langenberg, C., Launer, L. J., Lakatta, E. G., 
Laaksonen, R., Kyvik, K. O., Kronenberg, F., Konig, I. R., Khaw, K. T., Kaprio, J., Kaplan, L. 
M., Johansson, A., Jarvelin, M. R., Janssens, A. C., Ingelsson, E., Igl, W., Kees Hovingh, G., 
Hottenga, J. J., Hofman, A., Hicks, A. A., Hengstenberg, C., Heid, I. M., Hayward, C., 
Havulinna, A. S., Hastie, N. D., Harris, T. B., Haritunians, T., Hall, A. S., Gyllensten, U., 
Guiducci, C., Groop, L. C., Gonzalez, E., Gieger, C., Freimer, N. B., Ferrucci, L., Erdmann, 
J., Elliott, P., Ejebe, K. G., Doring, A., Dominiczak, A. F., Demissie, S., Deloukas, P., de 
Geus, E. J., de Faire, U., Crawford, G., Collins, F. S., Chen, Y. D., Caulfield, M. J., Campbell, 
 
 
162 
  
 
H., Burtt, N. P., Bonnycastle, L. L., Boomsma, D. I., Boekholdt, S. M., Bergman, R. N., 
Barroso, I., Bandinelli, S., Ballantyne, C. M., Assimes, T. L., Quertermous, T., Altshuler, D., 
Seielstad, M., Wong, T. Y., Tai, E. S., Feranil, A. B., Kuzawa, C. W., Adair, L. S., Taylor, H. 
A., Jr., Borecki, I. B., Gabriel, S. B., Wilson, J. G., Holm, H., Thorsteinsdottir, U., 
Gudnason, V., Krauss, R. M., Mohlke, K. L., Ordovas, J. M., Munroe, P. B., Kooner, J. S., 
Tall, A. R., Hegele, R. A., Kastelein, J. J., Schadt, E. E., Rotter, J. I., Boerwinkle, E., 
Strachan, D. P., Mooser, V., Stefansson, K., Reilly, M. P., Samani, N. J., Schunkert, H., 
Cupples, L. A., Sandhu, M. S., Ridker, P. M., Rader, D. J., van Duijn, C. M., Peltonen, L., 
Abecasis, G. R., Boehnke, M., and Kathiresan, S. (2010) Biological, clinical and population 
relevance of 95 loci for blood lipids. Nature 466, 707-713 
16. Hernaez, R., McLean, J., Lazo, M., Brancati, F. L., Hirschhorn, J. N., Borecki, I. B., Harris, T. 
B., Genetics of Obesity-Related Liver Disease, C., Nguyen, T., Kamel, I. R., Bonekamp, S., 
Eberhardt, M. S., Clark, J. M., Kao, W. H., and Speliotes, E. K. (2013) Association between 
variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based 
on data from the third National Health and Nutrition Examination Survey. Clin 
Gastroenterol Hepatol 11, 1183-1190 e1182 
17. Speliotes, E. K., Yerges-Armstrong, L. M., Wu, J., Hernaez, R., Kim, L. J., Palmer, C. D., 
Gudnason, V., Eiriksdottir, G., Garcia, M. E., Launer, L. J., Nalls, M. A., Clark, J. M., 
Mitchell, B. D., Shuldiner, A. R., Butler, J. L., Tomas, M., Hoffmann, U., Hwang, S. J., 
Massaro, J. M., O'Donnell, C. J., Sahani, D. V., Salomaa, V., Schadt, E. E., Schwartz, S. M., 
Siscovick, D. S., Nash, C. R. N., Consortium, G., Investigators, M., Voight, B. F., Carr, J. J., 
Feitosa, M. F., Harris, T. B., Fox, C. S., Smith, A. V., Kao, W. H., Hirschhorn, J. N., Borecki, 
I. B., and Consortium, G. (2011) Genome-wide association analysis identifies variants 
associated with nonalcoholic fatty liver disease that have distinct effects on metabolic 
traits. PLoS Genet 7, e1001324 
18. Manning, A. K., Hivert, M. F., Scott, R. A., Grimsby, J. L., Bouatia-Naji, N., Chen, H., Rybin, 
D., Liu, C. T., Bielak, L. F., Prokopenko, I., Amin, N., Barnes, D., Cadby, G., Hottenga, J. J., 
Ingelsson, E., Jackson, A. U., Johnson, T., Kanoni, S., Ladenvall, C., Lagou, V., Lahti, J., 
Lecoeur, C., Liu, Y., Martinez-Larrad, M. T., Montasser, M. E., Navarro, P., Perry, J. R., 
Rasmussen-Torvik, L. J., Salo, P., Sattar, N., Shungin, D., Strawbridge, R. J., Tanaka, T., 
van Duijn, C. M., An, P., de Andrade, M., Andrews, J. S., Aspelund, T., Atalay, M., 
Aulchenko, Y., Balkau, B., Bandinelli, S., Beckmann, J. S., Beilby, J. P., Bellis, C., Bergman, 
R. N., Blangero, J., Boban, M., Boehnke, M., Boerwinkle, E., Bonnycastle, L. L., Boomsma, 
D. I., Borecki, I. B., Bottcher, Y., Bouchard, C., Brunner, E., Budimir, D., Campbell, H., 
Carlson, O., Chines, P. S., Clarke, R., Collins, F. S., Corbaton-Anchuelo, A., Couper, D., de 
Faire, U., Dedoussis, G. V., Deloukas, P., Dimitriou, M., Egan, J. M., Eiriksdottir, G., Erdos, 
M. R., Eriksson, J. G., Eury, E., Ferrucci, L., Ford, I., Forouhi, N. G., Fox, C. S., Franzosi, M. 
G., Franks, P. W., Frayling, T. M., Froguel, P., Galan, P., de Geus, E., Gigante, B., Glazer, 
N. L., Goel, A., Groop, L., Gudnason, V., Hallmans, G., Hamsten, A., Hansson, O., Harris, 
T. B., Hayward, C., Heath, S., Hercberg, S., Hicks, A. A., Hingorani, A., Hofman, A., Hui, J., 
Hung, J., Jarvelin, M. R., Jhun, M. A., Johnson, P. C., Jukema, J. W., Jula, A., Kao, W. H., 
Kaprio, J., Kardia, S. L., Keinanen-Kiukaanniemi, S., Kivimaki, M., Kolcic, I., Kovacs, P., 
Kumari, M., Kuusisto, J., Kyvik, K. O., Laakso, M., Lakka, T., Lannfelt, L., Lathrop, G. M., 
Launer, L. J., Leander, K., Li, G., Lind, L., Lindstrom, J., Lobbens, S., Loos, R. J., Luan, J., 
Lyssenko, V., Magi, R., Magnusson, P. K., Marmot, M., Meneton, P., Mohlke, K. L., 
Mooser, V., Morken, M. A., Miljkovic, I., Narisu, N., O'Connell, J., Ong, K. K., Oostra, B. A., 
 
 
163 
  
 
Palmer, L. J., Palotie, A., Pankow, J. S., Peden, J. F., Pedersen, N. L., Pehlic, M., Peltonen, 
L., Penninx, B., Pericic, M., Perola, M., Perusse, L., Peyser, P. A., Polasek, O., Pramstaller, 
P. P., Province, M. A., Raikkonen, K., Rauramaa, R., Rehnberg, E., Rice, K., Rotter, J. I., 
Rudan, I., Ruokonen, A., Saaristo, T., Sabater-Lleal, M., Salomaa, V., Savage, D. B., 
Saxena, R., Schwarz, P., Seedorf, U., Sennblad, B., Serrano-Rios, M., Shuldiner, A. R., 
Sijbrands, E. J., Siscovick, D. S., Smit, J. H., Small, K. S., Smith, N. L., Smith, A. V., 
Stancakova, A., Stirrups, K., Stumvoll, M., Sun, Y. V., Swift, A. J., Tonjes, A., Tuomilehto, 
J., Trompet, S., Uitterlinden, A. G., Uusitupa, M., Vikstrom, M., Vitart, V., Vohl, M. C., 
Voight, B. F., Vollenweider, P., Waeber, G., Waterworth, D. M., Watkins, H., Wheeler, E., 
Widen, E., Wild, S. H., Willems, S. M., Willemsen, G., Wilson, J. F., Witteman, J. C., 
Wright, A. F., Yaghootkar, H., Zelenika, D., Zemunik, T., Zgaga, L., Replication, D. I. G., 
Meta-analysis, C., Multiple Tissue Human Expression Resource, C., Wareham, N. J., 
McCarthy, M. I., Barroso, I., Watanabe, R. M., Florez, J. C., Dupuis, J., Meigs, J. B., and 
Langenberg, C. (2012) A genome-wide approach accounting for body mass index 
identifies genetic variants influencing fasting glycemic traits and insulin resistance. 
Nature genetics 44, 659-669 
19. Tin, A., Balakrishnan, P., Beaty, T. H., Boerwinkle, E., Hoogeveen, R. C., Young, J. H., and 
Kao, W. H. (2016) GCKR and PPP1R3B identified as genome-wide significant loci for 
plasma lactate: the Atherosclerosis Risk in Communities (ARIC) study. Diabetic medicine 
: a journal of the British Diabetic Association 33, 968-975 
20. Palmer, N. D., Musani, S. K., Yerges-Armstrong, L. M., Feitosa, M. F., Bielak, L. F., 
Hernaez, R., Kahali, B., Carr, J. J., Harris, T. B., Jhun, M. A., Kardia, S. L., Langefeld, C. D., 
Mosley, T. H., Jr., Norris, J. M., Smith, A. V., Taylor, H. A., Wagenknecht, L. E., Liu, J., 
Borecki, I. B., Peyser, P. A., and Speliotes, E. K. (2013) Characterization of European 
ancestry nonalcoholic fatty liver disease-associated variants in individuals of African and 
Hispanic descent. Hepatology 58, 966-975 
21. Chambers, J. C., Zhang, W., Sehmi, J., Li, X., Wass, M. N., Van der Harst, P., Holm, H., 
Sanna, S., Kavousi, M., Baumeister, S. E., Coin, L. J., Deng, G., Gieger, C., Heard-Costa, N. 
L., Hottenga, J. J., Kuhnel, B., Kumar, V., Lagou, V., Liang, L., Luan, J., Vidal, P. M., Mateo 
Leach, I., O'Reilly, P. F., Peden, J. F., Rahmioglu, N., Soininen, P., Speliotes, E. K., Yuan, X., 
Thorleifsson, G., Alizadeh, B. Z., Atwood, L. D., Borecki, I. B., Brown, M. J., Charoen, P., 
Cucca, F., Das, D., de Geus, E. J., Dixon, A. L., Doring, A., Ehret, G., Eyjolfsson, G. I., 
Farrall, M., Forouhi, N. G., Friedrich, N., Goessling, W., Gudbjartsson, D. F., Harris, T. B., 
Hartikainen, A. L., Heath, S., Hirschfield, G. M., Hofman, A., Homuth, G., Hypponen, E., 
Janssen, H. L., Johnson, T., Kangas, A. J., Kema, I. P., Kuhn, J. P., Lai, S., Lathrop, M., 
Lerch, M. M., Li, Y., Liang, T. J., Lin, J. P., Loos, R. J., Martin, N. G., Moffatt, M. F., 
Montgomery, G. W., Munroe, P. B., Musunuru, K., Nakamura, Y., O'Donnell, C. J., 
Olafsson, I., Penninx, B. W., Pouta, A., Prins, B. P., Prokopenko, I., Puls, R., Ruokonen, A., 
Savolainen, M. J., Schlessinger, D., Schouten, J. N., Seedorf, U., Sen-Chowdhry, S., 
Siminovitch, K. A., Smit, J. H., Spector, T. D., Tan, W., Teslovich, T. M., Tukiainen, T., 
Uitterlinden, A. G., Van der Klauw, M. M., Vasan, R. S., Wallace, C., Wallaschofski, H., 
Wichmann, H. E., Willemsen, G., Wurtz, P., Xu, C., Yerges-Armstrong, L. M., Abecasis, G. 
R., Ahmadi, K. R., Boomsma, D. I., Caulfield, M., Cookson, W. O., van Duijn, C. M., 
Froguel, P., Matsuda, K., McCarthy, M. I., Meisinger, C., Mooser, V., Pietilainen, K. H., 
Schumann, G., Snieder, H., Sternberg, M. J., Stolk, R. P., Thomas, H. C., Thorsteinsdottir, 
U., Uda, M., Waeber, G., Wareham, N. J., Waterworth, D. M., Watkins, H., Whitfield, J. 
 
 
164 
  
 
B., Witteman, J. C., Wolffenbuttel, B. H., Fox, C. S., Ala-Korpela, M., Stefansson, K., 
Vollenweider, P., Volzke, H., Schadt, E. E., Scott, J., Jarvelin, M. R., Elliott, P., and Kooner, 
J. S. (2011) Genome-wide association study identifies loci influencing concentrations of 
liver enzymes in plasma. Nature genetics 43, 1131-1138 
22. Ligthart, S., de Vries, P. S., Uitterlinden, A. G., Hofman, A., group, C. I. w., Franco, O. H., 
Chasman, D. I., and Dehghan, A. (2015) Pleiotropy among Common Genetic Loci 
Identified for Cardiometabolic Disorders and C-Reactive Protein. PLoS ONE 10, e0118859 
23. Gasa, R., Jensen, P. B., Berman, H. K., Brady, M. J., DePaoli-Roach, A. A., and Newgard, C. 
B. (2000) Distinctive regulatory and metabolic properties of glycogen-targeting subunits 
of protein phosphatase-1 (PTG, GL, GM/RGl) expressed in hepatocytes. J Biol Chem 275, 
26396-26403 
24. Montori-Grau, M., Guitart, M., Lerin, C., Andreu, A. L., Newgard, C. B., Garcia-Martinez, 
C., and Gomez-Foix, A. M. (2007) Expression and glycogenic effect of glycogen-targeting 
protein phosphatase 1 regulatory subunit GL in cultured human muscle. The Biochemical 
journal 405, 107-113 
25. DOHERTY, M. J., Cadefau, J., Stalmans, W., Bollen, M., and COHEN, P. T. (1998) Loss of 
the hepatic glycogen-binding subunit (GL) of protein phosphatase 1 underlies deficient 
glycogen synthesis in insulin-dependent diabetic rats and in adrenalectomized starved 
rats. Biochemical Journal 333, 253-257 
26. Cohen, P. T. (2002) Protein phosphatase 1--targeted in many directions. Journal of cell 
science 115, 241-256 
27. Ceulemans, H., and Bollen, M. (2004) Functional diversity of protein phosphatase-1, a 
cellular economizer and reset button. Physiological reviews 84, 1-39 
28. Newgard, C. B., Brady, M. J., O'Doherty, R. M., and Saltiel, A. R. (2000) Organizing 
glucose disposal: emerging roles of the glycogen targeting subunits of protein 
phosphatase-1. Diabetes 49, 1967-1977 
29. Agius, L. (2015) Role of glycogen phosphorylase in liver glycogen metabolism. Mol 
Aspects Med 46, 34-45 
30. Armstrong, C. G., Doherty, M. J., and Cohen, P. T. (1998) Identification of the separate 
domains in the hepatic glycogen-targeting subunit of protein phosphatase 1 that 
interact with phosphorylase a, glycogen and protein phosphatase 1. The Biochemical 
journal 336 ( Pt 3), 699-704 
31. Fong, N. M., Jensen, T. C., Shah, A. S., Parekh, N. N., Saltiel, A. R., and Brady, M. J. (2000) 
Identification of binding sites on protein targeting to glycogen for enzymes of glycogen 
metabolism. J Biol Chem 275, 35034-35039 
32. Printen, J. A., Brady, M. J., and Saltiel, A. R. (1997) PTG, a protein phosphatase 1-binding 
protein with a role in glycogen metabolism. Science 275, 1475-1478 
33. Delibegovic, M., Armstrong, C. G., Dobbie, L., Watt, P. W., Smith, A. J., and Cohen, P. T. 
(2003) Disruption of the striated muscle glycogen targeting subunit PPP1R3A of protein 
phosphatase 1 leads to increased weight gain, fat deposition, and development of 
insulin resistance. Diabetes 52, 596-604 
34. HUBBARD, M. J., a d COHEN, P. 1  Regulatio  of protei  phosphatase‐1G fro  
rabbit skeletal muscle. European journal of biochemistry 186, 711-716 
35. Liu, J., and Brautigan, D. L. (2000) Insulin-stimulated phosphorylation of the protein 
phosphatase-1 striated muscle glycogen-targeting subunit and activation of glycogen 
synthase. J Biol Chem 275, 15940-15947 
 
 
165 
  
 
36. Kelsall, I. R., Rosenzweig, D., and Cohen, P. T. (2009) Disruption of the allosteric 
phosphorylase a regulation of the hepatic glycogen-targeted protein phosphatase 1 
improves glucose tolerance in vivo. Cell Signal 21, 1123-1134 
37. Crosson, S. M., Khan, A., Printen, J., Pessin, J. E., and Saltiel, A. R. (2003) PTG gene 
deletion causes impaired glycogen synthesis and developmental insulin resistance. 
Journal of Clinical Investigation 111, 1423-1432 
38. Rubio-Villena, C., Garcia-Gimeno, M. A., and Sanz, P. (2013) Glycogenic activity of R6, a 
protein phosphatase 1 regulatory subunit, is modulated by the laforin-malin complex. 
The international journal of biochemistry & cell biology 45, 1479-1488 
39. Munro, S., Ceulemans, H., Bollen, M., Diplexcito, J., and Cohen, P. T. (2005) A novel 
glycogen-targeting subunit of protein phosphatase 1 that is regulated by insulin and 
shows differential tissue distribution in humans and rodents. The FEBS journal 272, 
1478-1489 
40. Kelsall, I. R., Voss, M., Munro, S., Cuthbertson, D. J., and Cohen, P. T. (2011) R3F, a novel 
membrane-associated glycogen targeting subunit of protein phosphatase 1 regulates 
glycogen synthase in astrocytoma cells in response to glucose and extracellular signals. 
Journal of neurochemistry 118, 596-610 
41. Luo, X., Zhang, Y., Ruan, X., Jiang, X., Zhu, L., Wang, X., Ding, Q., Liu, W., Pan, Y., Wang, 
Z., and Chen, Y. (2011) Fasting-induced protein phosphatase 1 regulatory subunit 
contributes to postprandial blood glucose homeostasis via regulation of hepatic 
glycogenesis. Diabetes 60, 1435-1445 
42. Jurczak, M. J., Danos, A. M., Rehrmann, V. R., Allison, M. B., Greenberg, C. C., and Brady, 
M. J. (2007) Transgenic overexpression of protein targeting to glycogen markedly 
increases adipocytic glycogen storage in mice. Am J Physiol Endocrinol Metab 292, E952-
963 
43. Greenberg, C. C., Meredith, K. N., Yan, L., and Brady, M. J. (2003) Protein targeting to 
glycogen overexpression results in the specific enhancement of glycogen storage in 3T3-
L1 adipocytes. J Biol Chem 278, 30835-30842 
44. Danos, A. M., Osmanovic, S., and Brady, M. J. (2009) Differential regulation of 
glycogenolysis by mutant protein phosphatase-1 glycogen-targeting subunits. J Biol 
Chem 284, 19544-19553 
45. Towle, H. C., Kaytor, E. N., and Shih, H. M. (1997) Regulation of the expression of 
lipogenic enzyme genes by carbohydrate. Annual review of nutrition 17, 405-433 
46. Kabashima, T., Kawaguchi, T., Wadzinski, B. E., and Uyeda, K. (2003) Xylulose 5-
phosphate mediates glucose-induced lipogenesis by xylulose 5-phosphate-activated 
protein phosphatase in rat liver. Proceedings of the National Academy of Sciences of the 
United States of America 100, 5107-5112 
47. Beynen, A. C., Vaartjes, W. J., and Geelen, M. J. (1979) Opposite effects of insulin and 
glucagon in acute hormonal control of hepatic lipogenesis. Diabetes 28, 828-835 
48. Azzout-Marniche, D., Becard, D., Guichard, C., Foretz, M., Ferre, P., and Foufelle, F. 
(2000) Insulin effects on sterol regulatory-element-binding protein-1c (SREBP-1c) 
transcriptional activity in rat hepatocytes. The Biochemical journal 350 Pt 2, 389-393 
49. Horton, J. D., Goldstein, J. L., and Brown, M. S. (2002) SREBPs: activators of the complete 
program of cholesterol and fatty acid synthesis in the liver. The Journal of clinical 
investigation 109, 1125-1131 
 
 
166 
  
 
50. Koo, S. H., Dutcher, A. K., and Towle, H. C. (2001) Glucose and insulin function through 
two distinct transcription factors to stimulate expression of lipogenic enzyme genes in 
liver. J Biol Chem 276, 9437-9445 
51. Uyeda, K., and Repa, J. J. (2006) Carbohydrate response element binding protein, 
ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. 
Cell metabolism 4, 107-110 
52. Liang, G., Yang, J., Horton, J. D., Hammer, R. E., Goldstein, J. L., and Brown, M. S. (2002) 
Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice 
with selective deficiency of sterol regulatory element-binding protein-1c. J Biol Chem 
277, 9520-9528 
53. Foufelle, F., Gouhot, B., Pegorier, J. P., Perdereau, D., Girard, J., and Ferre, P. (1992) 
Glucose stimulation of lipogenic enzyme gene expression in cultured white adipose 
tissue. A role for glucose 6-phosphate. J Biol Chem 267, 20543-20546 
54. Girard, J., Ferre, P., and Foufelle, F. (1997) Mechanisms by which carbohydrates regulate 
expression of genes for glycolytic and lipogenic enzymes. Annual review of nutrition 17, 
325-352 
55. Thompson, K. S., and Towle, H. C. (1991) Localization of the carbohydrate response 
element of the rat L-type pyruvate kinase gene. J Biol Chem 266, 8679-8682 
56. Dentin, R., Pégorier, J.-P., Benhamed, F., Foufelle, F., Ferré, P., Fauveau, V., Magnuson, 
M. A., Girard, J., and Postic, C. (2004) Hepatic Glucokinase Is Required for the Synergistic 
Action of ChREBP and SREBP-1c on Glycolytic and Lipogenic Gene Expression. Journal of 
Biological Chemistry 279, 20314-20326 
57. Kawaguchi, T., Takenoshita, M., Kabashima, T., and Uyeda, K. (2001) Glucose and cAMP 
regulate the L-type pyruvate kinase gene by phosphorylation/dephosphorylation of the 
carbohydrate response element binding protein. Proceedings of the National Academy 
of Sciences 98, 13710-13715 
58. Stoeckman, A. K., and Towle, H. C. (2002) The Role of SREBP-1c in Nutritional Regulation 
of Lipogenic Enzyme Gene Expression. Journal of Biological Chemistry 277, 27029-27035 
59. Bae, J. S., Oh, A. R., Lee, H. J., Ahn, Y. H., and Cha, J. Y. (2016) Hepatic Elovl6 gene 
expression is regulated by the synergistic action of ChREBP and SREBP-1c. Biochem 
Biophys Res Commun 478, 1060-1066 
60. Puigserver, P., Rhee, J., Donovan, J., Walkey, C. J., Yoon, J. C., Oriente, F., Kitamura, Y., 
Altomonte, J., Dong, H., Accili, D., and Spiegelman, B. M. (2003) Insulin-regulated 
hepatic gluconeogenesis through FOXO1-PGC-1[alpha] interaction. Nature 423, 550-555 
61. Krssak, M., Brehm, A., Bernroider, E., Anderwald, C., Nowotny, P., Man, C. D., Cobelli, C., 
Cline, G. W., Shulman, G. I., Waldhäusl, W., and Roden, M. (2004) Alterations in 
Postprandial Hepatic Glycogen Metabolism in Type 2 Diabetes. Diabetes 53, 3048-3056 
62. Sarwar, N., Gao, P., Seshasai, S. R., Gobin, R., Kaptoge, S., Di Angelantonio, E., Ingelsson, 
E., Lawlor, D. A., Selvin, E., Stampfer, M., Stehouwer, C. D., Lewington, S., Pennells, L., 
Thompson, A., Sattar, N., White, I. R., Ray, K. K., and Danesh, J. (2010) Diabetes mellitus, 
fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-
analysis of 102 prospective studies. Lancet (London, England) 375, 2215-2222 
63. Kannel, W. B., and McGee, D. L. (1979) Diabetes and cardiovascular disease: The 
framingham study. JAMA 241, 2035-2038 
64. Cho, E., Rimm, E. B., Stampfer, M. J., Willett, W. C., and Hu, F. B. (2002) The impact of 
diabetes mellitus and prior myocardial infarction on mortality from all causes and from 
 
 
167 
  
 
coronary heart disease in men. Journal of the American College of Cardiology 40, 954-
960 
65. Fowler, M. J. (2008) Microvascular and Macrovascular Complications of Diabetes. 
Clinical Diabetes 26, 77 
66. McGarry, J. D. (2002) Banting lecture 2001 Dysregulation of fatty acid metabolism in the 
etiology of type 2 diabetes. Diabetes 51, 7-18 
67. Birkenfeld, A. L., and Shulman, G. I. (2014) Nonalcoholic fatty liver disease, hepatic 
insulin resistance, and type 2 diabetes. Hepatology 59, 713-723 
68. DeFronzo, R. A., and Tripathy, D. (2009) Skeletal Muscle Insulin Resistance Is the Primary 
Defect in Type 2 Diabetes. Diabetes care 32, S157-163 
69. Bellentani, S., and Marino, M. (2009) Epidemiology and natural history of non-alcoholic 
fatty liver disease (NAFLD). Annals of hepatology 8 Suppl 1, S4-8 
70. Richard, J., and Lingvay, I. (2011) Hepatic steatosis and Type 2 diabetes: current and 
future treatment considerations. Expert review of cardiovascular therapy 9, 321-328 
71. Feldstein, A. E. (2010) Novel insights into the pathophysiology of nonalcoholic fatty liver 
disease. Seminars in liver disease 30, 391-401 
72. Hassan, K., Bhalla, V., Ezz El Regal, M., and HH, A. K. (2014) Nonalcoholic fatty liver 
disease: A comprehensive review of a growing epidemic. World Journal of 
Gastroenterology : WJG 20, 12082-12101 
73. Cohen, J. C., Horton, J. D., and Hobbs, H. H. (2011) Human Fatty Liver Disease: Old 
Questions and New Insights. Science (New York, N.Y.) 332, 1519-1523 
74. Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., and Parks, E. 
J. (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients 
with nonalcoholic fatty liver disease. The Journal of clinical investigation 115, 1343-1351 
75. Samuel, V. T., and Shulman, G. I. (2016) The pathogenesis of insulin resistance: 
integrating signaling pathways and substrate flux. The Journal of clinical investigation 
126, 12-22 
76. Kahn, S. E., Hull, R. L., and Utzschneider, K. M. (2006) Mechanisms linking obesity to 
insulin resistance and type 2 diabetes. Nature 444, 840-846 
77. Schmittgen, T. D., and Livak, K. J. (2008) Analyzing real-time PCR data by the 
comparative CT method. Nature protocols 3, 1101-1108 
78. Li, W. C., Ralphs, K. L., and Tosh, D. (2010) Isolation and culture of adult mouse 
hepatocytes. Methods in molecular biology 633, 185-196 
79. Tsukamoto, K., Smith, P., Glick, J. M., and Rader, D. J. (1997) Liver-directed gene transfer 
and prolonged expression of three major human ApoE isoforms in ApoE-deficient mice. 
The Journal of clinical investigation 100, 107-114 
80. Leavens, K. F., Easton, R. M., Shulman, G. I., Previs, S. F., and Birnbaum, M. J. (2009) Akt2 
is required for hepatic lipid accumulation in models of insulin resistance. Cell 
metabolism 10, 405-418 
81. Strong, A., Ding, Q., Edmondson, A. C., Millar, J. S., Sachs, K. V., Li, X., Kumaravel, A., 
Wang, M. Y., Ai, D., Guo, L., Alexander, E. T., Nguyen, D., Lund-Katz, S., Phillips, M. C., 
Morales, C. R., Tall, A. R., Kathiresan, S., Fisher, E. A., Musunuru, K., and Rader, D. J. 
(2012) Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. 
The Journal of clinical investigation 122, 2807-2816 
 
 
168 
  
 
82. Saitoh, Y., Terada, N., Saitoh, S., Ohno, N., Fujii, Y., and Ohno, S. (2010) Histochemical 
approach of cryobiopsy for glycogen distribution in living mouse livers under fasting and 
local circulation loss conditions. Histochemistry and cell biology 133, 229-239 
83. Bollen, M., Keppens, S., and Stalmans, W. (1998) Specific features of glycogen 
metabolism in the liver. The Biochemical journal 336 ( Pt 1), 19-31 
84. Roach, P. J. (2002) Glycogen and its metabolism. Current molecular medicine 2, 101-120 
85. Stalmans, W., Bollen, M., and Mvumbi, L. (1987) Control of glycogen synthesis in health 
and disease. Diabetes/metabolism reviews 3, 127-161 
86. Villar-Palasi, C., and Guinovart, J. J. (1997) The role of glucose 6-phosphate in the control 
of glycogen synthase. FASEB journal : official publication of the Federation of American 
Societies for Experimental Biology 11, 544-558 
87. Roach, P. J., Depaoli-Roach, A. A., Hurley, T. D., and Tagliabracci, V. S. (2012) Glycogen 
and its metabolism: some new developments and old themes. The Biochemical journal 
441, 763-787 
88. Brady, M. J., Printen, J. A., Mastick, C. C., and Saltiel, A. R. (1997) Role of protein 
targeting to glycogen (PTG) in the regulation of protein phosphatase-1 activity. J Biol 
Chem 272, 20198-20204 
89. Lopez-Soldado, I., Zafra, D., Duran, J., Adrover, A., Calbo, J., and Guinovart, J. J. (2015) 
Liver glycogen reduces food intake and attenuates obesity in a high-fat diet-fed mouse 
model. Diabetes 64, 796-807 
90. Wang, L., Wang, H., Bell, P., McCarter, R. J., He, J., Calcedo, R., Vandenberghe, L. H., 
Morizono, H., Batshaw, M. L., and Wilson, J. M. (2010) Systematic evaluation of AAV 
vectors for liver directed gene transfer in murine models. Molecular therapy : the 
journal of the American Society of Gene Therapy 18, 118-125 
91. Ferrer, J. C., Favre, C., Gomis, R. R., Fernandez-Novell, J. M., Garcia-Rocha, M., de la 
Iglesia, N., Cid, E., and Guinovart, J. J. (2003) Control of glycogen deposition. FEBS letters 
546, 127-132 
92. Gain, K. R., Malthus, R., and Watts, C. (1981) Glucose homeostasis during the perinatal 
period in normal rats and rats with a glycogen storage disorder. The Journal of clinical 
investigation 67, 1569-1573 
93. Postic, C., and Magnuson, M. A. (2000) DNA excision in liver by an albumin-Cre 
transgene occurs progressively with age. Genesis 26, 149-150 
94. Postic, C., Shiota, M., Niswender, K. D., Jetton, T. L., Chen, Y., Moates, J. M., Shelton, K. 
D., Lindner, J., Cherrington, A. D., and Magnuson, M. A. (1999) Dual roles for glucokinase 
in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene 
knock-outs using Cre recombinase. J Biol Chem 274, 305-315 
95. Irimia, J. M., Meyer, C. M., Peper, C. L., Zhai, L., Bock, C. B., Previs, S. F., McGuinness, O. 
P., DePaoli-Roach, A., and Roach, P. J. (2010) Impaired glucose tolerance and 
predisposition to the fasted state in liver glycogen synthase knock-out mice. J Biol Chem 
285, 12851-12861 
96. Szymanska, E., Rokicki, D., Watrobinska, U., Ciara, E., Halat, P., Ploski, R., and Tylki-
Szymanka, A. (2015) Pediatric patient with hyperketotic hypoglycemia diagnosed with 
glycogen synthase deficiency due to the novel homozygous mutation in GYS2. Mol 
Genet Metab Rep 4, 83-86 
 
 
169 
  
 
97. Weinstein, D. A., Correia, C. E., Saunders, A. C., and Wolfsdorf, J. I. (2006) Hepatic 
glycogen synthase deficiency: an infrequently recognized cause of ketotic hypoglycemia. 
Molecular genetics and metabolism 87, 284-288 
98. O'Doherty, R. M., Jensen, P. B., Anderson, P., Jones, J. G., Berman, H. K., Kearney, D., and 
Newgard, C. B. (2000) Activation of direct and indirect pathways of glycogen synthesis 
by hepatic overexpression of protein targeting to glycogen. The Journal of clinical 
investigation 105, 479-488 
99. Doherty, M. J., Moorhead, G., Morrice, N., Cohen, P., and Cohen, P. T. (1995) Amino acid 
sequence and expression of the hepatic glycogen-binding (GL)-subunit of protein 
phosphatase-1. FEBS letters 375, 294-298 
100. Mikolasevic, I., Milic, S., Turk Wensveen, T., Grgic, I., Jakopcic, I., Stimac, D., Wensveen, 
F., and Orlic, L. (2016) Nonalcoholic fatty liver disease - A multisystem disease? World 
Journal of Gastroenterology 22, 9488-9505 
101. Targher, G., Marra, F., and Marchesini, G. (2008) Increased risk of cardiovascular disease 
in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 51, 
1947-1953 
102. Fargion, S., Porzio, M., and Fracanzani, A. L. (2014) Nonalcoholic fatty liver disease and 
vascular disease: state-of-the-art. World Journal of Gastroenterology : WJG 20, 13306-
13324 
103. Kahali, B., Halligan, B., and Speliotes, E. K. (2015) Insights from Genome-Wide 
Association Analyses of Nonalcoholic Fatty Liver Disease. Seminars in liver disease 35, 
375-391 
104. Buzzetti, E., Pinzani, M., and Tsochatzis, E. A. (2016) The multiple-hit pathogenesis of 
non-alcoholic fatty liver disease (NAFLD). Metabolism 65, 1038-1048 
105. Lattuada, G., Ragogna, F., and Perseghin, G. (2011) Why Does NAFLD Predict Type 2 
Diabetes? Current Diabetes Reports 11, 167-172 
106. Perry, Rachel J., Camporez, J.-Paulo G., Kursawe, R., Titchenell, Paul M., Zhang, D., Perry, 
Curtis J., Jurczak, Michael J., Abudukadier, A., Han, Myoung S., Zhang, X.-M., Ruan, H.-B., 
Yang, X., Caprio, S., Kaech, Susan M., Sul, Hei S., Birnbaum, Morris J., Davis, Roger J., 
Cline, Gary W., Petersen, Kitt F., and Shulman, Gerald I. Hepatic Acetyl CoA Links 
Adipose Tissue Inflammation to Hepatic Insulin Resistance and Type 2 Diabetes. Cell 
160, 745-758 
107. Suganami, T., Nishida, J., and Ogawa, Y. (2005) A paracrine loop between adipocytes and 
macrophages aggravates inflammatory changes: role of free fatty acids and tumor 
necrosis factor alpha. Arteriosclerosis, thrombosis, and vascular biology 25, 2062-2068 
108. Shimomura, I., Bashmakov, Y., and Horton, J. D. (1999) Increased levels of nuclear 
SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol 
Chem 274, 30028-30032 
109. Shimomura, I., Bashmakov, Y., Ikemoto, S., Horton, J. D., Brown, M. S., and Goldstein, J. 
L. (1999) Insulin selectively increases SREBP-1c mRNA in the livers of rats with 
streptozotocin-induced diabetes. Proceedings of the National Academy of Sciences of 
the United States of America 96, 13656-13661 
110. Monetti, M., Levin, M. C., Watt, M. J., Sajan, M. P., Marmor, S., Hubbard, B. K., Stevens, 
R. D., Bain, J. R., Newgard, C. B., Farese, R. V., Sr., Hevener, A. L., and Farese, R. V., Jr. 
(2007) Dissociation of hepatic steatosis and insulin resistance in mice overexpressing 
DGAT in the liver. Cell metabolism 6, 69-78 
 
 
170 
  
 
111. Yu, X. X., Murray, S. F., Pandey, S. K., Booten, S. L., Bao, D., Song, X. Z., Kelly, S., Chen, S., 
McKay, R., Monia, B. P., and Bhanot, S. (2005) Antisense oligonucleotide reduction of 
DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. 
Hepatology 42, 362-371 
112. Hoy, A. J., Bruce, C. R., Turpin, S. M., Morris, A. J., Febbraio, M. A., and Watt, M. J. (2011) 
Adipose triglyceride lipase-null mice are resistant to high-fat diet-induced insulin 
resistance despite reduced energy expenditure and ectopic lipid accumulation. 
Endocrinology 152, 48-58 
113. Minehira, K., Young, S. G., Villanueva, C. J., Yetukuri, L., Oresic, M., Hellerstein, M. K., 
Farese, R. V., Jr., Horton, J. D., Preitner, F., Thorens, B., and Tappy, L. (2008) Blocking 
VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or 
insulin sensitivity in mice. Journal of lipid research 49, 2038-2044 
114. Monsenego, J., Mansouri, A., Akkaoui, M., Lenoir, V., Esnous, C., Fauveau, V., Tavernier, 
V., Girard, J., and Prip-Buus, C. (2012) Enhancing liver mitochondrial fatty acid oxidation 
capacity in obese mice improves insulin sensitivity independently of hepatic steatosis. J 
Hepatol 56, 632-639 
115. Taniguchi, C. M., Ueki, K., and Kahn, R. (2005) Complementary roles of IRS-1 and IRS-2 in 
the hepatic regulation of metabolism. The Journal of clinical investigation 115, 718-727 
116. Macaluso, F. S., Maida, M., and Petta, S. (2015) Genetic background in nonalcoholic 
fatty liver disease: A comprehensive review. World Journal of Gastroenterology : WJG 
21, 11088-11111 
117. Damsbo, P., Vaag, A., Hother-Nielsen, O., and Beck-Nielsen, H. (1991) Reduced glycogen 
synthase activity in skeletal muscle from obese patients with and without type 2 (non-
insulin-dependent) diabetes mellitus. Diabetologia 34, 239-245 
118. Shulman, G. I., Rothman, D. L., Jue, T., Stein, P., DeFronzo, R. A., and Shulman, R. G. 
(1990) Quantitation of muscle glycogen synthesis in normal subjects and subjects with 
non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. The 
New England journal of medicine 322, 223-228 
119. Thorburn, A. W., Gumbiner, B., Bulacan, F., Wallace, P., and Henry, R. R. (1990) 
Intracellular glucose oxidation and glycogen synthase activity are reduced in non-insulin-
dependent (type II) diabetes independent of impaired glucose uptake. The Journal of 
clinical investigation 85, 522-529 
120. Iynedjian, P. B. (2009) Molecular physiology of mammalian glucokinase. Cellular and 
molecular life sciences : CMLS 66, 27-42 
121. Taylor, R., and Shulman, G. I. (2010) Regulation of Hepatic Glucose Uptake. in 
Comprehensive Physiology, John Wiley & Sons, Inc. pp  
122. Cohen, P. (1999) The Croonian Lecture 1998. Identification of a protein kinase cascade 
of major importance in insulin signal transduction. Philosophical transactions of the 
Royal Society of London. Series B, Biological sciences 354, 485-495 
123. Kersten, S. (2001) Mechanisms of nutritional and hormonal regulation of lipogenesis. 
EMBO Reports 2, 282-286 
124. Mashek, D. G. (2013) Hepatic fatty acid trafficking: multiple forks in the road. Advances 
in nutrition (Bethesda, Md.) 4, 697-710 
125. Koonen, D. P., Jacobs, R. L., Febbraio, M., Young, M. E., Soltys, C. L., Ong, H., Vance, D. 
E., and Dyck, J. R. (2007) Increased hepatic CD36 expression contributes to dyslipidemia 
associated with diet-induced obesity. Diabetes 56, 2863-2871 
 
 
171 
  
 
126. Miquilena-Colina, M. E., Lima-Cabello, E., Sanchez-Campos, S., Garcia-Mediavilla, M. V., 
Fernandez-Bermejo, M., Lozano-Rodriguez, T., Vargas-Castrillon, J., Buque, X., Ochoa, B., 
Aspichueta, P., Gonzalez-Gallego, J., and Garcia-Monzon, C. (2011) Hepatic fatty acid 
translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia 
and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut 60, 
1394-1402 
127. Harris, R. B. (2014) Direct and indirect effects of leptin on adipocyte metabolism. 
Biochimica et biophysica acta 1842, 414-423 
128. MacKay, E. M., and Bergman, H. (1932) The relation between glycogen and water 
storage in the liver. Journal of Biological Chemistry 96, 373-380 
129. Kawano, Y., and Cohen, D. E. (2013) Mechanisms of hepatic triglyceride accumulation in 
non-alcoholic fatty liver disease. Journal of Gastroenterology 48, 434-441 
130. Mandard, S., Muller, M., and Kersten, S. (2004) Peroxisome proliferator-activated 
receptor alpha target genes. Cellular and molecular life sciences : CMLS 61, 393-416 
131. Kersten, S., Seydoux, J., Peters, J. M., Gonzalez, F. J., Desvergne, B., and Wahli, W. (1999) 
Peroxisome proliferator-activated receptor alpha mediates the adaptive response to 
fasting. The Journal of clinical investigation 103, 1489-1498 
132. Shelness, G. S., and Sellers, J. A. (2001) Very-low-density lipoprotein assembly and 
secretion. Current opinion in lipidology 12, 151-157 
133. Tiwari, S., and Siddiqi, S. A. (2012) Intracellular trafficking and secretion of VLDL. 
Arteriosclerosis, thrombosis, and vascular biology 32, 1079-1086 
134. Qatanani, M., and Lazar, M. A. (2007) Mechanisms of obesity-associated insulin 
resistance: many choices on the menu. Genes & development 21, 1443-1455 
135. Roden, M. (2006) Mechanisms of Disease: hepatic steatosis in type 2 diabetes--
pathogenesis and clinical relevance. Nature clinical practice. Endocrinology & 
metabolism 2, 335-348 
136. Lewis, G. F., Carpentier, A., Adeli, K., and Giacca, A. (2002) Disordered fat storage and 
mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocrine 
reviews 23, 201-229 
137. Takahashi, Y., Soejima, Y., and Fukusato, T. (2012) Animal models of nonalcoholic fatty 
liver disease/nonalcoholic steatohepatitis. World Journal of Gastroenterology : WJG 18, 
2300-2308 
138. Kim, O. K., Jun, W., and Lee, J. (2015) Mechanism of ER Stress and Inflammation for 
Hepatic Insulin Resistance in Obesity. Annals of Nutrition and Metabolism 67, 218-227 
139. Wieckowska, A., Papouchado, B. G., Li, Z., Lopez, R., Zein, N. N., and Feldstein, A. E. 
(2008) Increased hepatic and circulating interleukin-6 levels in human nonalcoholic 
steatohepatitis. The American journal of gastroenterology 103, 1372-1379 
140. Klover, P. J., Zimmers, T. A., Koniaris, L. G., and Mooney, R. A. (2003) Chronic exposure 
to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52, 2784-2789 
141. Senn, J. J., Klover, P. J., Nowak, I. A., and Mooney, R. A. (2002) Interleukin-6 induces 
cellular insulin resistance in hepatocytes. Diabetes 51, 3391-3399 
142. Eisenberg, S. (1984) High density lipoprotein metabolism. Journal of lipid research 25, 
1017-1058 
143. Getz, G. S., and Reardon, C. A. (2009) Apoprotein E as a lipid transport and signaling 
protein in the blood, liver, and artery wall. Journal of lipid research 50, S156 
 
 
172 
  
 
144. Segrest, J. P., Jones, M. K., De Loof, H., and Dashti, N. (2001) Structure of apolipoprotein 
B-100 in low density lipoproteins. Journal of lipid research 42, 1346-1367 
145. Dongiovanni, P., Anstee, Q. M., and Valenti, L. (2013) Genetic Predisposition in NAFLD 
and NASH: Impact on Severity of Liver Disease and Response to Treatment. Current 
Pharmaceutical Design 19, 5219-5238 
146. Sumiyoshi, M., Sakanaka, M., and Kimura, Y. (2006) Chronic intake of high-fat and high-
sucrose diets differentially affects glucose intolerance in mice. The Journal of nutrition 
136, 582-587 
147. Santure, M., Pitre, M., Marette, A., Deshaies, Y., Lemieux, C., Lariviere, R., Nadeau, A., 
and Bachelard, H. (2002) Induction of insulin resistance by high-sucrose feeding does 
not raise mean arterial blood pressure but impairs haemodynamic responses to insulin 
in rats. British journal of pharmacology 137, 185-196 
148. Rizkalla, S. W. (2010) Health implications of fructose consumption: A review of recent 
data. Nutrition & Metabolism 7, 82-82 
149. Fernandes-Lima, F., Monte, T. L. R. G., Nascimento, F. A. M., and Gregório, B. M. (2015) 
Short Exposure to a High-Sucrose Diet a d the First Hit' of No alcoholic Fatty Liver 
Disease in Mice. Cells Tissues Organs 201, 464-472 
150. Gitzelmann, R., Spycher, M. A., Feil, G., Muller, J., Seilnacht, B., Stahl, M., and Bosshard, 
N. U. (1996) Liver glycogen synthase deficiency: a rarely diagnosed entity. Eur J Pediatr 
155, 561-567 
151. Bachrach, B. E., Weinstein, D. A., Orho-Melander, M., Burgess, A., and Wolfsdorf, J. I. 
(2002) Glycogen synthase deficiency (glycogen storage disease type 0) presenting with 
hyperglycemia and glucosuria: report of three new mutations. J Pediatr 140, 781-783 
152. Klok, M. D., Jakobsdottir, S., and Drent, M. L. (2007) The role of leptin and ghrelin in the 
regulation of food intake and body weight in humans: a review. Obesity reviews : an 
official journal of the International Association for the Study of Obesity 8, 21-34 
153. Zeng, W., Pirzgalska, R. M., Pereira, M. M., Kubasova, N., Barateiro, A., Seixas, E., Lu, Y.-
H., Kozlova, A., Voss, H., and Martins, G. G. (2015) Sympathetic neuro-adipose 
connections mediate leptin-driven lipolysis. Cell 163, 84-94 
154. Frederich, R. C., Hamann, A., Anderson, S., Lollmann, B., Lowell, B. B., and Flier, J. S. 
(1995) Leptin levels reflect body lipid content in mice: Evidence for diet-induced 
resistance to leptin action. Nat Med 1, 1311-1314 
155. Enriori, P. J., Evans, A. E., Sinnayah, P., Jobst, E. E., Tonelli-Lemos, L., Billes, S. K., Glavas, 
M. M., Grayson, B. E., Perello, M., Nillni, E. A., Grove, K. L., and Cowley, M. A. (2007) 
Diet-Induced Obesity Causes Severe but Reversible Leptin Resistance in Arcuate 
Melanocortin Neurons. Cell metabolism 5, 181-194 
156. Myers Jr, Martin G., Heymsfield, Steven B., Haft, C., Kahn, Barbara B., Laughlin, M., 
Leibel, Rudolph L., Tschöp, Matthias H., and Yanovski, Jack A. (2012) Challenges and 
Opportunities of Defining Clinical Leptin Resistance. Cell metabolism 15, 150-156 
157. Zeng, W., Pirzgalska, Roksana M., Pereira, Mafalda M. A., Kubasova, N., Barateiro, A., 
Seixas, E., Lu, Y.-H., Kozlova, A., Voss, H., Martins, Gabriel G., Friedman, Jeffrey M., and 
Domingos, Ana I. Sympathetic Neuro-adipose Connections Mediate Leptin-Driven 
Lipolysis. Cell 163, 84-94 
158. Ottaway, N., Mahbod, P., Rivero, B., Norman, Lee A., Gertler, A., D Alessio, David A., and 
Perez-Tilve, D. (2015) Diet-Induced Obese Mice Retain Endogenous Leptin Action. Cell 
metabolism 21, 877-882 
 
 
173 
  
 
159. Kasuga, M., Ogawa, W., and Ohara, T. (2003) Tissue glycogen content and glucose 
intolerance. Journal of Clinical Investigation 111, 1282-1284 
160. Kusunoki, M., Tsutsumi, K., Hara, T., Ogawa, H., Nakamura, T., Miyata, T., Sakakibara, F., 
Fukuzawa, Y., Suga, T., Kakumu, S., and Nakaya, Y. (2002) Correlation between lipid and 
glycogen contents in liver and insulin resistance in high-fat-fed rats treated with the 
lipoprotein lipase activator NO-1886. Metabolism 51, 792-795 
161. Wang, Y., Viscarra, J., Kim, S. J., and Sul, H. S. (2015) Transcriptional regulation of hepatic 
lipogenesis. Nature reviews. Molecular cell biology 16, 678-689 
162. Yahagi, N., Shimano, H., Hasty, A. H., Matsuzaka, T., Ide, T., Yoshikawa, T., Amemiya-
Kudo, M., Tomita, S., Okazaki, H., Tamura, Y., Iizuka, Y., Ohashi, K., Osuga, J., Harada, K., 
Gotoda, T., Nagai, R., Ishibashi, S., and Yamada, N. (2002) Absence of sterol regulatory 
element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin 
resistance in Lep(ob)/Lep(ob) mice. J Biol Chem 277, 19353-19357 
163. Iizuka, K., Miller, B., and Uyeda, K. (2006) Deficiency of carbohydrate-activated 
transcription factor ChREBP prevents obesity and improves plasma glucose control in 
leptin-deficient (ob/ob) mice. Am J Physiol Endocrinol Metab 291, E358-364 
164. Samuel, V. T., Liu, Z.-X., Qu, X., Elder, B. D., Bilz, S., Befroy, D., Romanelli, A. J., and 
Shulman, G. I. (2004) Mechanism of hepatic insulin resistance in non-alcoholic fatty liver 
disease. Journal of Biological Chemistry 279, 32345-32353 
165. Henriksen, E. J., and Dokken, B. B. (2006) Role of glycogen synthase kinase-3 in insulin 
resistance and type 2 diabetes. Current drug targets 7, 1435-1441 
166. Henriksen, E. J. (2010) Dysregulation of glycogen synthase kinase-3 in skeletal muscle 
and the etiology of insulin resistance and type 2 diabetes. Current diabetes reviews 6, 
285-293 
167. Neschen, S., Morino, K., Hammond, L. E., Zhang, D., Liu, Z. X., Romanelli, A. J., Cline, G. 
W., Pongratz, R. L., Zhang, X. M., Choi, C. S., Coleman, R. A., and Shulman, G. I. (2005) 
Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial acyl-
CoA:glycerol-sn-3-phosphate acyltransferase 1 knockout mice. Cell metabolism 2, 55-65 
168. McIntyre, T. M., Pontsler, A. V., Silva, A. R., St Hilaire, A., Xu, Y., Hinshaw, J. C., 
Zimmerman, G. A., Hama, K., Aoki, J., Arai, H., and Prestwich, G. D. (2003) Identification 
of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular 
PPARgamma agonist. Proceedings of the National Academy of Sciences of the United 
States of America 100, 131-136 
169. Wang, X., Devaiah, S. P., Zhang, W., and Welti, R. (2006) Signaling functions of 
phosphatidic acid. Progress in lipid research 45, 250-278 
170. Luukko e , P. K., Zhou, Y., Sädevirta, S., Leivo e , M., Arola, J., Orešič, M., Hyötyläi e , 
T., and Yki-Järvinen, H. (2016) Hepatic ceramides dissociate steatosis and insulin 
resistance in patients with non-alcoholic fatty liver disease. Journal of Hepatology 64, 
1167-1175 
171. Turpin, S. M., Nicholls, H. T., Willmes, D. M., Mourier, A., Brodesser, S., Wunderlich, C. 
M., Mauer, J., Xu, E., Hammerschmidt, P., Bronneke, H. S., Trifunovic, A., LoSasso, G., 
Wunderlich, F. T., Kornfeld, J. W., Bluher, M., Kronke, M., and Bruning, J. C. (2014) 
Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain 
and glucose intolerance. Cell metabolism 20, 678-686 
 
 
174 
  
 
172. Cai, D., Yuan, M., Frantz, D. F., Melendez, P. A., Hansen, L., Lee, J., and Shoelson, S. E. 
(2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-
[beta] and NF-[kappa]B. Nat Med 11, 183-190 
173. Bandsma, R. H., Smit, G. P., and Kuipers, F. (2002) Disturbed lipid metabolism in 
glycogen storage disease type 1. Eur J Pediatr 161 Suppl 1, S65-69 
174. Bandsma, R. H. J., Prinsen, B. H., de Sain-van der Velden, M., Rake, J.-P., Boer, T., Smit, 
G. P. A., Reijngoud, D.-J., and Kuipers, F. (2008) Increased de novo Lipogenesis and 
Delayed Conversion of Large VLDL into Intermediate Density Lipoprotein Particles 
Contribute to Hyperlipidemia in Glycogen Storage Disease Type 1a. Pediatric research 
63, 702-707 
175. Chatrath, H., Vuppalanchi, R., and Chalasani, N. (2012) Dyslipidemia in patients with 
nonalcoholic fatty liver disease. Seminars in liver disease 32, 22-29 
176. Katsiki, N., Mikhailidis, D. P., and Mantzoros, C. S. (2016) Non-alcoholic fatty liver 
disease and dyslipidemia: An update. Metabolism 65, 1109-1123 
177. Kosmas, C. E., Christodoulidis, G., Cheng, J.-w., Lerakis, S., and Vittorio, T. J. (2014) High-
Density Lipoprotein Functionality in Coronary Artery Disease. The American Journal of 
the Medical Sciences 347, 504-508 
178. Florentin, M., Liberopoulos, E. N., Wierzbicki, A. S., and Mikhailidis, D. P. (2008) Multiple 
actions of high-density lipoprotein. Current opinion in cardiology 23, 370-378 
179. Katsiki, N., Athyros, V. G., Karagiannis, A., and Mikhailidis, D. P. (2014) High-density 
lipoprotein, vascular risk, cancer and infection: a case of quantity and quality? Current 
medicinal chemistry 21, 2917-2926 
180. Kantartzis, K., Rittig, K., Cegan, A., Machann, J., Schick, F., Balletshofer, B., Fritsche, A., 
Schleicher, E., Haring, H. U., and Stefan, N. (2008) Fatty liver is independently associated 
with alterations in circulating HDL2 and HDL3 subfractions. Diabetes care 31, 366-368 
181. Ishibashi, S., Brown, M. S., Goldstein, J. L., Gerard, R. D., Hammer, R. E., and Herz, J. 
(1993) Hypercholesterolemia in low density lipoprotein receptor knockout mice and its 
reversal by adenovirus-mediated gene delivery. The Journal of clinical investigation 92, 
883-893 
182. Pendse, A. A., Arbones-Mainar, J. M., Johnson, L. A., Altenburg, M. K., and Maeda, N. 
(2009) Apolipoprotein E knock-out and knock-in mice: atherosclerosis, metabolic 
syndrome, and beyond. Journal of lipid research 50 Suppl, S178-182 
183. Izumida, Y., Yahagi, N., Takeuchi, Y., Nishi, M., Shikama, A., Takarada, A., Masuda, Y., 
Kubota, M., Matsuzaka, T., Nakagawa, Y., Iizuka, Y., Itaka, K., Kataoka, K., Shioda, S., 
Niijima, A., Yamada, T., Katagiri, H., Nagai, R., Yamada, N., Kadowaki, T., and Shimano, H. 
(2013) Glycogen shortage during fasting triggers liver-brain-adipose neurocircuitry to 
facilitate fat utilization. Nature communications 4, 2316 
184. Younossi, Z. M., Stepanova, M., Afendy, M., Fang, Y., Younossi, Y., Mir, H., and Srishord, 
M. (2011) Changes in the prevalence of the most common causes of chronic liver 
diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 9, 524-
530.e521; quiz e560 
185. Loomba, R., Sirlin, C. B., Schwimmer, J. B., and Lavine, J. E. (2009) Advances in Pediatric 
Nonalcoholic Fatty Liver Disease. Hepatology (Baltimore, Md.) 50, 1282-1293 
186. Lazo, M., Hernaez, R., Eberhardt, M. S., Bonekamp, S., Kamel, I., Guallar, E., Koteish, A., 
Brancati, F. L., and Clark, J. M. (2013) Prevalence of nonalcoholic fatty liver disease in 
 
 
175 
  
 
the United States: the Third National Health and Nutrition Examination Survey, 1988-
1994. American journal of epidemiology 178, 38-45 
187. Hamaguchi, M., Kojima, T., Takeda, N., Nakagawa, T., Taniguchi, H., Fujii, K., Omatsu, T., 
Nakajima, T., Sarui, H., Shimazaki, M., Kato, T., Okuda, J., and Ida, K. (2005) The 
metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Annals of internal 
medicine 143, 722-728 
188. He, S., Bao, W., Shao, M., Wang, W., Wang, C., Sun, J., Jiang, Y., Feng, X., and Niu, J. 
(2011) Risk factors for non-alcoholic fatty liver disease in a Chinese population. Acta 
gastro-enterologica Belgica 74, 503-508 
189. Neuschwander-Tetri, B. A. (2005) Nonalcoholic steatohepatitis and the metabolic 
syndrome. Am J Med Sci 330, 326-335 
190. Schwimmer, J. B., Celedon, M. A., Lavine, J. E., Salem, R., Campbell, N., Schork, N. J., 
Shiehmorteza, M., Yokoo, T., Chavez, A., Middleton, M. S., and Sirlin, C. B. (2009) 
Heritability of nonalcoholic fatty liver disease. Gastroenterology 136, 1585-1592 
191. Bambha, K., Belt, P., Abraham, M., Wilson, L. A., Pabst, M., Ferrell, L., Unalp-Arida, A., 
and Bass, N. (2012) Ethnicity and nonalcoholic fatty liver disease. Hepatology 55, 769-
780 
192. Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., 
Grundy, S. M., and Hobbs, H. H. (2004) Prevalence of hepatic steatosis in an urban 
population in the United States: impact of ethnicity. Hepatology 40, 1387-1395 
193. Filhoulaud, G., Guilmeau, S., Dentin, R., Girard, J., and Postic, C. (2013) Novel insights 
into ChREBP regulation and function. Trends in Endocrinology & Metabolism 24, 257-268 
194. Baldeweg, S. E., Golay, A., Natali, A., Balkau, B., Del Prato, S., and Coppack, S. W. (2000) 
Insulin resistance, lipid and fatty acid concentrations in 867 healthy Europeans. 
European Group for the Study of Insulin Resistance (EGIR). European journal of clinical 
investigation 30, 45-52 
195. Laws, A., Hoen, H. M., Selby, J. V., Saad, M. F., Haffner, S. M., and Howard, B. V. (1997) 
Differences in insulin suppression of free fatty acid levels by gender and glucose 
tolerance status. Relation to plasma triglyceride and apolipoprotein B concentrations. 
Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Arteriosclerosis, 
thrombosis, and vascular biology 17, 64-71 
196. Zhang, J., Zhao, Y., Xu, C., Hong, Y., Lu, H., Wu, J., and Chen, Y. (2014) Association 
between serum free fatty acid levels and nonalcoholic fatty liver disease: a cross-
sectional study. Scientific reports 4, 5832 
197. Tilg, H., and Moschen, A. R. (2010) Evolution of inflammation in nonalcoholic fatty liver 
disease: the multiple parallel hits hypothesis. Hepatology 52, 1836-1846 
198. Endo, M., Masaki, T., Seike, M., and Yoshimatsu, H. (2007) TNF-alpha induces hepatic 
steatosis in mice by enhancing gene expression of sterol regulatory element binding 
protein-1c (SREBP-1c). Experimental biology and medicine (Maywood, N.J.) 232, 614-621 
199. Jones, J. G. (2014) Identifying Sources of Hepatic Lipogenic Acetyl-CoA Using Stable 
Isotope Tracers and NMR. Advances in Radiology 2014, 9 
200. Previs, S. F., McLaren, D. G., Wang, S.-P., Stout, S. J., Zhou, H., Herath, K., Shah, V., 
Miller, P. L., Wilsie, L., Castro-Perez, J., Johns, D. G., Cleary, M. A., and Roddy, T. P. 
(2014) New methodologies for studying lipid synthesis and turnover: Looking backwards 
to enable moving forwards. Biochimica et Biophysica Acta (BBA) - Molecular Basis of 
Disease 1842, 402-413 
 
 
176 
  
 
201. Lei, S., Sun, R.-z., Wang, D., Gong, M.-z., Su, X.-p., Yi, F., and Peng, Z.-w. (2016) Increased 
Hepatic Fatty Acids Uptake and Oxidation by LRPPRC-Driven Oxidative Phosphorylation 
Reduces Blood Lipid Levels. Frontiers in Physiology 7, 270 
202. Bartels, E. D., Lauritsen, M., and Nielsen, L. B. (2002) Hepatic expression of microsomal 
triglyceride transfer protein and in vivo secretion of triglyceride-rich lipoproteins are 
increased in obese diabetic mice. Diabetes 51, 1233-1239 
203. Biddinger, S. B., Hernandez-Ono, A., Rask-Madsen, C., Haas, J. T., Aleman, J. O., Suzuki, 
R., Scapa, E. F., Agarwal, C., Carey, M. C., Stephanopoulos, G., Cohen, D. E., King, G. L., 
Ginsberg, H. N., and Kahn, C. R. (2008) Hepatic insulin resistance is sufficient to produce 
dyslipidemia and susceptibility to atherosclerosis. Cell metabolism 7, 125-134 
204. Tietge, U. J., Bakillah, A., Maugeais, C., Tsukamoto, K., Hussain, M., and Rader, D. J. 
(1999) Hepatic overexpression of microsomal triglyceride transfer protein (MTP) results 
in increased in vivo secretion of VLDL triglycerides and apolipoprotein B. Journal of lipid 
research 40, 2134-2139 
205. Schweiger, M., Eichmann, T. O., Taschler, U., Zimmermann, R., Zechner, R., and Lass, A. 
(2014) Measurement of Lipolysis. Methods in enzymology 538, 171-193 
206. Wei, J., Ferron, M., Clarke, C. J., Hannun, Y. A., Jiang, H., Blaner, W. S., and Karsenty, G. 
(2014) Bone-specific insulin resistance disrupts whole-body glucose homeostasis via 
decreased osteocalcin activation. The Journal of clinical investigation 124, 1781-1793 
207. Deems, R. O., Deacon, R. W., Ramlal, T., Volchuk, A., Klip, A., and Young, D. A. (1994) 
Insulin action on whole body glucose utilization and on muscle glucose transporter 
translocation in mice. Biochem Biophys Res Commun 199, 662-670 
208. Vergès, B. (2015) Pathophysiology of diabetic dyslipidaemia: where are we? 
Diabetologia 58, 886-899 
209. Rader, D. J., Alexander, E. T., Weibel, G. L., Billheimer, J., and Rothblat, G. H. (2009) The 
role of reverse cholesterol transport in animals and humans and relationship to 
atherosclerosis. Journal of lipid research 50, S189-S194 
210. Jung, U. J., and Choi, M.-S. (2014) Obesity and Its Metabolic Complications: The Role of 
Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, 
Dyslipidemia and Nonalcoholic Fatty Liver Disease. International Journal of Molecular 
Sciences 15, 6184-6223 
 
